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1.1  PrInCIPleS Of HeAlTH TeCHnOlOgy 
ASSeSSMenT
Along the evolution of methods in social and applied sciences such as clinical epidemi-
ology and health economics, Health Technology Assessment (HTA) has become, over 
the last few decades, an internationally active field supporting policy decisions in 
healthcare. HTA is defined as ‘’the systematic evaluation of the properties and effects 
of a health technology, addressing the direct and intended effects of this technology, 
as well as its indirect and unintended consequences, and aimed mainly at informing 
decision making regarding health technologies’’ [1]. In a context of wide expansion and 
diffusion of medical science and technologies leading to increased healthcare costs, 
HTA has been increasingly used to inform a fair decision-making process regarding 
the financing or reimbursement of medical technologies [2,3,4]. HTA is used to inform 
health care policy on how to allocate scarce resources in the most efficient way in a con-
text of constrained optimisation. Health technologies include diagnostic technologies, 
vaccines, pharmaceutical drugs, devices, medical and surgical procedures. Mass media 
campaigns or comprehensive healthcare strategies might also be assessed.
HTA is conducted by interdisciplinary groups that use frameworks drawing on differ-
ent methods [1]. Economic evaluations constitute the core of HTA and provide insight 
into the costs and effects of a new technology compared with another one [5]. They are 
defined as ‘’the comparative analysis of alternative courses of action in terms of both 
their costs and consequences” [5]. For example, the comparative effectiveness of a new 
diagnostic imaging tool can be assessed and balanced against the costs of an alternative 
diagnostic approach, such as current care or watchful waiting. As such, the incremental 
concept is a key component of the decision-making process that is captured by the 
incremental cost-effectiveness ratio (ICER). The ICER is the average cost that needs to be 
invested per patient to gain an additional unit of health when using the new technology 
compared to the existing one. Therefore, considering all relevant comparators against 
which to assess the value of a new technology is crucial [6]. Framing is an essential 
first step of an economic evaluation, during which the comparator but also the patient 
population, the indication, the decision-maker, the perspective and the outcomes are 
chosen. Cost-effectiveness analysis (CEA), and cost-utility analysis (CUA) more generally 
speaking, use the quality-adjusted life-year (QALY) as a generic measure of effect or 
health gain. The QALY combines the length of life in years with the quality of life spent 
during these years [5].
Economic evaluations usually require drawing on evidence from various sources. Eco-
nomic evaluations relying on empirical data from experimental or observational studies 
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have various limitations. To overcome these limitations, decision analytic modelling 
(which falls under economic evaluations) involves the application of mathematical tech-
niques to synthesise and bridge existing data and information from multiple sources 
concerning healthcare processes and their implications [5,7]. A key purpose of decision 
modelling in healthcare is to provide a framework for decision-making under the con-
ditions of uncertainty [6]. The key concepts of uncertainty that shape the exercise of 
decision modelling include variability across patients, parameter uncertainty, decision 
uncertainty and patient heterogeneity [6]. Variability refers to the inevitable difference 
in clinical events and health-related quality of life experienced by patients [6]. Param-
eter uncertainty relates to the precision of an input estimate (probability of a clinical 
event or cost) and can be addressed with stochastics (random probability distribution) 
or non-stochastic (bootstrapping) statistical methods. Decision uncertainty relates to 
the cumulative effect of the uncertainty around all parameters. Patient heterogeneity 
relates to the uncertainty driven by the patient’s characteristics such as age, gender 
or individual risk factor. In addition to these, the model structure itself, by its design 
and the structural assumptions it relies on, is a source of uncertainty. The inclusion of a 
relevant comparator (often current care), the inclusion of relevant events (in a decision 
tree, for example), the use of alternative statistical methods and the clinical uncertainty 
were identified as four categories of structural uncertainty [8]. Dealing with uncertainty 
is particularly relevant when CEAs are performed in the early stages of development of 
a new medical technology.
Early-CEAs are used to inform industry and other relevant stakeholders about the po-
tential value of a new technology alongside the research and development process [9]. 
The goal of early-CEAs is to mitigate the risks perceived by the stakeholders and increase 
the chances for market access and reimbursement [9]. Early-CEAs may help the manu-
facturer in identifying and selecting high value development strategies that provide 
substantial returns on investments as well as patient and societal value at an early stage 
[10]. Diagnostic technologies are characterised by specificities that make their early-
CEA particularly relevant and efficient [11]. These specificities include lower barriers to 
development and market entry and increased number of potential uses or indications, 
compared with therapeutics, as well as an increasing range of new diagnostics being 
developed [11]. These facts, combined with the rapidly increasing costs of advanced 
diagnostic technologies, support an earlier and iterative approach to economic evalua-
tions of diagnostics along the development phase [11]. This early approach can be key in 
improving the efficiency of the innovation process of diagnostics [11]. Early assessment 
of an imaging tests may encourage developers to improve the technical features (reso-




In various countries worldwide, reimbursement decision-making by the payer (mostly 
government agencies) requires the submission of a value dossier by the manufacturer. 
Values dossiers cover a variety of topics and methods in which HTA plays a prominent 
role in gathering clinical and economic evidence. These dossiers are subject to assess-
ment that can lead to a positive or negative reimbursement decision. A negative rec-
ommendation may have serious consequences in terms of market access and diffusion 
of the technology. Reimbursement decision-making remains the sole responsibility of 
each country and variations in the use of HTA practices have led to differences in reim-
bursement recommendations and decisions across European jurisdictions [12,13,14]. In 
the United States (US), HTA is used in a more indirect way ‘’in the background’’, by clinical 
guidelines writers for example. The resistance to economic evidence in the US mostly 
found its roots in both a lack of understanding and training about resource constraints 
and tradeoffs and a lack of trust in the methods of CEAs [15,16].
In a context of an increasing number of medical technologies developed and sometimes 
fast evolving care, transferring health economic evidence from a country to another 
one might be a fast and efficient method to inform decision makers in various jurisdic-
tions. Economic evaluations are considered to be generalisable when their results can 
be applied without additional adaptation to other countries [17]. In contrast, they are 
considered transferable when adaptations (adjustments based on local parameters) 
are necessary [17]. Various critical factors might hinder the transferability of economic 
evaluations [18]. The value of a health technology is highly dependent on the context 
in which it will be used. For example, an imaging test that is cost-effective in the United 
Kingdom (UK) might provide bad value for money in Hungary or the US. Similarly, an 
imaging test that is cost-effective for a population of patients at the country level might 
be an investment that is not cost-effective at the hospital level.
As mentioned before, diagnostic technologies are characterised by specificities that 
might affect their reimbursement by health authorities. First, diagnostic tests are often 
reimbursed either as part of a medical package for a disease, as part of a diagnosis-
related group (DRG) or based on a fee-for-service, contrary to therapeutics that are 
reimbursed for a specific indication. Second, a diagnostic test provides only information 
and this fact implies that its efficacy is indirect. More precisely, a test can have an impact 
on patients only via specific actions such as a change in medication or the decision to 
perform a surgery. Therefore, the health economic value of a test depends on whether 
or not these actions will lead to a health gain at an overall acceptable cost. The hier-
archical model of efficacy by Fryback and Thornbury illustrates that even the highest 
technical efficacy (resolution) or the highest accuracy (sensitivity, specificity) of an 
imaging test may not necessarily guarantee patient outcome efficacy or societal efficacy 
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[19]. Third, tests have different purposes, and therefore different applications, along the 
progression of a single disease. These purposes range from risk factor screening, disease 
screening, diagnosing, prognosing, testing for the choice of therapy, testing to monitor 
the response of a therapy and testing for surveillance [20]. For these reasons, it is crucial 
to define the ultimate goal of a test for the patient, in terms of biological outcomes, 
risk reduction of clinical events (like stroke or myocardial infarction) or improvement in 
length and/or quality of life. Altogether, these specificities make the health economic 
assessment of diagnostic tests more challenging compared to drugs, and the framing 
of the study crucial. These specificities also imply that the evaluation of the long-term 
impact of diagnostics requires a combination of data from clinical research and disease 
and population modelling.
1.2 CArDIOvASCulAr DISeASeS
Cardiovascular diseases (CVD) are a group of disorders of the heart and blood vessels 
[21]. Among others, they include coronary heart diseases (diseases of the blood vessels 
supplying the heart muscle) and cerebrovascular diseases (diseases of the blood vessels 
supplying the brain) [21]. Atherosclerosis, which is characterised by the deposition of 
fatty materials on the inner wall of arteries, and its complications, are responsible for the 
large majority of all cases of CVD. Globally, CVD are the number one cause of death [21]. 
By 2030, 23.6 million people are projected to die from CVD, mainly from heart diseases 
and stroke [21]. In addition to the high morbidity, CVD lead to a high economic burden 
worldwide [22,23]. This thesis focuses on two CVD disorders: stroke (and specifically 
ischaemic stroke) and two subcategories of coronary artery disease (CAD) (acute coro-
nary syndrome (ACS) and non-obstructive coronary artery disease (NOCAD)).
1.2.1 Stroke
Definition of the disease and epidemiology
Stroke is defined by the World Health Organization as a “a clinical syndrome typified 
by rapidly developing signs of focal or global disturbance of cerebral functions, lasting 
more than 24 hours or leading to death, with no apparent causes other than of vascular 
origin” [24]. Globally, about 80% of strokes are caused by ischaemia, which is an interrup-
tion of the blood supply, usually caused by a blood clot, while the remaining 20% is due 
to haemorrhage, which is characterised by a rupture of a blood vessel or an abnormal 




Given their different cause, ischaemic and haemorrhagic strokes require different thera-
peutic strategies.
In 2016, stroke was the second largest cause of death globally, with 13.7 million people 
experiencing an incident stroke and 5.5 million people dying from it [26]. Furthermore, 
important geographical variations have been observed worldwide from 1990 to 2016: 
the largest increase in stroke incidence was observed in East Asia and the largest de-
crease in southern Latin America [26]. The incidence of stroke increases significantly with 
age. Finally, stroke incidence amongst those aged 55-75 years is significantly greater for 
men than for women [26].
Humanistic and economic burden of disease
Stroke is the second leading cause of death and a major contributor of disability in the 
world [26]. Although mortality rates have decreased sharply from 1990 to 2016, the 
decrease in incidence has been less important, which suggests that the burden of stroke 
is inclined to remain high [26]. Considering the demographic transitions of populations 
in the developing countries and the ageing of the world population, the worldwide 
burden is even likely to increase [27]. Prevention of stroke in people aged 75 years and 
above is expected to play a major role in relieving the future global burden. Many stroke 
survivors are chronically disabled or functionally dependent and suffer from severe 
health loss.
Stroke is a huge public health burden with consequences such as increased healthcare 
utilisation, decreased productivity (resulting from morbidity and mortality) or the need 
for informal care, which result in substantial personal and societal costs. As such, costs 
are divided into direct healthcare costs (transport, hospitalisation and acute care, medi-
cation, rehabilitation, physician consultations, nursing care, long-term care facilities), 
and indirect costs (lost productivity, informal care).
Impact of stroke on quality of life and life expectancy
The impact of stroke on the patients’ quality of life depends on the severity of the stroke, 
which determines the degree of disability or dependence in daily life. Survivors of a 
stroke can experience a wide range of physical and cognitive impairments that include 
language and communication disorders (aphasia), limb weakness causing difficulties in 
walking and balancing, visual impairment, fatigue, difficulties in swallowing leading to 
a higher risk of pneumonia, loss of bladder and bowel control, anxiety or depression 
[28-33]. These effects can have a huge impact on social integration. Various studies have 
measured the quality of life of stroke survivors, based on the severity of the stroke. For 
example, based on a literature review, utility values assigned by stroke survivors ranged 
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from 0.72 after a minor stroke to 0.41 after a major stroke [34]. Furthermore, dependent 
patients experience an increased mortality compared to independent patients, who 
themselves experience an increased mortality compared to the general population 
[35,36].
Diagnosis and diagnostic imaging of acute ischaemic stroke
Acute patients presenting with stroke-like symptoms need to receive a timely assess-
ment of the nature and extent of brain damage before clinicians can decide on the type 
of acute treatment. In this context, the role of diagnostic neuroimaging has become piv-
otal. A variety of imaging techniques are available to reliably identify a stroke, determine 
the stroke type, assess the eligibility of treatment options and predict the outcomes [37]. 
Differential diagnosis aims at distinguishing an ischaemic stroke from a haemorrhage 
one or other causes and is reliably determined using unenhanced computed tomogra-
phy (CT) imaging or magnetic resonance imaging (MRI). Once a haemorrhage has been 
ruled out, the selection of patients with ischaemic stroke for treatment requires crucial 
additional imaging information related to stroke infarct core, ischaemic penumbra or 
degree of collaterals, vessel occlusion and thrombus location [37]. In addition to com-
mon modalities (CT, CT angiography (CTA) and MRI), advanced imaging modalities such 
as perfusion CT and MR angiography (MRA) provide relevant and accurate information 
[37]. The diagnostic workup of the patient with ischaemic stroke is based on a combina-
tion of these imaging modalities (CT + CTA + CTP, for example). This combination varies 
based on the availability of the imaging techniques and on the patient’s prior eligibility 
to treatments delivered in the healthcare facility. Over the past years, the need for this 
advanced imaging information has been created and intensified by the rapid evolution 
of treatments for ischaemic strokes.
Acute ischaemic stroke treatments
The effectiveness of acute ischaemic stroke treatments is time dependent. Under certain 
patient eligibility criteria, acute ischaemic strokes can be treated by an intravenous 
recombinant tissue plasminogen activator (tPA) which dissolves the blood clot and 
restores the blood flow in the brain. Intravenous tPA has been proven most effective 
and recommended within 4.5 hours from stroke onset [38-40]. Recent evidence has 
showed the efficacy of tPA until 9 hours after stroke onset [41,42]. In addition, intra-
arterial mechanical thrombectomy (MT), which consists of the surgical removal of the 
blood clot with a stent retriever, has become, over the last decade, the cornerstone of 
acute ischaemic stroke management in patients with a large vessel occlusion. Multiple 
randomised trials have confirmed the efficacy of this treatment within 6, 8 and 12 hours 
from stroke onset in case of a large occlusion [43]. Recent evidence demonstrated its 




Patients with acute ischaemic stroke and large vessel occlusion are eligible to the late-
window (6 to 24 hours) MT based on strict advanced imaging criteria [44,45]. Evidence 
suggests that patients who do not meet these criteria do not benefit from MT. Finally, MT 
and tPA can be administered alone or in combination with each other.
Potential value of new imaging test
In the current context of ischaemic stroke care, which relies on a comprehensive and 
relatively expensive imaging workup, new emerging and innovative technologies such 
as dual energy CT and, more recently, spectral photon-counting CT (SPCCT) could add 
value. Currently being developed with the goal to be a widely accessible technology, 
SPCCT is expected to improve acute stroke treatment decision-making by better quan-
tification of brain perfusion impairment [46,47]. This improved quantification would be 
eased by a higher spatial resolution and, in turn, better characterisation of brain tissues 
[48]. These technical improvements would allow more accurate identification of stroke 
patients who would benefit from late MT, exclude patients who will not benefit from 
treatments, and, as such, ensure an optimised use of healthcare resources and maximise 
patient health outcomes. Furthermore, SPCCT, by substituting the comprehensive im-
aging diagnostic workup of ischaemic stroke patients with a single imaging test could 
decrease the current diagnostic time and therefore contribute to increasing patient 
health outcomes. Finally, by allowing a diagnosis based on a single test, SPCCT could 
simplify the logistical organisation, be less expensive than the current imaging workup, 
more widely affordable to hospitals and contribute to increased patient access to acute 
ischaemic stroke care.
1.2.2  Coronary artery disease, acute coronary syndrome and non-
obstructive coronary artery disease
Definition of the disease and epidemiology
CAD usually is characterised by the progressive narrowing of the coronary arteries by 
atherosclerosis, which is the buildup of fatty deposits or plaques. Plaques and plaque 
rupture or erosion can cause vessel occlusion and lead to cardiovascular events, such as 
MI, stroke and/or death). ACS is a subcategory of CAD that refers to a range of conditions 
where the blood supplied to the heart muscle is suddenly blocked or significantly re-
duced, which can lead to the death of cells in the heart tissues. Patients with ACS almost 
always present with severe chest pain or discomfort which are the leading symptoms 
initiating the diagnosis and require immediate referral to the emergency ward [49]. ACS 
includes myocardial infarction (MI) and unstable angina that differ by their physiopa-
thology and treatment [49,50]. Non-obstructive CAD (NOCAD) is another subcategory of 
CAD in which the atherosclerotic plaques do not obstruct the blood flow [51]. Patients 
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with NOCAD can be symptomatic or asymptomatic but they experience a higher aver-
age risk of major adverse cardiovascular events (such as MI and stroke), compared with 
individuals with no apparent CAD [51,52].
Although the incidence has decreased over time in developed countries, CAD remains 
a major cause of death and disability in these countries [53,54]. In low- and middle-
income countries, CAD is the leading cause of death in adults [54,55]. While women were 
historically at a lower risk of CAD, they have been experiencing an increase in cardiac 
events such as MI [54,56]. The incidence of coronary events increases with age in both 
sexes.
Humanistic and economic burden of disease
Based on 2016 estimates, the worldwide prevalence of CAD accounted for 32.7% of 
the global burden of cardiovascular diseases and 2.2% of the global burden of diseases 
[57,58]. Furthermore, coronary heart diseases were reported to be the cause of death 
in 19% of men and 20% of women in Europe [59]. The clinical consequences of CAD 
include major adverse cardiovascular events, such as death, MI and stroke, but also heart 
failure [58]. A significant proportion of the patients experiencing an MI dies before they 
reach the hospital or during hospitalisation [60,61].
The largest contributors to the total costs of cardiovascular events are hospital stay and 
revascularisation procedures, such as cardiac surgery or interventions [58,62,63]. The 
medication costs for primary and secondary prevention of CAD also contribute to the 
disease’s economic burden [62]. Finally, the indirect costs related to productivity loss 
due to morbidity and mortality are considerable [58,59].
Impact on quality of life and life expectancy
CAD can lead to hospitalisation and disability and can potentially impact the daily ac-
tivities of patients [58]. Evidence has shown that survivors of an ACS experience a lower 
quality of life compared with the general population [64,65]. Marked impairments were 
found in the dimensions of pain or discomfort, usual activities, depression and fatigue 
[64,65]. MI specifically remains a feared diagnosis for patients. Following an ACS, the 
quality of life rises as time passes [66]. Based on the literature, a patient surviving a MI 
would have a utility of 0.67 during the 12 months post-event and could regain a utility 
of 0.82 after the first year [67]. Patients with NOCAD can be asymptomatic or experience 
on-going or episodes of chest pain, which can affect their quality of life. CAD, including 





Current care in ACS
Patients diagnosed with an ACS by electrocardiogram and blood tests undergo imaging 
investigation(s) so that clinicians can personalise the acute treatment. While invasive 
coronary angiography or coronary CT angiography (CCTA) reveal narrowed or blocked 
coronary arteries, echocardiogram shows whether the heart is pumping correctly 
and myocardial perfusion imaging shows the blood flow reduction through the heart 
muscle. Together with imaging, stress test play an important role in showing how well 
the heart works under exercise.
The treatment of ACS depends on the clinical type that is diagnosed. Various medica-
tions for emergency ACS care may be prescribed, with different goals such as dissolving 
the clot, improving blood flow or slowing the heart rate, for example. Surgery and other 
procedures might be needed to restore the blood flow to the heart muscles. These pro-
cedures include, among others, percutaneous coronary intervention (PCI) or a coronary 
artery bypass graft (CABG). PCI, also known as angioplasty with a stent, is a non-surgical 
endovascular procedure during which a stent is used to open up the part of the blood 
vessel narrowed by plaque build-up and restore the blood flow. In contrast, CABG is an 
invasive surgery which diverts the blood around the narrowed part of an artery by creat-
ing a new route with a graft from another part of the patient’s body. Evidence suggests 
differences and ACS care within Europe [70].
Current care in nOCAD
The diagnosis of NOCAD is currently based on clinical presentation (chest pain) and 
imaging. CCTA is usually used to establish the degree of coronary artery plaque-related 
stenosis; NOCAD refers to a degree of stenosis below the commonly accepted threshold 
of 50% [71]. CCTA provides limited information regarding the vulnerability of plaques to 
rupture and the risk of subsequent cardiovascular events [72]. The long-term treatment 
goals for patients with NOCAD are to relieve symptoms, if any, and lower the risk of 
cardiovascular events that are caused by plaque rupture. Although medical treatment 
may stabilise plaques, the residual risks and mechanisms of plaque rupture are unclear. 
Therefore, the treatment presents great challenges and the optimal therapy per patient 
is yet to be determined [71]. Medical therapeutic recommendations include a variety of 
options, including statins, with different levels of evidence regarding their effects [71]. 
Lifestyle changes are known to play an important role here.
Potential value of new imaging test
In order to reduce the risk of an ACS and CVD in general, unstable atherosclerosis (i.e. 
plaques at high risk of rupture) has to be detected at an early stage of its development.
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Current treatment strategies (medication, PCI and surgical approaches) rely on the 
quantification of the plaque-related stenosis. This quantification is impaired by the 
presence of plaque calcification and the spatial resolution of current imaging technolo-
gies. SPCCT, by its higher sensitivity to calcification and increased spatial resolution, is 
expected to improve the accuracy of stenosis measurement. This would reduce the 
number of unnecessary referrals of a large proportion of patients with CAD to invasive 
procedures. In addition to stenosis quantification, the improved spatial resolution 
of SPCCT and its novel image reconstruction algorithms could enable an enhanced 
characterisation (structure and biology) of atherosclerotic plaques, compared with the 
currently available imaging techniques. A prototype of SPCCT has shown the ability to 
differentiate plaque features and components (such as lipid, calcium or fibrosis) [73]. 
These advances in the analysis of plaque components are expected to allow a better 
identification of plaques that are at risk of rupture and the implementation of preventive 
treatment strategies for patients with CAD. These prospects would be particularly valu-
able in NOCAD which poses a diagnostic challenge.
1.3 Objectives and research questions
The overall objective of this thesis is to assess the potential cost-effectiveness of a 
currently developed advanced diagnostic imaging technology (SPCCT), to support 
healthcare decision making in cardiovascular diseases, taking into account international 
variation. Four research questions are covered:
1) What is known about current care and its variation in four European countries regard-
ing the diagnostic workup and therapeutic interventions for patients presenting with 
a suspected stroke and patients presenting with ACS?
2) Is SPCCT cost-effective in patients with ischaemic stroke in the UK and the US?
3) Is there international variation in the cost-effectiveness of SPCCT for patients with 
ischaemic stroke in Europe and is the transfer of an economic model a valid method to 
obtain country-specific estimates?
4) What is the cost-effectiveness of SPCCT in patients with NOCAD in the UK?
1.4 Outline
Chapter 2 provides a description of stroke imaging and an overview of practice variation 
across four European countries (Hungary, Germany, Sweden and the UK) based on a 
systematic literature review. In Chapter 3, we described the patterns of stroke imaging 
and acute revascularisation therapy and examined variations across European countries 
based on a clinician survey. In Chapter 4, we used modelling methods to investigate 
the potential cost-effectiveness of advanced imaging* and MT beyond 6 hours from 
stroke onset, compared to conventional imaging and standard medical care in the UK. 




stroke onset following advanced imaging*, compared with standard medical care, for 
29 subgroups of ischaemic patients in the US. In Chapter 6, we explored the validity 
of the process of transferring an economic model developed for the UK to Hungary, 
Germany and Sweden and compared the country-specific cost-effectiveness estimates. 
In Chapter 7, we examined the diagnostic and treatment strategies for suspected or 
confirmed ACS, based on a clinician survey, and identified variations in responses across 
European countries and regions. Chapter 8 provides a model-based CEA of SPCCT versus 
CCTA in selecting patients with NOCAD who would benefit from statin therapy. Finally, 
in Chapter 9, we summarise and discuss the results of all the chapters and highlight 
further research challenges.
*  In Chapters 4, 5 and 6, advanced imaging was used as a generic term for publications and should be 
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The cost-effectiveness of clinical interventions is often assessed using current care as 
comparator. However, evidence suggests practice variation in stroke imaging across 
countries. For the purpose of feeding into cost-effectiveness analysis, this research aims 
to describe the patterns of stroke imaging, examine practice variations across countries 
and, as such, obtain results reflecting current care.
Areas covered
A systematic literature review was conducted to identify original studies reporting the 
imaging workup used in acute stroke care in clinical practice in Hungary, Germany, 
Sweden and the UK. Information regarding the type and frequency of stroke imaging 
was analysed. Computed Tomography (CT) was reported as the main diagnostic imag-
ing modality used in stroke care (78–98% across patient profiles and time periods). This 
review revealed patterns that were not observed in individual studies. Comparisons of 
UK studies revealed considerable variations in the proportion of scanned patients and 
timing of imaging.
expert commentary
While the evidence about thrombectomy is difficult to translate in clinical practice, the 
evidence regarding the optimal imaging approach to diagnose stroke patients is lack-
ing. The heterogeneity in stroke imaging reinforces the need to compare the quality of 
stroke care within and between countries.
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2.1 InTrODuCTIOn
The rapid evolution of stroke treatment over the past years has been geared toward 
thrombolysis and more recently thrombectomy. Patients presenting with stroke-like 
symptoms in the hospital require a quick assessment of brain damage and perfusion 
impairment, making the use of neuroimaging essential. Besides common modalities 
such as computed tomography (CT), CT angiography (CTA), and magnetic resonance 
Imaging (MRI), advanced imaging techniques such as perfusion-computed tomography 
(CTP) and magnetic resonance angiography (MRA) are available and able to provide 
relevant information during the diagnostic workup in stroke care. Among the new 
emerging technologies, dual energy CT, and more recently, spectral photon-counting 
CT (SPCCT) are innovative imaging tools expected to improve stroke treatment decision-
making in emergency settings by better quantification of brain perfusion impairment 
[1]. However, the potential added value of these new techniques in acute stroke care 
is currently unknown and can only be determined by comparison with the modalities 
used in current clinical care.
In the management of complex diseases, such as stroke, diagnostic imaging tests influence 
outcomes indirectly by determining the treatment choice and clinical decision-making [2]. 
Thus, the relation between the use of an imaging test and the health outcomes is uncer-
tain, making cost-effectiveness evaluations of diagnostic tests sometimes difficult [3]. A 
crucial first step in assessing the potential value of an imaging technology is to understand 
the specific clinical context and the current level of provision of competing technologies 
used in clinical practice: Who and how do we image? Why do we image? For these reasons, 
assessing the relative value of new technologies such as SPCCT, both in terms of patient 
outcome and costs, requires an exact understanding of the current imaging practice in 
acute stroke care. Clinical guidelines are often assumed to represent current practice and 
used as a proxy in cost-effectiveness evaluations. The European Stroke Organisation (ESO) 
guidelines for the management of ischemic stroke recommend that patients with sus-
pected transient ischemic attack (TIA) or stroke receive urgent axial brain imaging (cranial 
CT or MRI). Urgent vascular imaging, such as ultrasound, CTA or MRA, is recommended for 
patients with a TIA or minor stroke [4].
The assumption that current care is aligned on guidelines is inappropriate when clinical 
practice substantially differs from guidelines and problematic when clinical practice dif-
fers between hospitals or countries. Evidence suggests differences in stroke care [5] and 
outcomes [6–9] within European countries. The scarcity of and the need for international 
comparisons and databases have been pointed out by different authors [6–8], suggest-
ing that variations in care need to be understood better. In this context, we conducted 
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a systematic literature review to identify studies informing of the diagnostic patterns in 
acute stroke imaging and to examine variations between countries.
2.2 MeTHOD
2.2.1 Search strategy
A de novo search strategy for finding relevant papers was designed by the researcher 
(ACP) together with the biomedical information specialist of the medical library of Eras-
mus Medical Centre of Rotterdam, The Netherlands. The search strategy can be found in 
the supplemental material number 1. The following databases were researched on the 
18 August 2016: Embase, Medline, Web of Science, the Cochrane Library and Google 
Scholar. All records retrieved from the databases were merged into one database and 
duplicates were removed. The remaining studies were screened by title and abstract by 
two independent reviewers (ACP and either KR or JLS) and ineligible publications were 
excluded based on predefined criteria (described below). The results of both review-
ers were compared and any discrepancies were discussed and resolved by consensus. 
After title/abstract selection, all remaining publications were read in their entirety to 
determine which ones met all inclusion and exclusion criteria (ACP).
2.2.2 Inclusion and exclusion criteria
Non-English-language publications were excluded, as were conference abstracts, edito-
rials, letters, reviews and books. Articles published before 2008 were also excluded since 
that was the year in which the latest ESO guidelines for the management of ischemic 
stroke were published. Non-observational studies such as pilot studies, experimental 
studies, and RCTs (randomized controlled trials) which did not include an arm focusing 
on current care were excluded.
Because we were interested in examining a range of healthcare systems, articles were 
eligible for inclusion only if they reported information on the diagnosis pattern of 
suspected stroke patients in the real-life practice of all types of hospitals (university, 
non-university, specialized, community, county) or clinics of Germany, Hungary, Sweden 
or the UK. Whereas Sweden is known for its early adoption of medical technologies, 
Hungary tends to be a late adopter. Besides, the UK is of major interest for its publicly 
funded system while Germany is characterized by its decentralized healthcare organiza-
tion in which private practitioners play a relatively important role.
The therapeutic scope of the selected studies included ischemic or hemorrhagic stroke, 
TIA, cerebellar infarction, intracerebral hemorrhage or subarachnoid hemorrhage. Stud-
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ies based on a patient population were included only if the sample contained more than 
an arbitrary cut off of 100 patients. Articles using data collected before and after 2008 
were only included if the results after 2008 could be separated from the previous years.
2.2.3 Data extraction
One reviewer extracted the main characteristics from the included studies: first author’s 
name, year of publication, country, clinical setting, study population, study design, 
origin of data, data collection period and the study goal.
Data extracted with the aim of describing and analysing the state of care included 
timing indicators related to the process of stroke care and information on the imaging 
techniques used. Whenever the data was available, the proportion of patients benefiting 
from each technology was reported. Extracted data were then analyzed and aggregated 
in a qualitative and quantitative synthesis. The extraction, calculation and reporting 
method is detailed in the supplementary material 2.
2.3 reSulTS
2.3.1. Search results
Figure 2.1 provides an overview of the search steps based on the Preferred Reported 
Items for Systematic Review and Meta-Analysis (PRISMA) guidelines [10]. The literature 
search using the Embase, Medline, Web of Science, the Cochrane Library and Google 
Scholar databases yielded 1565, 1636, 666, 59 and 200 records, respectively. After du-
plicates were removed, 2481 records remained for title and abstract selection, which 
eventually resulted in the selection of 122 records. The full-text assessment identified 15 
articles that met all the inclusion criteria.
2.3.2. Study characteristics
The general characteristics of the included studies are presented in Table 2.1. Three 
studies were conducted in Germany [6,11,12], three in Sweden [13–15], and 10 in the 
UK [5,12,16–23]; no study conducted in Hungary met the inclusion criteria for the final 
analysis. One of the three studies conducted in Germany reported results based on a 
combination of German and Austrian hospitals [11]. Nevertheless, given the detailed 
level of information provided, the choice was made to include this study for final analy-
sis. Another study [12] describing care in both the UK and Germany was included for 
analysis based on the fact that information for each country was available.
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Most selected articles were observational studies based on national registries, among 
which the Stroke Improvement National Audit Program (SINAP) and the Swedish stroke 
register that were found in 4 [17,18,20,21] and 2 studies [13,15], respectively. All the 
studies reported individual patient data, except the one from Jäkel et al. that was de-
signed on data collected from telephone interviews with clinicians [12]. Since this study 
reported data related to TIA patients only, we decided to include it for the final quantita-
tive synthesis. The study populations in the different publications differed slightly across 
studies. Most of them focused on stroke patients [5,6,13–19,21–23], two on ischemic 
stroke patients [11,20] and one on TIA patients [12]. Most of the studies based on a 
patient population database focused on adults, with the exception of one paper on 
children from 29 days to 15.99 years [23]. Among the adult populations studied, the 
mean reported ages varied slightly.
figure 2.1 Preferred reporting items for systematic review and meta-analysis (PRISMA) flowchart.
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Data found in the different studies were related to a wide range of hospital groups. While 
two studies included all hospitals in a country [13,15], the other studies focused on a 
geographic or institutional subgroup of hospitals. Public hospitals were the center of 
investigation in two studies [5,22] while emergency hospitals were selected for analysis 
in one study [14]. Finally, one studies restricted the observations to stroke centers [11].
The aims widely varied across the different studies and covered a wide range of topics 
from a qualitative and/or quantitative perspective. The most frequent topics covered 
the relationship between the process of care and mortality, the pattern and magnitude 
of variation of care over the week, inequalities in the delivery of care and outcomes 
associated with a reconfiguration of care, and real-world trends in the management of 
acute stroke patients.
The level and amount of information regarding the type and frequency of imaging tech-
nique used are heterogeneously documented across studies. While detailed data were 
extracted from the studies conducted in Germany and the UK, more general information 
was found in the Swedish studies. Furthermore, the majority of the papers focusing on 
the UK reported information about the timing of the imaging workup in clinical settings. 
Nevertheless, after consolidation of the data originating from different authors, it was 
possible to present results that go beyond the findings provided by individual studies 
and identify patterns per country.
Studies performed in the UK often attempted to assess the quality of care by examining 
the use of imaging tests over time. Figure 2.2 plots the proportion of patients tested 
with a brain scan per time range after admission to the hospital in the UK. Data related to 
different investigated periods, different time categories of hospital admission (in hours 
or out of hours), and different geographic areas are presented and can be compared. 
Based on Figure 2.2, 51–70% of patients underwent a brain scan within 3 h following 
hospital admission and that 78–95% of the patients had undergone a brain scan within 
24 h. Differences in the reported values can arise for various reasons. That is, since the 
results are drawn from different studies, some of the observed variations could be attrib-
uted to differences in study design, the period of investigation, geographical area, type 
of investigated health center and chance (due to sampling error). To minimize the effect 
of potential bias, focus on the results reported in a same publication might be relevant. 
For example, looking at the results by Ramsay, the frequency of brain scan use at 3 h 
varies from 56% in Greater Manchester to 70% in London which most likely reflects true 
differences in the way imaging is delivered to stroke patients across the UK. Ramsay also 
reports the frequency of brain scan use at 3 h and 24 h for two different areas. Strong 
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24 h) and urban areas of England where acute stroke services were not centralized (54% 
scanned at 3 h and 91% at 24 h).
Overall, both Lazzarino and Palmer reported lower proportions than the other authors, 
partly because they looked at the time in days after admission rather than in hours after 
admission. Their results are partly due to the fact that they used a timing indicator which 
reflects the time in days after admission rather than in hours. Thus, they reported that 
35–48% of patients received a head scan during the day of admission. This low propor-
tion might be partially influenced by the fact that some patients arriving at the hospital 
later in the day would receive a head scan after midnight and be registered as ‘the day 
after’ in the study. However, this consideration can probably not fully explain the low 
frequency that they reported. That is, by reporting 59% of patients tested during their 
day of admission or the day after, Lazzarino et al. present a lower frequency than Bray, 
Campbell, Power and Ramsay, who report 78–95% of patients scanned within 24 h. It 
is worth mentioning that Lazzarino’s results refer to the period of 2008–2009, which 
might partly explain why the frequencies they report are lower than those from authors 
who investigated more recent periods. Furthermore, Campbell and Palmer examined 
the association between the time of admission during the week and the proportion of 
scanned patient. They report disparities between the rate of scans delivered in hours 
or during the weekdays compared to the rate of scans delivered out of hours or during 
the weekend. Their results show that patients seen out of hours or during the weekend 
experience longer delays to receive a scan. Finally, it is worth mentioning that no as-
sociation was found between the patient populations and the reported differences in 
the frequency of imaging. The inclusion criteria determining the characteristics of the 
patients from the different studies can be found in the supplementary material 2.
Figure 2.3 provides more detailed information regarding the type of imaging technolo-
gies used in clinical practice in the UK. As such, it illustrates the frequency of usage of dif-
ferent modalities by subgroups of patients during different periods. CT appeared to be 
the most frequently used modality across the investigated periods (2008–2011), places 
and patient profiles. While Power reported that 78% of the stroke patients received a CT 
scan within 24 h of hospital admission in 2009, Hunter reported that same technology 
was used for 94% of the stroke patients in 2010–2011. Mallick et al. also found that CT 
was the most common initial imaging modality for children: in their study population, 
98%of the cases of hemorrhagic stroke received a CT as first imaging workup. In con-
trast, MRI was the initial imaging modality for 29% of the children with ischemic stroke 
and only 2% of the children with hemorrhagic stroke. Another notable result presented 
by Hunter et al. is the relatively high proportion (68%) of stroke patients imaged with 
MRI in the London Hyperacute Stroke Units over 2010 and 2011. Conversely, only 2–29% 
38
Chapter 2
of the patients in the other subgroups were reported to be imaged with this modality. 
Of the stroke patients recorded in the study by Hunter et al., 63 and 49%received a CT 
angiography and echocardiogram, respectively.
Figure 2.4 illustrates the frequency of usage of CT, MRI, and carotid artery imaging in 
Sweden across different settings and time periods. CT appeared to be the most reported 
imaging modality in Sweden from 2010 through 2013. Across the observed periods 
and types of hospitals, 98–99% of the patients received a CT scan. In contrast, studies 
reported considerably smaller proportions of patients who received an MRI in the same 
period. In addition, variations in the proportion of patients who received an MRI were 
seen, with the highest rate recorded for the years 2012–2013 and in university hospitals. 
Use of carotid artery imaging was characterized by intermediate frequencies of usage 
varying between 52 and 63% of the ischemic stroke patients over 2010 and 2011. Again, 
it is in university hospitals that the proportion of patients examined with carotid artery 
imaging was the highest. It is worthwhile to note that both Asplund and Sundström 
[13,14] investigated the frequencies of more than a single imaging modality. Their 
comparative results might be more accurate than results compared across different 
studies. Indeed, variations in imaging frequency could arise for various reasons such as 
different study populations and study methodologies. However, the individual studies 
investigating the frequency of CT, MRI, and carotid artery imaging found differences in 
the use of these imaging modalities. This observation demonstrates that the differences 
in frequency are caused by actual heterogeneity in clinical practice.
figure 2.3 Frequency of different imaging modalities in the UK.
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The frequency of usage of various imaging modalities per subgroup of stroke patients 
in Germany is depicted in Figure 2.5. Different clinical settings were covered over the 
years 2009–2012 in the set of selected studies. More than 99% of the suspected stroke 
patients were reported to have received either a CT or an MRI in 2012. The frequency of 
CT also appeared to exceed 80% in the groups of suspected TIA patients (emergency 
room setting) and endovascular stroke treatment (EVT) patients. Whereas the frequency 
of MRA and MRI differed substantially between the different groups of patients, the two 
figure 2.4 Proportion of stroke patients receiving different imaging modalities over various periods and 
categories of hospital in Sweden.
figure 2.5 Proportion of subgroups of patients receiving different imaging modalities over time and cat-
egories of hospital in Germany.
MRI DWI: magnetic resonance imaging diffusion weighted imaging; CTT: cranial computed tomography; 
NMR: nuclear magnetic resonance.
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modalities appeared to be relatively evenly used within the groups. The suspected TIA 
patients (hospital specialist setting) are associated with the highest MRI and MRA fre-
quency of 47 and 46%, respectively. Within the groups of suspected TIA patients (ER and 
EVT patients), the rates of MRI and MRA slightly varied between 15 and 20%, similarly 
to the level observed in Sweden. Finally, heart ultrasound and carotid Doppler were 
reported for the group of TIA patients (hospital specialist) only and accounted for a rate 
exceeding 95%. The study by Jakel et al. shows how frequencies of imaging tests vary 
across clinical settings (emergency room versus hospital specialist). Their comparative 
results reinforce the evidence that the differences in frequency are caused by actual 
heterogeneity in clinical practice rather than by the differences in study characteristics.
2.4 DISCuSSIOn
This systematic review included published studies reporting data about the diagnosis 
workup of acute stroke patients in routine clinical practice in four selected European 
countries. Routine clinical data related to the diagnosis of stroke appeared to be un-
evenly reported across countries for the investigated period. The vast majority of the 
selected studies was conducted in the UK, while 3 papers related to the Swedish practice 
and 2 papers related to the German practice were identified. No study about Hungarian 
clinical practice was found.
The studies found in this review often reported limited or heterogeneous clinical data 
on the routine practice of stroke diagnosis. While most studies provided the proportion 
of patients receiving a brain scan across varying timeframes during the acute phase, the 
entire range of imaging modalities used during the diagnosis workup was reported in 
only one study [11]. The limitation of data found in hospital-based registries could be 
the reason why most studies focused on just one test [15,19]. The fact that a single head 
scan is the preferred strategy in some health centers where clinicians try to minimize the 
delay to treatment could also explain why most studies do not report data about the full 
range of tests. However, recent studies suggest that another approach, which consists 
of a more comprehensive imaging workup, is also advocated [24]. This comprehensive 
approach includes a combination of imaging modalities which improves patient selec-
tion for treatment. In this context, we hypothesize that the current practice is divided 
between the strategy of a single test and one involving a more comprehensive imaging 
workup. Since our analysis is constrained by the limited available data, more complete 
data would be needed to validate this assumption and assess the frequency at which 
these two approaches are used. For instance, the exhaustive list of imaging modalities 
routinely used for diagnosis would need to be analyzed.
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Moreover, gaining insights into real-world trends of the current diagnosis approaches 
is hampered by the heterogeneity of the indicators used in the different studies. The 
imaging performance can be captured by indicators assessing the number of CT scans 
or MRIs. The performance is also assessed through more generic indicators tracking the 
number of head scans, without specifying the imaging modalities that are part of it. 
Likewise, time performance (the use of scans at different time points following a stroke) 
is assessed via a broad variety of indicators. To start with, time might be measured from 
symptom onset, from the patient’s call for assistance or from hospital admission. Then, 
delays might be measured starting at any of these points in time and ending at the first 
head scan, the admission to the stroke unit, the first encounter with a specialist or the 
start of treatment. Time might be reported as a mean or median. Performance might 
be expressed in terms of unit of time (minutes, days, weeks) or proportion of patients 
tested or receiving care by a certain time threshold. This multiplicity of options found in 
the studies impeded a more comprehensive comparative analysis.
Furthermore, none of the included studies provided information about the time for 
imaging interpretation or the time between scanning and reporting. However, Mallick et 
al. acknowledged a study limitation in choosing the time when the diagnostic imaging 
is performed as an end point [23]. That is, the time of imaging differs from the time of 
diagnosis based on interpretation of the images and from the time of communication 
of the results to other clinicians. None of the 15 included studies provides the method 
used to report the imaging findings in clinical practice. However, the information used 
from an imaging test and the manner, content and level of details of imaging reports 
might differ across radiologists, health centers and countries. The frequency and extent 
to which radiologists use the reporting standards by imaging modality [25] would need 
to be analyzed. It might be worth investigating the frequency at which radiologists 
report the Alberta Stroke Program Early CT Score (ASPECTS) after performing a CT, as 
this indicator has proven to be useful in predicting outcomes and reperfusion [25–27].
Despite these obstacles, the strength of this review is to reveal patterns that could not 
be observed in individual studies. First, the consolidated results support the assumption 
that CT scan is the most common modality for stroke diagnosis in Germany, Sweden 
and the UK. Remarkably, high rates of CT scan use (from 68 to 99%) are reported across 
different time periods, clinical settings and patient subgroups (including children). This 
finding is consistent with previous studies [24] and is presumably seen because access 
to CT is more rapid and requires less organization, logistics and resources than access 
to MRI [24]. Whether the widespread use of CT is the most effective way of dealing with 
stroke patients is a legitimate question. Interestingly, not all patients are imaged with CT 
despite its wide availability. Conversely, MR imaging, despite being reported in six stud-
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ies [11–14,21,23], appears to be used less frequently for the diagnosis of stroke patients 
in these countries.
Second, we have confronted results from different authors that reflect disparities across 
studies. Time, space and patient selection criteria were reported and discussed as poten-
tial reasons why these differences could arise. Given the degree of variation found in the 
results, it seems unlikely that changes over years alone can fully explain these differences. 
Besides, no association was found between the patient populations and the reported 
differences in the frequency of imaging. Although we cannot exclude the influence of 
change over years, our analysis supports the hypothesis that large variations exist in the 
imaging management of stroke patients across category of hospitals (university versus 
non-university) in Sweden, across geographical areas and across the time of day and day 
of week in the UK. These findings are also consistent with the conclusions from several of 
the individual studies and suggest that inequalities exist in the provision of stroke imag-
ing for patients admitted out of hours, during the weekend, in non-university hospitals 
and in areas where acute stroke services are not centralized. According to our results, 
these patients are less likely to receive (timely) access to imaging.
Guidelines uniformly claim that timely brain imaging and interpretation are critical in 
the diagnosis and management of stroke patients. However, previous studies in the UK 
reported that ‘more than 60% of neurosurgical centers did not have an interventional 
radiologist available 7 days a week… and 90% of all hospitals did not have access to 
computed tomography scanning 24 h per day and 7 days every week’ [28]. A recent 
report describes the mismatch in the UK between the increase in clinical demand for CT 
scans (29%) and the growth in workforce (5%) from 2012 and 2015 [29]. An even more 
drastic gap is reported for Scotland. Overall, the UK is known to have the second lowest 
number of radiologists per capita across all European countries.
2.5 lIMITATIOnS
Our study encountered some limitations which include the heterogeneity of studies 
included, the lack of data regarding the use of multiple modalities and the lack of com-
parative data.
For feasibility reasons, we did not include studies written in German, Swedish, and Hun-
garian and might have missed part of the existing literature. Besides, we did not have 
access to 13 studies out of 122 that were selected based on title/abstract reading. An 
important inherent limitation of any systematic literature review is that it only describes 
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what happened in the past and not what is currently taking place in clinical practice. 
This is worth mentioning as clinical practice in the field of stroke imaging is expected to 
evolve considerably fast. Whether the results we present are still relevant would need 
to be investigated, preferably via other complementary research methods. Finally, the 
proportions and frequency of imaging tests are subject to different types of bias derived 
from the original studies. Inconsistent coding of imaging tests within and across hos-
pitals and data originating from both voluntary and involuntary hospital participation 
might affect the validity of the reported results. However, in countries where coding 
is being used for reimbursement purposes, it is likely that coding errors are minimal 
and that coding is rather consistent across hospitals. Finally, while Wiedmann reported 
no major differences between voluntary and non-voluntary participating hospitals [6], 
Asplund reported no systematic differences in data quality from the different types of 
hospitals [13]. Nevertheless, the value of this systematic review is that we determined 
what is currently known about the current imaging practices in stroke care in order to 
inform future modeling on the potential added value of new diagnostic modalities. Our 
results, by showing that access to imaging varies across settings, implies that disparities 
will need to be reflected in the imaging strategies included in the modeling exercises. 
Our results also suggest that some scanning strategies might not be relevant for a spe-
cific hospital or country.
2.6 COnCluSIOn
To our knowledge, our study is the first to focus on a comparative analysis of the imaging 
workup used to diagnose and assess strokes across different European healthcare sys-
tems. This systematic literature review allows synthesizing the work done in the field and 
draws attention to the obstacles preventing a more complete analysis and synthesis. 
The evidence from the scientific literature is scarce and thus insufficient for an accurate 
between-country comparison of the imaging workup used in stroke care. Alternative 
research methods (i.e. survey) might be relevant to provide comprehensive data on cur-
rent access to imaging for stroke patients and to inform the cost-effectiveness modeling. 
Further consideration should also be given to investigate the optimal imaging workup 
to diagnose stroke patients and select a more personalized therapy for individual pa-
tients. Given the heterogeneity of stroke care, further research is also needed to identify 




A major weakness in clinical management lies in the slow and difficult translation and 
implementation of the evidence in routine clinical practice. The first proof of principle 
for intravenous thrombolysis arose in 1995 with the National Institute of Neurologi-
cal Disorders and Stroke (NINDS) study [30]. After years of RCTs showing conflicting 
evidence [31] (and leaving the stroke community divided), the Cochrane review of 2014 
[32] clearly demonstrated the efficacy and safety of intravenous thrombolysis. Although 
thrombolysis has been proven effective in acute ischemic strokes, its dissemination in 
routine clinical practice in various countries has been slow and limited to only a small 
proportion of eligible patients [33–36]. In 2014, the MR-CLEAN trial [37] provided the 
proof of principle for endovascular treatment and was followed by several RCTs which 
all confirmed the efficacy of this intervention. Evidence [38] shows that thrombectomy 
should be the standard of care for acute stroke caused by a large vessel occlusion and 
now needs to be translated in routine clinical practice across the world. While throm-
bolysis is relatively easy to implement, the use of thrombectomy in clinical practice faces 
logistical constraints that many hospitals have not overcome yet. The heterogeneity of 
stroke treatments delivered in clinical practice makes the need for neuroimaging differ-
ent across health centers.
Furthermore, there is a lack of evidence regarding the optimal imaging approach for 
the diagnostic of stroke patients. Opening the artery only leads to a positive clinical 
outcome when viable brain tissue remains to be saved. The ideal neuroimaging method 
to be used to identify salvageable tissue in acute stroke patient is largely debated [39]. 
Although perfusion imaging is theoretically the best method to assess brain tissue vi-
ability [40], huge variations exist between commercial and academic imaging softwares. 
In practice, a set of clinical data (age, National Institutes of Health Stroke Scale (NIHSS), 
time from onset) combined to radiological data (ASPECTS, non-contrast-enhanced CT 
and grading of collaterals) are used by clinicians to assess tissue viability. Technology 
assessments of diagnostic tests for stroke are lacking [41] and would be needed to 
harmonize clinical practices and allow for a more systematic approach.
Further research is needed to understand the causes and drivers to heterogeneous clini-
cal practice patterns in stroke imaging. Beyond these considerations, it would certainly 
be worth comparing the quality of stroke care within and between countries and to 
investigate to what extent the lack of harmonization creates inequalities in terms of 
health outcomes between patients. Since imaging tests do not directly affect long-term 
patient outcomes, the real impact of these tests on patients is not easily quantifiable. 
The benefits from imaging tests in stroke care depend not only on test performance 
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characteristics, but also on the prevalence of strokes and on the effectiveness of the 
existing treatments.
Cost-effectiveness analyses could provide a framework to compare different stroke im-
aging strategies through the prism of maximizing health benefit within the constraint of 
limited resources. There are various challenges in performing cost-effectiveness studies 
of stroke imaging. In stroke care, the decision-making process and resource utilization 
that follows imaging tests is complex and driven by many factors that can be difficult 
to model. Parameters (test accuracy, efficacy of treatment options, costs, health states 
values, etc.) are assessed based on multiple assumptions that can cause bias and inaccu-
racy of results. Comprehensive and complete data from large sample sizes are needed. 
It is not enough to capture the frequency of CT scan received by stroke patients. Stud-
ies should inform on the complete imaging workup used in stroke care and compare 
alternative strategies.
2.8 fIve-yeAr vIeW
Imaging tests are valuable tools only when they influence the decision-making process 
and treatment choice. In current stroke care, the value of imaging is mainly found in 
its ability to identify and better select ischemic patients for intravenous thrombolysis 
or thrombectomy. The rise of these new treatment modalities has been changing the 
role of imaging in the stroke care pathway. Ruling out brain hemorrhage (most often 
by means of CT) is still needed in the first place to identify ischemic stroke patients 
but no longer sufficient to decide how to treat them. Information regarding the size 
of the occlusion should be obtained before clinicians decide to perform endovascular 
intervention. A CTA of the circle of Willis and ideally of the aortic arch and the neck 
vessels provides valuable information for treatment decision-making [42].
As mentioned above, the key challenge remains on implementing accessible and ef-
fective thrombectomy centers where both patients and relevant information must be 
transferred in a timely manner. This could be achieved by organizing networks of stroke 
care that would rely on a strong collaboration between health centers and on the defi-
nition of brain imaging standards. Thus, endovascular treatment would be performed 
only in high-volume centers where interventional radiologists would be available 24/24. 
Technical solutions already exist to allow neurologists in a given hospital to be in contact 
with neuroradiologists from another hospital regarding the management of an acute 
stroke patient [43]. Developing such collaboration would contribute to a more efficient 
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use of the imaging equipment and workforce and would erase part of the dramatic 
variations observed in stroke care.
If CT remains the mainstay of the imaging workup in stroke, it is probably because its ac-
cess is fast, requires little organization, logistics, and resources. The speed of acquisition 
and the large volume coverage provided by modern multislice CT allow for an almost 
instant examination of the whole brain and for an assessment of the feeding arteries 
with a high spatial and temporal resolution. Some researchers have evaluated the 
feasibility of a ‘one-stop’ machine combining CT acquisition of the heart with ECG syn-
chronization [44] and imaging of great vessels. By using this technology, they were able 
to inform on the origin of stroke (clot in the left atrium generating brain embolism for 
example) while generating a neck and brain CT image. An opportunity of development 
lies in hybrid systems, combining CT and angiography suite in one unique room which 
would minimize the time of stroke imaging work-up. Furthermore, some companies are 
investigating how to miniaturize CT to make it a mobile and transportable device [45]. 
These developments will certainly shape the future of stroke care and imply consider-
able changes in the logistic organization, by allowing early scan of patients from even 
remote places and fast transfer of data to clinicians via the Internet.
Given the shortage of radiologists, another area for development may lie in the use of 
artificial intelligence in stroke care. Automated techniques have already been tested for 
stroke diagnosis and prognosis purposes and have shown variable performances across 
applications [46]. Interestingly, automated diagnosis based on the assessment of the 
ASPECTS by means of an e-ASPECTS software has been attempted [47,48]. This software 
showed a non-inferior performance in comparison to conventional human assessment 
of the score.
Finally, photon counting is likely to be the next breakthrough in CT technology [49]. 
Although time-to-market is kept confidential by manufacturers, it is suggested that 
the technology could be commercially available within 2–4 years [49]. Assuming this 
timeline, early health technology assessment (HTA) [50] of SPCCT is necessary to assess 
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Key issues
•	 The	number	and	quality	of	studies	devoted	to	the	evaluation	of	the	process	and	qual-
ity of stroke care seem to vary greatly across countries.
•	 Variability	was	found	with	regards	to	the	indicators	reported	in	the	different	studies.	
Large-scale international studies that use standardized methodological approaches 
are needed to assess the process of stroke care and compare it across countries.
•	 Ascertaining	the	use	of	imaging	modalities	in	current	stroke	care	requires	a	combina-
tion of research approaches. As such, it would be worth complementing our systematic 
review by an extensive and detailed international survey to clinicians in order to obtain 
the most recent and complete data regarding the use of imaging modalities.
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Supplemental material 1: search strategy
embase.com
(‘cerebrovascular accident’/exp OR ‘brain infarction’/de OR ‘brain ischemia’/de OR ‘stroke 
unit’/de OR (cerebrovascul*-accident* OR cva OR stroke OR ((brain OR cerebral*) NEAR/3 
(ischem* OR ischaem* OR infarct*))):ab,ti) AND (‘diagnosis’/exp OR ‘cerebrovascular ac-
cident’/exp/dm_di OR (diagnos*)) AND (‘clinical practice’/exp OR ‘total quality manage-
ment’/de OR ‘delayed diagnosis’/de OR ‘diagnostic accuracy’/de OR ‘diagnostic error’/de 
OR ‘personal experience’/de OR (((clinical* OR pattern* OR current* OR medical*) NEAR/6 
practice*) OR ((current OR state) NEAR/6 (practice OR care OR healthcare OR system* OR 
process*)) OR ((characterist* OR compar*) NEAR/6 (service* OR procedure*)) OR (region* 
NEAR/6 differen*) OR (guideline* NEAR/6 (adheren* OR complian* OR nonadheren* 
OR noncomplian* OR follow*)) OR disparit* OR disadvantag* OR (diagnos* NEAR/6 
(trend* OR improve* OR precision* OR accura*)) OR (quality NEAR/3 (management* OR 
improvement*)) OR (delay* NEAR/6 diagnos*) OR adequa* OR ((early OR earlier OR late 
OR later OR sooner OR timing) NEAR/6 (scan OR ct OR imaging OR nonimaging )) OR 
((personal* OR patient*) NEAR/6 experience*) OR Misdiagnos* OR (diagnos* NEAR/3 
(error*)) OR (false NEXT/1 (positive* OR negative*)) OR ((national* OR nationwide* OR 
nation-wide* ) NEAR/10 (audit* OR stud* OR observat* OR survey* OR questionnaire* 
OR association* OR register*)) OR ((national* OR uk OR united-kingdom OR england OR 
english OR scotland OR scottish OR wales OR welsh OR north*-ireland* OR north*-irish* 
OR hungar* OR swed* OR german*) NEAR/10 (audit* OR survey* OR register*)) OR (stroke 
NEAR/6 (register* OR data-bank* OR databank*)) OR routine):ab,ti) AND (‘Germany’/exp 
OR ‘Sweden’/de OR ‘Hungary’/de OR ‘United Kingdom’/de OR (German* OR Sweden OR 
Swedish OR Hungar* OR ‘United Kingdom’ OR uk OR great-britain OR british OR wales 
OR welsh OR england OR english OR schotland OR schottish OR north*-Ireland OR 
north*-Irish OR nhs OR national-health-service* OR london* OR Aberdeen OR Belfast 
OR Birmingham OR Bradford OR (Brighton NEXT/2 Hove) OR Bristol OR (Cambridge 
NOT Cambridge-University-Press) OR Canterbury OR Cardiff OR Carlisle OR Chelmsford 
OR Westminster OR Coventry OR Derby OR Derry OR Londonderry OR Dundee OR 
Edinburgh OR Exeter OR Glasgow OR Gloucester OR Kingston OR Lancaster OR Leeds 
OR Leicester OR Lisburn OR Liverpool OR Manchester OR Newcastle OR Newport OR 
Norwich OR Nottingham OR (Oxford NOT Oxford-University-Press ) OR Peterborough 
OR Plymouth OR Portsmouth OR Preston OR Salford OR Sheffield OR Southampton OR 
St-Albans OR Stoke-on-Trent OR Sunderland OR Swansea OR Wakefield OR Winchester 
OR Wolverhampton OR (York NOT new-york) OR (berlin NOT Springer-Verlag-Berlin 
NOT Gruyter-Berlin ) OR  Munich OR  Cologne OR  Frankfurt OR  Essen OR  Dortmund 
OR ( Stuttgart NOT Thieme-Verlag ) OR  Dusseldorf OR  Bremen OR  Hanover OR  Duis-
burg OR  Nuremberg OR  Leipzig OR  Dresden OR  Bochum OR  Wuppertal OR  Bielefeld 
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OR  Bonn OR  Mannheim OR  Karlsruhe OR  Gelsenkirchen OR  Wiesbaden OR  Munster 
OR   Monchengladbach OR   Chemnitz OR   Augsburg OR   Braunschweig OR   Aachen 
OR  Krefeld OR  Halle OR  Kiel OR  Magdeburg OR  Oberhausen OR  Lubeck OR  Freiburg 
OR  Hagen OR  Erfurt OR  Kassel OR  Rostock OR  Mainz OR  Hamm OR  Saarbrucken 
OR  Herne OR  Mulheim OR  Solingen OR  Osnabruck OR  Ludwigshafen OR  Leverkusen 
OR  Oldenburg OR budapest OR Debrecen OR Miskolc OR Szeged OR Pecs OR Gyor OR 
Nyiregyhaza OR Kecskemet OR stockholm OR goteborg OR Gothenburg OR malmo OR 
birmingham OR Uppsala OR Vasteras OR Orebro ):ab,ti) NOT ([Conference Abstract]/lim 
OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim)
Medline Ovid
(exp “Stroke”/ OR “Brain Ischemia”/ OR (cerebrovascul*-accident* OR cva OR stroke OR 
((brain OR cerebral*) ADJ3 (ischem* OR ischaem*))).ab,ti.) AND (exp “diagnosis”/ OR 
diagnosis.xs. OR “stroke”/di OR (diagnos*)) AND (“Practice Patterns, Physicians’”/ OR 
“Total Quality Management”/ OR “Delayed Diagnosis”/ OR “diagnostic accuracy”/ OR “Di-
agnostic Errors”/ OR “guideline adherence”/ OR (((clinical* OR pattern* OR current* OR 
medical*) ADJ6 practice*) OR ((current OR state) ADJ6 (practice OR care OR healthcare 
OR system* OR process*)) OR ((characterist* OR compar*) ADJ6 (service* OR proce-
dure*)) OR (region* ADJ6 differen*) OR (guideline* ADJ6 (adheren* OR complian* OR 
nonadheren* OR noncomplian* OR follow*)) OR disparit* OR disadvantag* OR (diagnos* 
ADJ6 (trend* OR improve* OR precision* OR accura*)) OR (quality ADJ3 (management* 
OR improvement*)) OR (delay* ADJ6 diagnos*) OR adequa* OR ((early OR earlier OR 
late OR later OR sooner OR timing) ADJ6 (scan OR ct OR imaging OR nonimaging )) OR 
((personal* OR patient*) ADJ6 experience*) OR Misdiagnos* OR (diagnos* ADJ3 (error*)) 
OR (false ADJ (positive* OR negative*)) OR ((national* OR nationwide* OR nation-wide* ) 
ADJ10 (audit* OR stud* OR observat* OR survey* OR questionnaire* OR association* OR 
register*)) OR ((national* OR uk OR united-kingdom OR england OR english OR scotland 
OR scottish OR wales OR welsh OR north*-ireland* OR north*-irish* OR hungar* OR 
swed* OR german*) ADJ10 (audit* OR survey* OR register*)) OR (stroke ADJ6 (register* 
OR data-bank* OR databank*)) OR routine).ab,ti.) AND (exp “Germany”/ OR “Sweden”/ 
OR “Hungary”/ OR exp “United Kingdom”/ OR (German* OR Sweden OR Swedish OR 
Hungar* OR “United Kingdom” OR uk OR great-britain OR british OR wales OR welsh OR 
england OR english OR schotland OR schottish OR north*-Ireland OR north*-Irish OR 
nhs OR national-health-service* OR london* OR Aberdeen OR Belfast OR Birmingham 
OR Bradford OR (Brighton ADJ2 Hove) OR Bristol OR (Cambridge NOT Cambridge-
University-Press) OR Canterbury OR Cardiff OR Carlisle OR Chelmsford OR Westminster 
OR Coventry OR Derby OR Derry OR Londonderry OR Dundee OR Edinburgh OR Exeter 
OR Glasgow OR Gloucester OR Kingston OR Lancaster OR Leeds OR Leicester OR Lisburn 
OR Liverpool OR Manchester OR Newcastle OR Newport OR Norwich OR Nottingham OR 
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(Oxford NOT Oxford-University-Press ) OR Peterborough OR Plymouth OR Portsmouth 
OR Preston OR Salford OR Sheffield OR Southampton OR St-Albans OR Stoke-on-Trent 
OR Sunderland OR Swansea OR Wakefield OR Winchester OR Wolverhampton OR (York 
NOT new-york) OR (berlin NOT Springer-Verlag-Berlin NOT Gruyter-Berlin ) OR  Munich 
OR  Cologne OR  Frankfurt OR  Essen OR  Dortmund OR ( Stuttgart NOT Thieme-Verlag 
) OR   Dusseldorf OR   Bremen OR   Hanover OR   Duisburg OR   Nuremberg OR   Leipzig 
OR   Dresden OR   Bochum OR   Wuppertal OR   Bielefeld OR   Bonn OR   Mannheim 
OR  Karlsruhe OR  Gelsenkirchen OR  Wiesbaden OR  Munster OR  Monchengladbach 
OR  Chemnitz OR  Augsburg OR  Braunschweig OR  Aachen OR  Krefeld OR  Halle OR  Kiel 
OR  Magdeburg OR  Oberhausen OR  Lubeck OR  Freiburg OR  Hagen OR  Erfurt OR  Kas-
sel OR  Rostock OR  Mainz OR  Hamm OR  Saarbrucken OR  Herne OR  Mulheim OR  Solin-
gen OR  Osnabruck OR  Ludwigshafen OR  Leverkusen OR  Oldenburg OR budapest OR 
Debrecen OR Miskolc OR Szeged OR Pecs OR Gyor OR Nyiregyhaza OR Kecskemet OR 
stockholm OR goteborg OR Gothenburg OR malmo OR birmingham OR Uppsala OR 
Vasteras OR Orebro ).ab,ti.)
Cochrane
((cerebrovascul*-accident* OR cva OR stroke OR ((brain OR cerebral*) NEAR/3 (ischem* 
OR ischaem* OR infarct*))):ab,ti) AND ((diagnos*)) AND ((((clinical* OR pattern* OR cur-
rent* OR medical*) NEAR/6 practice*) OR ((current OR state) NEAR/6 (practice OR care OR 
healthcare OR system* OR process*)) OR ((characterist* OR compar*) NEAR/6 (service* 
OR procedure*)) OR (region* NEAR/6 differen*) OR (guideline* NEAR/6 (adheren* OR 
complian* OR nonadheren* OR noncomplian* OR follow*)) OR disparit* OR disadvan-
tag* OR (diagnos* NEAR/6 (trend* OR improve* OR precision* OR accura*)) OR (quality 
NEAR/3 (management* OR improvement*)) OR (delay* NEAR/6 diagnos*) OR adequa* OR 
((early OR earlier OR late OR later OR sooner OR timing) NEAR/6 (scan OR ct OR imaging 
OR nonimaging )) OR ((personal* OR patient*) NEAR/6 experience*) OR Misdiagnos* OR 
(diagnos* NEAR/3 (error*)) OR (false NEXT/1 (positive* OR negative*)) OR ((national* OR 
nationwide* OR nation-wide* ) NEAR/10 (audit* OR stud* OR observat* OR survey* OR 
questionnaire* OR association* OR register*)) OR ((national* OR uk OR united-kingdom 
OR england OR english OR scotland OR scottish OR wales OR welsh OR north*-ireland* 
OR north*-irish* OR hungar* OR swed* OR german*) NEAR/10 (audit* OR survey* OR 
register*)) OR (stroke NEAR/6 (register* OR data-bank* OR databank*)) OR routine):ab,ti) 
AND ((German* OR Sweden OR Swedish OR Hungar* OR ‘United Kingdom’ OR uk OR great-
britain OR british OR wales OR welsh OR england OR english OR schotland OR schottish 
OR north*-Ireland OR north*-Irish OR nhs OR national-health-service* OR london* OR 
Aberdeen OR Belfast OR Birmingham OR Bradford OR (Brighton NEXT/2 Hove) OR Bristol 
OR (Cambridge NOT Cambridge-University-Press) OR Canterbury OR Cardiff OR Carlisle 
OR Chelmsford OR Westminster OR Coventry OR Derby OR Derry OR Londonderry OR 
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Dundee OR Edinburgh OR Exeter OR Glasgow OR Gloucester OR Kingston OR Lancaster 
OR Leeds OR Leicester OR Lisburn OR Liverpool OR Manchester OR Newcastle OR Newport 
OR Norwich OR Nottingham OR (Oxford NOT Oxford-University-Press ) OR Peterborough 
OR Plymouth OR Portsmouth OR Preston OR Salford OR Sheffield OR Southampton OR 
St-Albans OR Stoke-on-Trent OR Sunderland OR Swansea OR Wakefield OR Winchester 
OR Wolverhampton OR (York NOT new-york) OR (berlin NOT Springer-Verlag-Berlin 
NOT Gruyter-Berlin ) OR  Munich OR  Cologne OR  Frankfurt OR  Essen OR  Dortmund 
OR ( Stuttgart NOT Thieme-Verlag ) OR  Dusseldorf OR  Bremen OR  Hanover OR  Duis-
burg OR  Nuremberg OR  Leipzig OR  Dresden OR  Bochum OR  Wuppertal OR  Bielefeld 
OR  Bonn OR  Mannheim OR  Karlsruhe OR  Gelsenkirchen OR  Wiesbaden OR  Munster 
OR   Monchengladbach OR   Chemnitz OR   Augsburg OR   Braunschweig OR   Aachen 
OR  Krefeld OR  Halle OR  Kiel OR  Magdeburg OR  Oberhausen OR  Lubeck OR  Freiburg 
OR  Hagen OR  Erfurt OR  Kassel OR  Rostock OR  Mainz OR  Hamm OR  Saarbrucken 
OR  Herne OR  Mulheim OR  Solingen OR  Osnabruck OR  Ludwigshafen OR  Leverkusen 
OR  Oldenburg OR budapest OR Debrecen OR Miskolc OR Szeged OR Pecs OR Gyor OR 
Nyiregyhaza OR Kecskemet OR stockholm OR goteborg OR Gothenburg OR malmo OR 
birmingham OR Uppsala OR Vasteras OR Orebro):ab,ti)
Web of science
TS=(((cerebrovascul*-accident* OR cva OR stroke OR ((brain OR cerebral*) NEAR/2 
(ischem* OR ischaem* OR infarct*)))) AND ((diagnos*)) AND ((((clinical* OR pattern* OR 
current* OR medical*) NEAR/5 practice*) OR ((current OR state) NEAR/5 (practice OR care 
OR healthcare OR system* OR process*)) OR ((characterist* OR compar*) NEAR/5 (ser-
vice* OR procedure*)) OR (region* NEAR/5 differen*) OR (guideline* NEAR/5 (adheren* 
OR complian* OR nonadheren* OR noncomplian* OR follow*)) OR disparit* OR disadvan-
tag* OR (diagnos* NEAR/5 (trend* OR improve* OR precision* OR accura*)) OR (quality 
NEAR/2 (management* OR improvement*)) OR (delay* NEAR/5 diagnos*) OR adequa* 
OR ((early OR earlier OR late OR later OR sooner OR timing) NEAR/5 (scan OR ct OR imag-
ing OR nonimaging )) OR ((personal* OR patient*) NEAR/5 experience*) OR Misdiagnos* 
OR (diagnos* NEAR/2 (error*)) OR (false NEAR/1 (positive* OR negative*)) OR ((national* 
OR nationwide* OR nation-wide* ) NEAR/9 (audit* OR stud* OR observat* OR survey* OR 
questionnaire* OR association* OR register*)) OR ((national* OR uk OR united-kingdom 
OR england OR english OR scotland OR scottish OR wales OR welsh OR north*-ireland* 
OR north*-irish* OR hungar* OR swed* OR german*) NEAR/9 (audit* OR survey* OR 
register*)) OR (stroke NEAR/5 (register* OR data-bank* OR databank*)) OR routine)) AND 
((German* OR Sweden OR Swedish OR Hungar* OR “United Kingdom” OR uk OR great-
britain OR british OR wales OR welsh OR england OR english OR schotland OR schottish 
OR north*-Ireland OR north*-Irish OR nhs OR national-health-service* OR london* OR 
Aberdeen OR Belfast OR Birmingham OR Bradford OR (Brighton NEAR/1 Hove) OR Bristol 
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OR (Cambridge NOT Cambridge-University-Press) OR Canterbury OR Cardiff OR Carlisle 
OR Chelmsford OR Westminster OR Coventry OR Derby OR Derry OR Londonderry OR 
Dundee OR Edinburgh OR Exeter OR Glasgow OR Gloucester OR Kingston OR Lancaster 
OR Leeds OR Leicester OR Lisburn OR Liverpool OR Manchester OR Newcastle OR Newport 
OR Norwich OR Nottingham OR (Oxford NOT Oxford-University-Press ) OR Peterborough 
OR Plymouth OR Portsmouth OR Preston OR Salford OR Sheffield OR Southampton OR 
St-Albans OR Stoke-on-Trent OR Sunderland OR Swansea OR Wakefield OR Winchester 
OR Wolverhampton OR (York NOT new-york) OR (berlin NOT Springer-Verlag-Berlin 
NOT Gruyter-Berlin ) OR  Munich OR  Cologne OR  Frankfurt OR  Essen OR  Dortmund 
OR ( Stuttgart NOT Thieme-Verlag ) OR  Dusseldorf OR  Bremen OR  Hanover OR  Duis-
burg OR  Nuremberg OR  Leipzig OR  Dresden OR  Bochum OR  Wuppertal OR  Bielefeld 
OR  Bonn OR  Mannheim OR  Karlsruhe OR  Gelsenkirchen OR  Wiesbaden OR  Munster 
OR   Monchengladbach OR   Chemnitz OR   Augsburg OR   Braunschweig OR   Aachen 
OR  Krefeld OR  Halle OR  Kiel OR  Magdeburg OR  Oberhausen OR  Lubeck OR  Freiburg 
OR  Hagen OR  Erfurt OR  Kassel OR  Rostock OR  Mainz OR  Hamm OR  Saarbrucken 
OR  Herne OR  Mulheim OR  Solingen OR  Osnabruck OR  Ludwigshafen OR  Leverkusen 
OR  Oldenburg OR budapest OR Debrecen OR Miskolc OR Szeged OR Pecs OR Gyor OR 
Nyiregyhaza OR Kecskemet OR stockholm OR goteborg OR Gothenburg OR malmo OR 
birmingham OR Uppsala OR Vasteras OR Orebro)) ) AND DT=(article)
google scholar
“cerebrovascular accident”|stroke diagnosis|diagnostic “clinical|current practice”|”practice 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































What stroke image do we want? european 
survey on acute stroke imaging and 
revascularisation treatment
Anne-Claire Peultier, William K. Redekop, Diederik W.J. Dippel, 
Daniel Bereczki, Salim Si-Mohamed, Philippe C. Douek, Johan L. Severens





•	 CT	 and	 CTA	 remain	 the	 primary	 routine	modalities	 of	 the	 comprehensive	 imaging	
workup in acute stroke care in Europe.




•	 The	United	Kingdom	 respondents	 reported	particularly	 low	 rates	of	 thrombectomy	
and high rates of intravenous thrombolysis compared to Sweden and Germany.
•	 A	mismatch	was	identified	between	the	preferred	treatment	and	the	treatment	that	
Hungarian and UK-respondents actually administer to ischaemic stroke patients with 
large occlusion.
Abbreviations
ABN, Association of British Neurologists; ASPECTS, Alberta Stroke Program Early CT score; BASP, British 
Association of Stroke Physicians; CT, computed tomography; CTA computed tomography angiography; 
DWI, diffusion-weighted imaging; ESO, European Stroke Organisation; ESNR, European Society of Neuro-
radiology; IA, intra-arterial; IV, intravenous; IVT, intravenous thrombolysis; MR, magnetic resonance com-
bined; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; NRSG, Neurosonology 
Research Group; NIHSS, National Institutes of Health Stroke Scale; SPCCT, spectral photon-counting 
computed tomography; TIA transient ischemic attack
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Abstract
Introduction
The evolution of stroke treatment has been geared toward thrombolysis and thrombec-
tomy, which requires quick imaging assessment. Various imaging and treatment options 
are available and current evidence suggests European differences in stroke care. We 
aimed to describe the patterns of stroke imaging and acute revascularisation therapy 
and examine variations across countries.
Methods
A web-based clinician survey was developed and circulated to clinicians through email 
distribution lists and websites of European professional societies. Statistical analyses 
were performed.
results
We received responses from Sweden (21), the UK (16), Hungary (15), Germany (12) 
and Europe (47). Large variations are observed in revascularisation treatment: German 
respondents report that 81% of their ischaemic stroke patients diagnosed with a large 
vessel occlusion within 4.5 h receive intravenous thrombolysis and thrombectomy, com-
pared to 12% reported by the UK-respondents. For patients diagnosed with an extensive 
ischaemic stroke within 2 h from onset, 75% of UK-respondents state thrombectomy as 
their preferred revascularisation treatment, but only 13% report to use it. Computed 
Tomography (CT) is reported as the most widely used first imaging test (for 81% to 
93% of patients across geographic areas), while Magnetic Resonance Imaging (MRI) is 
a distant second.
Conclusion
The diagnostic workup and, to a greater extent, the revascularisation treatments of typi-
cal stroke patients vary considerably across European countries. This study reinforces the 
need to compare the quality of stroke care in terms of process and outcomes between 
countries. Research is also needed to investigate the cost-effectiveness of second-line 




The rapid evolution of stroke treatment over the past years has been geared toward 
thrombolysis and more recently thrombectomy, both of which have been proven highly 
effective [1]. These treatments require a quick differentiation between ischaemic and 
haemorrhagic brain damage, as well as perfusion impairment. This makes neuroimaging 
essential in the acute phase. Computed Tomography (CT) combined with CT Angiogra-
phy (CTA) or Magnetic Resonance (MR) combined with Magnetic Resonance Angiogra-
phy (MRA) form the imaging standard of diagnostic workup. However, other imaging 
technologies exist and new technologies emerge: dual energy CT and, more recently, 
spectral photon-counting CT (SPCCT) are innovative imaging tools expected to improve 
treatment decision-making in stroke in emergency settings by better quantifying brain 
perfusion impairment [2]. To assess the relative value of innovation, current clinical 
practices need to be assessed. Much of what is known about clinical practice regarding 
stroke care is based upon registry data (for instance Riksstroke in Sweden [3] and SSNAP 
in the UK [4]). As far as imaging is concerned, the SSNAP registry reports the number 
of patients scanned within certain time windows without describing the sequence of 
diagnostic modalities. Furthermore, these registries concern heterogeneous group 
of (ischaemic) stroke patients and are limited to specific countries. Evidence suggests 
differences in stroke care and outcomes within European countries [5]. The scarcity of 
and the need for international comparisons and databases have been pointed out by 
different authors, suggesting that variations in care need to be understood better. 
In this context, we developed and used an online survey aiming to describe current clini-
cal practice in acute stroke care in Europe and to examine variations between countries. 




In order to assess clinical practice in Europe regarding acute stroke care, an online 
clinician survey was developed, pilot-tested and distributed. The survey questions were 
formulated based on expert opinion and feedback collected from a European expert 
panel, which included five neurologists, two radiologists and one neuro-radiologist. A 
pilot phase was conducted before the survey was launched in October 2016. The survey 
was conducted using the online software “Google form” and was made available online. 
The target population included neurologists, stroke physicians, neurointerventionalists, 
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neuroradiologists, neurosurgeons and emergency physicians (including those complet-
ing their specialisation). Because we were interested in examining a range of healthcare 
systems, Germany, Hungary, Sweden and the United Kingdom were chosen as main tar-
get countries. Whereas Sweden is known for its early adoption of medical technologies, 
Hungary tends to be a late adopter. Besides, the UK is of major interest for its publicly 
funded system while Germany is characterised by its decentralised healthcare organisa-
tion in which private practitioners play a relatively important role. No financial incentive 
was offered to participants and survey completion was voluntary.
Structure
A closed and structured format in English was chosen to enable clinicians to select their 
responses among multiple predefined choices. An introduction provided the framework of 
the study and was followed by general questions regarding the respondents’ work setting. 
Subsequently, respondents were asked about the routine imaging workup and treatment 
used in their centre and the proportion of stroke patients receiving each of these modalities. 
Section three contained questions about the imaging modalities used to diagnose stroke 
and make therapy decisions. In sections four and five, respondents were asked about the 
treatment modalities used in acute stroke care in their centre. In section six, respondents 
were asked about the typical follow-up imaging strategy used after reperfusion therapy. We 
investigated the clinicians’ opinion towards progress in section seven and requested them 
to report the guidelines they use in section eight. The questions focused on different patient 
profiles that are summarised in Table 3.1. The survey questions can be found in supplement.
Table 3.1 Patient profiles as defined in the survey
Ca
se
Patient profile Procedure Maximum time from
symptom onset to
procedure (hours)
A Suspected of acute stroke Initial imaging for 
differential diagnosis
-*




C With minor ischaemic stroke or TIA -*
D With haemorrhagic stroke





F Male aged 65, admitted with complete aphasia, 
NIHSS score of 14. CTA at admission showed an 
occlusion of the first segment of the left middle 
cerebral artery (M1). ASPECTS score was 5. No 
contraindication for thrombolysis or thrombectomy
2
G Who received reperfusion therapy Follow-up imaging
after reperfusion
48
ASPECTS: Alberta Stroke Program Early CT score.
NIHSS: National Institutes of Health Stroke Scale.
TIA: transient ischemic attack.




The online survey link was circulated through email distribution lists and websites of na-
tional and European professional societies. Given our interest in the four different health 
care systems, the British Association of Stroke Physicians (BASP), the Hungarian Stroke 
Society and the Swedish Acute Neurology Society invited their members to participate 
in the survey through personal emails. The European Society of Neuroradiology (ESNR) 
and the Association of British Neurologists (ABN) advertised the survey to their mem-
bers via their November newsletter. The Neurosonology Research Group (NSRG) and the 
Hungarian Stroke Society encouraged their members to participate by circulating the 
survey through their website.
To boost participation, we adopted a complementary strategy and sent emails to the 
department leads of 39 Hungarian and 80 German stroke centres with the request to in-
vite their personnel to participate in the survey. In addition, we sent an email containing 
the survey link to 20 English and 37 Swedish clinicians whose contact information was 
found on the internet. Up to three reminder emails were sent to potential respondents.
Statistical analysis
Reported percentages of patients receiving imaging or treatment modalities and 
percentages of clinicians reporting to use different treatments were extracted from the 
clinicians’ responses. Mean percentages were calculated for five geographic areas: the 
four countries and the whole group of European countries (including the four countries). 
The 95% confidence intervals surrounding the mean estimates were computed using 
the percentile of the bootstrap distributions [6]. This involved randomly resampling the 
original samples with replacement 500 times, which corresponded to the number of 
replications needed to ensure stability and accuracy. Each bootstrapped sample yielded 
a bootstrap statistic (e.g. mean frequency). The bootstrap distribution was computed 
from the 500 bootstrap statistics, per geographic area. Frequencies of CT versus MRI 
usage were compared using T-tests and between- country comparisons of imaging and 
treatments were derived using one-way anova tests in SPSS (version 23).
3.3 reSulTS
We received responses from 172 clinicians. Of those respondents, 55 dropped out of the 
survey before completing 70% of the questions (up to question 14c), corresponding to a 
drop rate of 32%. Data from these 55 respondents as well as data from 6 non-European 
clinicians were taken out of the analysis. Among the 111 remaining respondents, 21 
were from Sweden, 16 from the UK, 15 from Hungary, 12 from Germany and 47 from 
69
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19 other European countries. Details about the respondents’ characteristics and work 
environment can be found in Table 3.2.
Diagnosis
First line imaging test for differential diagnosis
Non-contrast-enhanced brain CT is reported as the primary routine modality used to 
diagnose suspected stroke patients (profile A) and differentiate ischaemic from haemor-
rhagic strokes (Figure 3.1). On the basis of the responses, it is obtained for more than 
80% of the patients in each of the four different countries and Europe as a whole and 
used significantly more than MRI (p < 0.001). Hungary shows the most extreme differ-
ences between the frequency of CT usage versus MRI usage (p < 0.001).
Table 3.2 Respondent characteristics
number %





















Neurologist and stroke physician
Neurointerventionalist and neuroradiologist
Neurointerventionalist
Completing specialty in neurology















































Stroke unit 102 92
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Second line imaging tests for prognosis and treatment choice
Following the diagnosis of moderate to severe ischaemic stroke within 4 h of onset (pro-
file B), vascular imaging is reported to be routinely obtained as a second-line modality to 
evaluate the prognosis and determine the treatment choice (Figure 3.2a). According to 
the clinicians’ responses, CTA is performed in 62% of the patients in Europe, 30% of the 
patients in the UK, 58% of the patients in Hungary, 66% of the patients in Germany and 
79% of the patients in Sweden. Moreover, non-contrast-enhanced CT and CT perfusion 
play a relatively important role in this phase while MRI (DWI, Flair, T2*, T2, T1) and ultra-
sound appear to be less frequently used. Finally, MR perfusion and MRA are used for an 
average of 4% and 9% of patients across Europe, respectively (results not shown). Figure 
3.2b reports the frequencies of different imaging modalities for patients diagnosed with 
a TIA or minor stroke (profile C). It illustrates the degree of between-country heteroge-
neity and the large combinability of imaging tests used in second line. The results show 
that CTA is obtained for 53% of Swedish patients but for only 4% of English patients. 
While ultrasound is obtained for 44% of the patients in Hungary, it is used for an average 
of 22% of the patients in Europe.

































































































Similarly, CTA is routinely performed as the second imaging test, after the diagnosis of 
a haemorrhagic stroke (profi le D) (Figure 3.2c). Substantial proportions of the European 
patients also receive a brain CT (30%) or an MRI (14%). Remarkably, the German respon-
dents report to perform 48% more imaging tests than their European peers (1.52 versus 
1.03) following the initial diagnosis of a haemorrhagic stroke.
Treatment
Figure 3.3 shows the frequencies of revascularisation treatments given to ischaemic 
patients diagnosed with a large occlusion and within 4.5 h of symptom onset (profi le 
E). For these typical patients, German respondents reported to use mechanical throm-
bectomy signifi cantly more often than the UK-respondents (p = 0.017) and Hungarian 
respondents (p = 0.044). Interestingly, the UK shows the lowest rate of thrombectomy 
(19% of the patients), in favour of the highest rate of thrombolysis (80% of the patients) 
amongst the investigated geographic areas. With 73% of English patients from profi le E 
receiving it, intravenous thrombolysis (IVT) is signifi cantly more used in the UK than in 
Europe (p < 0.001), Sweden (p < 0.001) and Germany (p < 0.001).
The time window of revascularisation treatments varies substantially between and 
within countries. In Germany, while 33% of the respondents report to use mechanical 
thrombectomy up to a maximum of 6 h after symptom onset, 50% perform this treat-
ment up to 7–10 h. A similar variation can be observed in Sweden. In addition, 10% of 
the clinicians in Europe do not use thrombectomy at all and this proportion increases to 
20% and 24% in Hungary and in the UK, respectively.
figure 3.3 Proportion of patients (profi le E) receiving revascularisation treatment
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Detailed clinical case
During the survey, the respondents were asked to indicate their choice of revascularisa-
tion treatment for a typical patient belonging to profile F (see Table 3.1). The respon-
dents had to indicate both their preferred treatment and the actual treatment they 
would provide in their health centre. Most respondents in Europe overall (73%) stated 
that IVT combined with mechanical thrombectomy was the preferred treatment option; 
this was also true in each of the four countries (Figure 3.4). While the German and Swed-
ish practice tended to be aligned on this preference, wide variations were observed 
between the preferred and current options in the UK (56 percentage points), in Hungary 
(33 percentage points) and, to a lesser extent, in Europe (19 percentage points). In these 
three areas, mechanical thrombectomy was less frequently used than IVT.
follow-up imaging
The vast majority of the European clinicians (93%) responded that follow-up imaging 
was performed for all patients from profile G. After reperfusion therapy, 82% of the Eu-
ropean patients receive a follow-up CT. While MRI also plays a relatively important role in 
this clinical phase (27% of the European patients receiving it), CTA, MRA and transcranial 
doppler are less frequently used (for 9%, 19% and 11% of the patients respectively).
Confidence analysis
We calculated the uncertainty around the means presented in Figure 3.2 , 3.3 and 3.4 
(Figure 3.5). Even when we consider this uncertainty, differences shown in the previous 
figures appear to be statistically significant except regarding the instances for which 
confidence intervals overlap. 
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Summarizing the above, on the basis of the responses received, non-contrast-enhanced 
brain CT is the first-line routine imaging modality to differentiate ischaemic from haem-
orrhagic patients. Once a moderate or severe ischaemic stroke is diagnosed, vascular 
imaging (CTA) is predominantly used for acute therapeutic decisions across the investi-
gated areas. Once a TIA or minor stroke is diagnosed, a CTA and ultrasound are almost 
equally likely to be obtained as second-line test. Haemorrhagic stroke patients are likely 
to receive either a CT (brain CT or CTA) or MR (MRI or MRA) scan. The imaging workup 
for minor stroke/TIA and haemorrhagic stroke patients tends to be less harmonised 
than for severe strokes across the areas. A substantial proportion of patients receives 
a comprehensive imaging work-up which includes a combination of imaging tests. 
Finally, non-contrast-enhanced brain CT remains the routine follow-up modality after 
revascularisation treatment of ischaemic stroke.
3.4 DISCuSSIOn
To the best of our knowledge, this study presents the first online survey aiming to de-
scribe current clinical practice in acute stroke care in Europe and to examine potential 
variations between countries.
Main findings
This survey revealed that variation in acute stroke care is limited regarding the first line 
imaging test (differential diagnosis) but increases at later stages of the imaging workup 
and in the choice of treatment. CT is the mainstay of the stroke imaging workup in the 
initial phase and this observation holds in later phases of acute care. This finding is pre-
sumably seen because access to CT is more rapid and requires less organisation, logistics 
and resources than access to MRI and is consistent with previous studies [7]. Whether 
the widespread use of CT is the most effective way of dealing with stroke patients is a 
legitimate question. Interestingly, clinicians reported that not all their patients are im-
aged with CT despite its wide availability.
Besides, our study shows that a comprehensive imaging workup is used in stroke care 
which includes a combination of vascular (CTA and MRA), core (brain CT and MRI) and 
penumbra imaging (CT and MR perfusion). However, our results suggest that stroke im-
aging is less frequently used in Hungary and the UK compared to Germany, Sweden and 
the rest of Europe. German clinicians appear to image their patients substantially more 
often than their European peers do, both during the second-line imaging phase and 
during the follow-up imaging phase. Ideally, the diagnostic accuracy or prognostic value 
of an imaging modality should determine its use in clinical practice. However, recent 
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evidence suggests that within 6 h from symptom onset, perfusion imaging does not 
help in identifying patients who will not benefit from endovascular treatment [8]. This 
suggests that the imaging workup used by many clinicians in stroke care is not optimal 
for treatment decisions.
In addition to finding variations in the imaging workup between countries, we also 
found variations in the choice of revascularisation treatment for ischaemic patients. The 
main factor of between-country practice variation is related to thrombectomy among 
the severe stroke patients receiving treatment within 4.5 h of symptom onset: the low-
est rates are reported in the UK and the highest in Germany. This observation shows 
that European stroke guidelines are unequally implemented across countries. Indeed, 
the European Stroke Organisation (ESO) and three other European associations have 
recommended mechanical thrombectomy, in addition to IVT, to treat stroke patients 
with large artery occlusions in the anterior circulation, up to 6 hours after symptom 
onset [9]. Furthermore, they have recommended mechanical thrombectomy as first-line 
treatment in large vessel occlusions when IVT is contraindicated. Interestingly, the re-
sults of the SSNAP national stroke audit performed in the UK were released in December 
2016 [4]. According to these results, only 18% of the patients have access to mechanical 
thrombectomy on-site, 50% of them can access the treatment by referral to another site 
and 32% do not have access to it at all. Our survey results are consistent with these find-
ings. Their audit reports that only 83 consultants perform thrombectomies and mentions 
that the service is only available during the week (not in the weekend). Logistical and 
workforce issues are pointed out as causes for the limited availability of this procedure 
[10]. Further research would be needed to identify barriers to thrombectomy.
The mismatch we identified between the clinicians’ preferred treatment and the treat-
ment they actually administer might be explained by the fact that thrombectomy is not 
sufficiently available, especially in the UK and Hungary. Furthermore, the maximum time 
window applied to perform revascularisation treatment is not harmonised among clini-
cians. Although treatment has been proven beneficial within a certain amount of time 
from the onset (for instance within 4.5 h for IVT [11]), large practice variations are seen, 
both within and between countries.
This paper adds to the existing literature in two ways. First, it informs about the diagnos-
tic and treatment workup for specific groups of stroke patients and, as such, provides a 
different level of information compared to registries that focus on the whole group of 
(ischaemic) stroke patients. Second, it provides insight into the diagnostic and treat-
ment pathway for stroke care in Germany and Hungary. In these two countries, no (or 
only very limited) information related to stroke care is publicly available.
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3.5 lIMITATIOnS
As a limitation to our study, we acknowledge that a limited number of responses was 
received. Our survey faced the inherent disadvantage of any survey, which is the chal-
lenge to reach respondents. Since most of the professional associations advertised the 
survey on their website or via their newsletter, we assume that only a few clinicians 
actually found the survey link and were given the opportunity to fill in the web-based 
questionnaire. Generalizability might be limited by survey-typical selection bias and 
further research is needed to confirm and generalise our findings. Yet, our results 
appeared to be statistically significant and consistent with previous findings and the 
survey method allowed to explore current stroke imaging practices in details. To the 
best of our knowledge, this is the first study to provide that level of insight in European 
stroke imaging practices and thus makes an important contribution to the literature.
3.6 COnCluSIOn
The diagnostic workup and, to an even greater extent, the revascularisation treatments 
of typical stroke patients vary considerably across European countries. However, CT 
and CTA remain the primary routine modalities of the comprehensive imaging workup. 
Further research is needed to identify the causes for the variations seen in our study, 
the barriers to treatment and to compare the quality of stroke care between and within 
countries in terms of both process and outcomes. Further consideration should also be 
given to investigate the most cost-effective second-line imaging workup to diagnose 
stroke patients. This knowledge may be used as input in evaluations comparing the 
potential added value of new imaging modalities with the ones currently used in clinical 
practice.
ethical approval
No financial incentive was offered to participants and survey completion was voluntary. 
Completion of the survey by participants was established as a means of consent to 
participate. We received an approval by the board of the Medical Ethics Committee from 
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SuPPleMenTAl MATerIAl




Q1a: In what COUNTRY is your health centre located?
Q2: In what CITY is your health centre located?
Q3: What is your exact function?
Q4: When did you or will you complete your main specialty?
Q5: What is the teaching category of your health centre?
Q6: Is your health centre publicly or privately funded?
Q7a: How many ISCHEMIC DIAGNOSED STROKE PATIENTS does your health centre receive annually?
Q7b: How many HEMORRHAGIC DIAGNOSED STROKE PATIENTS does your health centre receive annually?
Q8: Is there a stroke unit in your health centre?
Q9a: WHAT IMAGING TECHNIQUES are available for use in the emergency department of your main 
health centre for all acute cares and WHEN are they available?
Q9b: If you marked ‘’other imaging test(s)’’ in the previous question, please describe the modality used.
IMAgIng MODAlITIeS
Q10a: Among all suspected stroke patients in your health centre, what is the imaging modality used to 
establish the DIFFERENTIAL DIAGNOSIS of ischemic versus hemorrhagic stroke? For each imaging modal-
ity used, please indicate the proportion of the patients that undergo that modality.
Q10b: If you marked ‘’other imaging test(s)’’ in the previous question, please describe the modalities used.
Q11a: In your health center, when a patient is diagnosed with a MODERATE TO SEVERE ISCHEMIC STROKE 
based on the first imaging test and within 4 hours of onset, for what proportion of patients do you 
use the following second imaging test(s) for the ACUTE THERAPEUTIC DECISION MAKING? (more than 1 
answer is possible).
Q11b: If you marked ‘’other imaging test’’ in the previous question, please describe the modality used.
Q12a: In your health center, when a patient is diagnosed with a MINOR ISCHEMIC STROKE OR TIA based 
on the first imaging test, for what proportion of patients do you use the following second imaging test(s) 
for the ACUTE THERAPEUTIC DECISION MAKING? (more than 1 answer is possible).
Q12b: If you marked ‘’other imaging test’’ in the previous question, please describe the modality used.
Q13a: In your health center, when a patient is diagnosed with a HEMORRHAGIC STROKE based on the 
first imaging test, for what proportion of patients do you use the following second imaging test(s) for the 
ACUTE THERAPEUTIC DECISION MAKING? (more than 1 answer is possible).




Q14a: For patients diagnosed with an ISCHEMIC STROKE AND A LARGE OCCLUSION, within 4.5 hours 
from symptom onset, what revascularization treatment method(s) do you choose and for what propor-
tion of patients? (more than 1 answer is possible).
Q14b: What is your maximum time window of revascularization treatment for the following options? 
(Please fill in at least the 5 first rows)
Q14c: If you marked ‘’other treatment(s)” in one of the 2 previous questions, please describe the modality 
used.
TreATMenT - ClInICAl CASe
A 65-year-old male patient presenting with a suspected stroke was admitted with COMPLETE APHASIA 
and with a NIHSS* score at 14.
A computed tomography (CT) angiogram scan performed at admission showed that a M1 segment of 
the left middle cerebral artery was occluded and the patient’s ASPECTS** score was 5.
There was no contraindication of thrombolysis or thrombectomy.
*National Institutes of Health Stroke Scale ‘’NIHSS’’ is a 15-item neurologic examination stroke scale used 
to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, 
visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. An observer 
rates the patent’s ability to answer questions and perform activities. Ratings for each item are scored 
with 3 to 5 grades with 0 as normal while a higher score is indicative of some level of impairment. The 
maximum recordable NIHSS score is 42. NIH Stroke scores > 22 are considered very significant and may 
predict increased complication risk.
**Alberta Stroke Program Early CT Score ‘’ASPECTS’’ is a 10-point quantitative topographic CT scan score. 
A normal CT scan receives ASPECTS of 10 points. A score of 0 indicates diffuse involvement throughout 
the middle cerebral artery territory. 1 point is deducted from the initial score of 10 for every region 
involved. A sharp increase in dependence and death occurs with a score of 7 or less.
Q15a: For this specific case, what would be your PREFERRED treatment at 2 hours from symptom onset? 
(Please note, thrombectomy may remain your preferred treatment option even if no neurosurgeon is 
available in your health centre)
Q15b: For this specific case, what would be the treatment GIVEN in your health centre at 2 hours from 
symptom onset?
fOllOW-uP IMAgIng
Q16: Do you routinely perform follow-up imaging after reperfusion therapy and within the 48 hour 
window after symptom onset?
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yOur OPInIOn On PrOgreSS
Q18a: In your opinion, which are the main clinical stages where progress in imaging capabilities could 
improve the clinical practice, improve patient outcomes or decrease healthcare costs? Please prioritize 
(1: most important stage, 3: least important phase)
Q18b: If you wish, please clarify your answer here.
guIDelIneS
Q19: What guidelines do you use as a reference? (more than one answer is possible)
Interested in the SPCCT research project?
Q20: Are you interested in receiving the results of the survey and/or participating in a subsequent phase 
of the SPCCT research project?
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In the United Kingdom, mechanical thrombectomy (MT) for acute ischemic stroke patients 
assessed beyond 6 hours from symptom onset will be commissioned up to 12 hours pro-
vided that advanced imaging (AdvImg) demonstrates salvageable brain tissue. While the 
accuracy of AdvImg differs across technologies, evidence is limited regarding the propor-
tion of patients who would benefit from late MT. We compared the cost-effectiveness of 
2 care pathways: (1) MT within and beyond 6 hours based on AdvImg selection versus (2) 
MT only within 6 hours based on conventional imaging selection. The impact of varying 
AdvImg accuracy and prior probability for acute ischemic stroke patients to benefit from 
late MT was assessed.
Methods
A decision tree and a Markov trace were developed. A hypothetical United Kingdom 
cohort of suspected stroke patients aged 71 years with first event was modeled. Costs, 
health outcomes, and probabilities were obtained from the literature. Outcomes 
included costs, life years (LYs), quality-adjusted life years (QALYs), and incremental cost-
effectiveness ratios. Probabilistic sensitivity analyses were performed. Various scenarios 
with prior probabilities of 10%, 20%, and 30%, respectively, for acute ischemic stroke 
patients to benefit from late MT, and with perfect accuracy, 80% sensitivity, and 70% 
specificity of AdvImg were studied.
results
Incremental cost-effectiveness ratios resulting from our deterministic analyses varied 
from $8199 (£6164) to $49 515 (£37 229) per QALY gained. AdvImg accuracy impacted 
the incremental cost-effectiveness ratio only when its specificity decreased. Over lifetime 
horizons, all scenarios including late MT improved QALYs and LYs. Depending on the sce-
nario, the probabilistic sensitivity analyses showed probabilities varying between 46% 
and 93% for the late MT pathway to be cost-effective at a willingness to pay threshold of 
$39 900 (£30 000) per QALY.
Conclusions
Late MT based on AdvImg selection may be good value for money. However, additional 
data regarding the implementation of AdvImg and prior probability to benefit from late 
MT are needed before its cost-effectiveness can be fully assessed.
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4.1 InTrODuCTIOn
Recently, 2 prospective randomized control trials demonstrated superior health benefits 
of mechanical thrombectomy (MT) beyond 6 hours from symptom onset (late MT) plus 
standard medical care versus standard medical care alone in acute ischemic stroke (AIS) 
patients. Patient selection was based on advanced imaging (AdvImg), namely perfusion 
imaging with computed tomography (CT) or magnetic resonance [1,2]. As new evidence 
emerged, policymakers updated their recommendations and the National Health 
Service (NHS) England issued a document in March 2018 announcing that MT would 
be routinely commissioned provided it can be achieved within 6 hours of the onset of 
stroke [3]. Furthermore, NHS England will commission MT until 12 hours where AdvImg 
indicates substantial salvageable brain tissue [3].
In the vast majority of the randomized clinical trials establishing the benefit of MT in 
AIS patients, CT followed by CT angiography (CTA) were the imaging modalities used 
to assess the brain tissue and intracranial vessels [4]. In the United Kingdom (UK), as in 
western countries, the standard diagnostic imaging workup in centers performing MT 
within 6 hours since stroke onset closely matches the imaging techniques used in these 
clinical trials [5,6]. AdvImg, by allowing brain perfusion assessment, can more accurately 
assess the volumes of the infarct core and, above all, salvageable brain tissue (penum-
bra). It is, therefore, expected to better identify AIS patients with large vessel occlusion 
who will benefit from late MT in clinical practice. The accuracy of imaging differs across 
technologies or remains unknown for devices under development. In addition, evidence 
is limited regarding the proportion of patients who would benefit from late MT [7,8]. In 
fact, this proportion is influenced by the different inclusion criteria used in trials. Since 
the availability of AdvImg is expected to influence future care of AIS patients, the aim 
of this study was to explore the cost-effectiveness of 2 care pathways or strategies for 
patients presenting with a suspected stroke in the UK: (1) MT within and beyond 6 hours, 
up to 24 hours, based on AdvImg selection versus (2) MT only within 6 hours based on 
conventional imaging selection (ie, CT and CTA). We also assessed the impact of jointly 
varying the AdvImg accuracy and the prior probability for AIS patients to benefit from 
late MT.
4.2 MeTHODS




general Description of the Study Methodology
The formal steps of modeling were followed with conceptualizing, scoping, structuring, 
populating, analyzing, and addressing uncertainty [9,10]. A decision-analytic model 
was designed in Microsoft Excel to analyze and compare the cost-effectiveness of 2 
care pathways for the population of suspected stroke patients: (1) allowing MT within 
and beyond 6 hours, up to 24 hours, from symptom onset based on AdvImg selection 
versus (2) MT only within 6 hours from onset and based on conventional imaging 
selection with CT and CTA. The first care pathway will be referred to as AdvImg with 
early and late MT (AIELMT), whereas the second one will be referred to as CT-CTA with 
early MT (CCEMT). We also assessed the impact of jointly varying the AdvImg accuracy 
and the prior probability for AIS patients to benefit from late MT. The CCEMT pathway 
represented the standard UK pathway of the past few years: suspected stroke patients 
receive a CT and CTA systematically precedes MT. AIS patients whose onset is beyond 
6 hours or unknown after CT assessment (ie, not receiving MT) will not receive CTA. 
The remainder of the AIS patients not receiving MT may, or not, have been assessed 
by CTA. The 2 care pathways were compared based on their respective diagnostic and 
subsequent treatment options. In addition to the treatments that were explicitly mod-
eled (IV-tPA [intravenous tissue-type plasminogen activator] and MT), we assumed that 
patients received standard medical care (including antiplatelet therapy, blood pressure 
management, complication prevention, and rehabilitation).
A hypothetical UK cohort of suspected stroke patients aged 71 years with a first-ever 
stroke was modeled. A literature search was performed to populate the input parameters, 
and clinical experts were consulted to ascertain some of them. Using 2 time-horizons of, 
respectively, 3 months and lifetime, costs, quality-adjusted life years (QALYs), and life 
years (LY) were calculated for each care pathway. Costs and effects were discounted at 




A short-run decision tree model (Figure 4.1A) was built to predict the costs and clinical 
outcomes at 90 days after the first suspected stroke. A hypothetical cohort of initially 
independent patients (ie, with a modified Rankin Scale [mRS] of 0–2) was distributed at 
90 days into 1 of 4 possible subgroups, as follows: recovered (mRS 0), independent (mRS 
1 or 2), dependent (mRS 3, 4, or 5) and dead (mRS 6). Treatment effects were assumed 
to occur during the acute phase. From the initial cohort of suspected stroke patients, 
hemorrhagic stroke patients, and nonstroke patients (tumors, other conditions) were 
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assumed to have the same health outcomes in the CCEMT strategy as in the AIELMT 
strategy and were, therefore, not modeled in detail. Furthermore, we assumed that 
AdvImg performs as good as unenhanced CT in diagnosing hemorrhagic strokes and 
equal or better than CT+CTA in identifying nonstrokes. Clinical judgment was assumed 
to complement CT and AdvImg. The probabilities for a patient to end up in each group 
(ie, recovered [mRS 0], independent [mRS 1 or 2], dependent [mRS 3, 4, or 5], or dead 
[mRS 6]) at 90 days were calculated using data provided by trials and registries. We ap-
plied the probabilities reported in Table I in the Data Supplement.
Markov Model
Data from the short-run model related to AIS patients fed into a long-run Markov state-
transition model (Figure 4.1B) built to predict, from initial diagnosis, the lifetime costs, 
and outcomes. The model was based on 3-month cycles and ran until all patients died 
to reflect a lifetime time horizon (150 cycles appeared adequate for this purpose). Given 
the data available, patients in mRS 0 and mRS 1–2 were grouped together in mRS 0–2 in 
the Markov model. It was assumed that patients in mRS 0–2 and mRS 3–5 could move 
between these states only during the first year, due to deterioration or rehabilitation. 
Patients experiencing a recurrent stroke could either maintain the status they were in 
before recurrence or deteriorate. Previous studies indicated that dependent patients 
(mRS 3–5) have increased mortality compared to independent patients (mRS 0–2) 
[11,12]. We used a 1.29 hazard ratio for mRS 0–2 and a 3.33 hazard ratio for mRS 3–5 
compared with UK population averages (see Table II in the Data Supplement). We used 
UK life tables for age- and sex-adjusted all-cause mortality rates applying from year 2 
onwards. As the life table data from the UK were truncated at 100 years, the mortality 
starting at 101 years was kept constant and equal to the mortality at 100 years.
Patients experiencing a recurrent stroke were managed based on the same strategy 
as during their initial stroke. If an independent patient experienced a recurrent stroke, 
the probabilities of remaining in mRS 0–2, moving to mRS 3–5, or dying were the same 
as the probabilities after the initial stroke. However, a dependent patient experiencing 
recurrent stroke could only remain in the dependent state or die. Furthermore, the prob-
ability of an individual in the dependent state to die from recurrent stroke was assumed 
to be the same as that of an independent patient experiencing recurrent stroke. Based 
on previous studies, the risk of recurrence was assumed to be equal for mRS 0–2 and 
mRS 3–5 [13,14]. A maximum of 1 recurrent stroke per patient per 3-month cycle was 
assumed. The transition probabilities can be found in Table I in the Data Supplement.
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figure 4.1 Structure of the decision tree model and Markov model. A, Decision tree model representing the 
diagnostic, acute treatment and outcomes at 90 d after initial stroke. B, Markov model reflecting long-term 
expectations for post-initial stroke patients.
A
B
AdvImg indicates advanced imaging; AIELMT, AdvImg with early and late MT; CCEMT, CT-CTA with early MT; 
CT, computed tomography; CTA, CT angiography; FN, false negative; FP, false positive; IV-tPA, intravenous 
tissue-type plasminogen activator; mRS, modified Rankin Scale; MT, mechanical thrombectomy; TN, true 
negative; and TP, true positive.
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Modeling AdvImg Accuracy in the AIelMT Strategy
Late MT after 6 hours from onset was only possible if it was indicated by AdvImg; 
therefore, only patients in the AIELMT strategy could undergo late MT. The choice was 
made to model late MT for AIS patients who did not receive IV-tPA previously (see Figure 
4.1A). In the decision tree, the value of similar input parameters in the 2 strategies was 
kept equal, except for parameters related to MT beyond 6 hours. As such, AdvImg was 
assumed to have the same accuracy as CT+CTA to refer patients to MT until 6 hours from 
onset, and the model was structured to investigate the difference in effects and costs 
driven by performing late MT (AIELMT path) versus no late MT (CCEMT path). For this 
reason, the uncertainty regarding the benefits of MT was explicitly modeled only after 
6 hours from onset. The accuracy of AdvImg beyond 6 hours was varied (see section 
about simulated scenarios). Health outcomes of late MT at 90 days (AIELMT strategy) 
were stratified according to the ability of AdvImg to correctly identify AIS patients for 
late MT. Outcomes were simulated for true positive, false positive, false negative, and 
true negative patients (Table III in the Data Supplement). Outcomes for false positive 
patients were based on the outcomes for true negative patients but corrected for the 
risk of procedural complications [15]. It was assumed that all false positive AIS patients, 
irrespective of the stroke severity, had an equal mortality risk due to complications (see 
Table IVa and IVb in the Data Supplement).
Costs and resource use
All costs were calculated in British pounds (£) for the year 2018 and presented in US$ us-
ing an exchange rate of £1=US$1.33. Costs originating from previous years were inflated 
based upon the pay and price index for Hospital and Community Health Services for 
2017 [16]. The inflation factor from 2016 to 2017 (1.018) was used to inflate costs to 
2018. Costs and resource used in the model are presented in Table I in the Data Supple-
ment. The imaging cost of identifying the nonischemic stroke patients (nonstroke and 
hemorrhage) was computed to account for the cost difference between the diagnosis 
by CT-CTA and AdvImg (Figure 4.1A). The cost of IV-tPA consists of drug acquisition and 
drug administration. Details about the calculations can be found in Table Va and Vb in 
the Data Supplement. Based on clinical expert review, the cost of MT was sourced from a 
microcosting study and inflated to 2018 [14]. The mean acute costs incurred during the 
first 90 days after AIS and the mean 3-monthly long-term healthcare costs were found 
to be specific to the severity of the outcome (mRS) in the literature. These costs included 
nurse visits, general practitioner visits, emergency care, outpatient visits, day cases, and 
hospitalizations. CT costs were deducted from the costs of the first 3 months since the 
found estimates already included initial diagnostic tests for a suspected stroke. The cost 
of a recurrent stroke, including the cost of the 3 following months, was based upon the 
findings of the short-run model and was assumed to be specific to either the CCEMT 
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strategy or AIELMT strategy. Therefore, it represents the deterministic estimate of the 
cost to identify and treat an average ischemic stroke according to the care pathways 
defined in the decision tree. Costs incurred in the future were assumed to be similar to 
those incurred in the present and the first 3 months following a recurrent stroke to be 
equally costly as the 90 days following the initial stroke.
utilities/Quality of life
Utilities were assigned to each of the 3 possible health states of the mRS based on a 
study by Wardlaw et al who performed a review of utilities used in previous economic 
evaluations [17]. Utility values ranged from 0.71 for mRS 0–2 to 0.20 for mRS 3–5 to 0 for 
mRS 6. The utility of a recurrent ischemic stroke was derived from the short-run model 
and, therefore, assumed to be specific to the CCEMT strategy and AIELMT strategy. Utili-
ties were varied according to a beta distribution (see Table I in the Data Supplement).
Simulated Scenarios
In line with the principles of economic evaluations of diagnostic technologies, we ran 
scenario analyses on 2 important parameters, test accuracy, and prior probability to 
benefit from late MT, to assess their impact on the cost-effectiveness of the AIELMT 
strategy. Because evidence regarding the effectiveness of late MT is lacking due to the 
experimental nature of the indication, we simulated different proportions of patients 
potentially benefitting from an intervention beyond 6 hours from onset. As such, 3 
scenarios were simulated in which the prior probability of benefitting from MT (before 
AdvImg information is obtained) was varied from 10% to 20% and 30% (Table). The prior 
probability was defined as the probability for an AIS patient imaged beyond 6 hours 
after onset to benefit from late MT. In the CCEMT path, patients with an onset above 6 
hours (therefore not receiving MT) were split between those who would theoretically 
benefit from late MT and those who would not, based on the prior probability. Patients 
in the AIELMT strategy were, in theory, referred to late MT according to the AdvImg 
preprocedural findings. CT perfusion is the most commonly used AdvImg technique in 
the diagnosis of AIS patients. Its accuracy was reported mainly when image acquisition 
occurred within the 6-hour window from onset with a mean sensitivity of 80% and a 
mean specificity of 95% [18]. We assumed that the sensitivity of AdvImg beyond 6 hours 
would not go below the sensitivity reported for testing within 6 hours and used 80% 
as the minimal value in our scenario analysis. Specificity was tested for its impact on 
the cost-effectiveness results and was set to a minimum value of 70%. Therefore, we 
simulated a perfect AdvImg test (sensitivity=specificity=100%), a test with reduced 
sensitivity to 80% (and 100% specificity) and a test with reduced specificity to 70% (and 
100% sensitivity). The probability to be referred to late MT based on AdvImg, therefore, 
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varied according to 9 scenarios based on the pairwise combination of prior probability 
and accuracy of imaging (Table 4.1).
Sensitivity Analysis
A probabilistic sensitivity analysis (PSA) was performed to assess the impact of the 
uncertainty around the input parameter values. This was implemented by assigning a 
distribution to each parameter to represent the uncertainty around its mean value. A 
random value was sampled from each distribution, and the results were calculated using 
the set of sampled values. This process was repeated in 3000 simulations per scenario 
to generate 3000 estimates of the costs, QALYs, and LY in each scenario of each strategy. 
This number of simulations matched the number needed to obtain stable estimates. The 
proportion of simulations when the AIELMT path had the highest net monetary benefit 
was calculated for a range of values of the willingness to pay for a QALY. The results 
were presented with cost-effectiveness acceptability curves. Each curve represented 
the probability that the AIELMT strategy was cost-effective compared with the CCEMT 
strategy at different thresholds for cost-effectiveness.
Table 4.1 Parameters for the 9 scenario analyses based on pairwise variation of prior probability and Ad-
vImg accuracy























AdvImg test with a sensitivity of 80%  
















AdvImg test with a sensitivity of 100%  





















At 90 days after the initial AIS, most AIELMT scenarios (1, 2, 3, 4, 5, 6, 7, and 8) increased 
the proportions of fully recovered patients, decreased mortality, and generally improved 
outcomes on the mRS scale, compared with the CCEMT strategy. Scenario 9 (sensitivity 
100%; specificity 70%) increased mortality (because of MT-related mortality risk in false 
positive patients) at 90 days but still increased QALYs. The distribution of AIS patients 
across the mRS scale at 90 days was used as the starting point in the Markov model and 
can be found in Table VI in the Data Supplement.
At lifetime horizon, in the 9 scenarios, the AIELMT strategy was associated with a health 
gain, ranging from 0.09 to 0.45 QALYs, per AIS patient. It was also associated with a higher 
cost per AIS patient, ranging from $1051 (£790) to $5932 (£4460) (Table VII in the Data 
Supplement). QALYs and LYs are higher in the AIELMT path as this strategy saves lives 
and improves health outcomes on the mRS scale compared with the CCEMT strategy. 
The incremental long-term costs were induced by the cost of MT and the longer survival 
of patients in the AIELMT strategy. A higher prior probability of benefitting from late MT 
led to higher additional costs and more QALYs in the AIELMT strategy.
Based on a lifetime horizon, there is a similar linear relationship between the incremen-
tal costs and incremental QALYs in the 6 scenarios of the perfect test and the reduced 
sensitivity test (Figure 4.2A). Although incremental costs and incremental QALYs 
increase as the prior probability increases, the incremental cost-effectiveness ratios (at 
different prior probabilities) for the perfect test and the reduced sensitivity test remain 
almost equal. In the reduced specificity scenario, when increasing the prior probability, 
incremental effects are increasing faster than incremental costs, which results in a lower 
lifetime incremental cost-effectiveness ratio (cost per QALY gained) as the prior prob-
ability rises ($49 515 [£37 229] at 10%, $21 156 [£15 906] at 20%, and $14 765 [£11 101] 
at 30%; Figure 4.2B). In the reduced specificity scenario, when the prior probability 
increases, smaller impacts are observed on costs, as the frequency of false positive goes 
down. Details about the incremental cost-effectiveness ratios at 90 days and lifetime 
related to both the LYs and QALYs can be found in Table VIII in the Data Supplement.
Probabilistic sensitivity analyses confirmed that the higher the prior probability, the 
higher the cost difference and the effect difference between the 2 care pathways, with 
increased costs and effects observed in the AIELMT strategy (Figure 4.3A). Furthermore, 
at a constant prior probability, the cost difference increased in the case of the decreased 
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The cost-effectiveness acceptability curves for the AIELMT strategy show that, at a 
willingness to pay of $39 900 (£30 000), the probability of being cost-effective was 
above 46% in the 9 scenarios (Figure 4.3C). With reduced specificity, the probability of 
the AIELMT strategy to be cost-effective at low willingness to pay thresholds dropped 
substantially.
figure 4.2 Lifetime results for the 9 scenarios. A, Cost and quality-adjusted life year (QALY) differences 
between computed tomography (CT)–CT angiography with early mechanical thrombectomy (CCEMT) and 
advanced imaging with early and late MT (AIELMT) strategy for the 9 scenarios. % refers to the prior prob-
ability to benefit from late MT. B, Incremental cost-effectiveness ratio (ICER) at lifetime time horizon for 
different levels of advanced imaging accuracy.
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Our main finding is that AdvImg, by extending the time window beyond 6 hours (up to 
24 hours) for MT, improves health outcomes but increases costs when compared with 
conventional imaging (CT+CTA) coupled to MT up to only 6 hours from symptom onset. 
Incremental cost-effectiveness ratios resulting from our deterministic analyses varied 
from $8199 (£6164) to $49 515 (£37 229) per QALY gained. This study suggests that late 
MT based on AdvImg selection is cost-effective in the UK. However, at a willingness to 
pay threshold of $39 900 (£30 000), the probability of an AIELMT strategy to be cost-
effective varies widely across scenarios.
Since the evidence regarding the probability to benefit from late MT based on AdvImg 
criteria is limited, extensive scenario and uncertainty analyses were performed. These 
analyses showed that reduced specificity of AdvImg reduces the cost-effectiveness. 
However, the magnitude of this impact decreases as the prior probability for AIS patients 
to benefit from late MT increases. These findings suggest that advanced neuroimaging 
should focus on excluding patients without sufficient salvageable tissue to avoid unnec-
essary interventions and make the benefit of (late) MT worth the considerable resource 
utilization.
Compared with previous economic studies that assessed the value of MT after IV-tPA ver-
sus IV-tPA alone, our study presents comprehensive results about the cost-effectiveness 
of an integrative UK care pathway that combines AdvImg and all possible subsequent 
early and late acute treatments [14,19,20,21]. Despite methodological differences, our 
results on the value of late MT are consistent with the results published by Pizzo et al. 
who demonstrated that MT performed between 6 and 24 hours after onset is cost-
effective in the UK [19]. To the best of our knowledge, our study is the first to explore 
the combined impact of uncertainty from imaging accuracy and prior probability on the 
cost-effectiveness of late MT.
Our results may have important policy implications. Commissioning criteria for late MT 
by NHS England are based on the identification of substantial salvageable brain tissue 
up to 12 hours after onset by perfusion or multiphase CTA [3]. Strong evidence about the 
accuracy of these imaging techniques for late MT referral is crucial to ascertain whether 
the NHS policy commissions a cost-effective practice. As shown above, a decreased 
specificity might considerably lower the probability for an AIELMT strategy to be cost-
effective. Strong evidence also implies the assessment of technology-specific preproce-
dural findings in terms of their ability to predict clinical outcomes. Quantification of the 
amount of salvageable brain tissue required before neurointervention and definition 
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of the target in terms of clinical outcomes per patient might be needed to clarify the 
commissioning policy. Once this is clear, the AIELMT pathway may be implemented.
Implementation of the AIELMT pathway will have considerable consequences for the 
NHS in terms of number of patients treated and costs. From April 2016 to March 2017, 
85 122 cases of strokes were reported in the UK, Wales, and Northern Ireland [22]. As-
suming that 85% of those were ischemic, we estimated about 72 350 AIS patients [3]. 
According to the probabilities used in our model, 76% of these patients (about 55 000) 
were imaged beyond 4.5 hours, and 97% of the latter (about 53 350) were imaged be-
yond 6 hours from onset. Applying a prior probability of 20%, a decreased sensitivity of 
80%, and a perfect specificity, about 8500 of these patients would receive MT, should 
the infrastructure and manpower allow this capacity. Compared with data on recent 
care (2016–2017), in which 580 MT were performed, the incremental budget impact of 
performing AdvImg and late MT would be around $93 (£70) million [22].
However, providing widely accessible AdvImg is likely to be an organizational challenge 
for the NHS, for 2 reasons. First, AdvImg would probably be available only at compre-
hensive stroke centers. Assuming that around 25% of stroke patients would be directly 
attending a comprehensive center (providing MT) and 75% first attending a local acute 
stroke unit (providing IV-tPA only), a major question arises on how to handle the stroke 
patients at local units providing only CT and CTA and whether to transfer them to a com-
prehensive center [23]. Second, there is currently no emergency transfer infrastructure 
supporting a system based on widely accessible AdvImg and MT. So, probably more re-
alistically, only those directly attending a comprehensive stroke center will have access 
to AdvImg and late MT. This illustrates the challenge of embedding new technologies 
in the existing healthcare system and the need for the organization of stroke care to 
evolve. In that respect, the optimal ratio of comprehensive stroke centers versus local 
acute stroke units should be determined.
We acknowledge limitations in our study. First, our model combines treatment out-
comes per time since onset from different studies investigating slightly different AIS 
populations. Given the model structure, it was impossible to use inputs based on one 
single comprehensive source of treatment outcomes. To overcome this limitation, 
comprehensive real-world data are needed, especially regarding the first 3 months 
after AIS onset. However, since this limitation influences equally, the 2 strategies of our 
comparison, the incremental results of our model are not affected. More importantly, 
the outcomes of the DAWN trial (Diffusion Weighted Imaging or Computerized Tomog-
raphy Perfusion Assessment With Clinical Mismatch in the Triage of Wake Up and Late 
Presenting Strokes Undergoing Neurointervention With Trevo) were used, that included 
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5% of patients who received IV-tPA in the intervention arm and 13% in the control arm. 
This contrast slightly influences our incremental results by underestimating the value 
of the AIELMT pathway. Second, we conservatively assumed no difference between the 
AdvImg and CT-CTA strategies regarding the ability to detect stroke mimics. Inclusion of 
an improved ability by AdvImg to detect stroke mimics would have resulted in a more 
favorable estimated cost-effectiveness. Third, although we used the best available cost 
data for generalizability, these were based on a patient population presenting with a 
history of atrial fibrillation [24].
We explored the value of AdvImg for late MT. Beyond our investigation, crucial research 
questions remain to assess the comprehensive value of AdvImg and how it could im-
prove the early stroke care pathway. First, with a single image acquisition, AdvImg might 
save time and diagnose more patients within the 4.5- and 6-hour window, compared 
with CT+CTA and, in turn, refer more patients to treatment. Second, AdvImg might offer 
increased accuracy within the 6-hour window compared with the currently used imag-
ing techniques. Since the accuracy of AdvImg in AIS is specific to the lesion type and 
size, to the location of the lesion in the brain, and to the time since onset, assessing the 
full value of AdvImg along the stroke care pathway is challenging. Third, further clinical 
research regarding the percentage of patients likely to benefit from late MT is needed to 
optimize the stroke care pathway in the UK.
Finally, although US dollar equivalents are provided, this analysis does not reflect the US 
healthcare costs and is not generalizable to the US healthcare setting. Although diag-
nostic and treatment guidelines for AIS patients are similar in the Unites States and the 
UK, the reported mean lifetime cost of AIS is $140 000 in the United States, which is 2.33× 
our UK estimate [25]. Based on exploratory analyses, the remuneration of physicians and 
the cost of hospitalization and IV-tPA are the main contributors to the cost difference 
(data not shown). These observations suggest that AdvImg and late MT would be more 
cost-effective in the United States than in the UK.
4.5 COnCluSIOnS
Based on these exploratory results, referring AIS patients to MT beyond the 6-hour win-
dow by means of AdvImg may be good value for money in the UK. However, additional 
data regarding the prior probability to benefit from late MT and the accuracy of imaging 
for AIS patients is needed before MT can be widely implemented in clinical practice.
99
4
Cost-effectiveness of MT beyond 6 h following advanced imaging in the UK
references
 1. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al; DEFUSE 3 Investiga-
tors. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 
2018;378:708–718.
 2. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al; DAWN Trial Investigators. 
Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J 
Med. 2018;378:11–21.
 3. Clinical Commissioning Policy: Mechanical thrombectomy for acute ischaemic stroke (all ages). 
NHS England. Reference: 170033P. https://www.england.nhs.uk/wp-content/uploads/2018/03/
d04-mechanical-thrombectomy-for-acute-ischaemic-stroke-v2.pdf. Accessed September 15, 
2018.
 4. Román LS, Menon BK, Blasco J, Hernández-Pérez M, Dávalos A, Majoie CBLM, et al; HERMES Col-
laborators. Imaging features and safety and efficacy of endovascular stroke treatment: a meta-
analysis of individual patient-level data. Lancet Neurol. 2018;17:895–904.
 5. Wahlgren N, Moreira T, Michel P, Steiner T, Jansen O, Cognard C, et al; and for ESO-KSU, ESO, 
ESMINT, ESNR and EAN. Mechanical thrombectomy in acute ischemic stroke: consensus state-
ment by ESO-karolinska stroke update 2014/2015, supported by ESO, ESMINT, ESNR and EAN. Int 
J Stroke. 2016;134–147.
 6. Stroke service standards. Clinical standards committee. British Association of Stroke Physicians. 
2014. http://www.wnecumbria.nhs. uk/wp-content/uploads/2016/09/Stroke-service-standards-
Jun-2014- British-Association-of-Stroke-Physicians.pdf. Accessed August 12, 2018.
 7. Vanacker P, Lambrou D, Eskandari A, Mosimann PJ, Maghraoui A, Michel P. Eligibility and predic-
tors for acute revascularization procedures in a stroke center. Stroke. 2016;47:1844–1849.
 8. Jadhav AP, Desai SM, Kenmuir CL, Rocha M, Starr MT, Molyneaux BJ, et al. Eligibility for endovas-
cular trial enrollment in the 6- to 24-hour time window: analysis of a single comprehensive stroke 
center. Stroke. 2018;49:1015–1017.
 9. Caro JJ, Briggs AH, Siebert U, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task 
Force. Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good 
research practices task force-1. Med Decis Making. 2012;32:667–677.
 10. Drummond M, Sculpher TG, O’Brien BS. Methods for the Economic Evaluation of Health Care 
Programmes. 3rd ed. New York: Oxford University Press; 2005.
 11. Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, et al. Cost-effectiveness of 
recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current 
evidence. Stroke. 2014;45:3032–3039.
 12. Samsa GP, Reutter RA, Parmigiani G, Ancukiewicz M, Abrahamse P, Lipscomb J, et al. Performing 
cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision 
model: application to treatment of acute ischemic stroke. J Clin Epidemiol. 1999;52:259– 271.
 13. Guzauskas GF, Boudreau DM, Villa KF, Levine SR, Veenstra DL. The cost-effectiveness of primary 
stroke centers for acute stroke care. Stroke. 2012;43:1617–1623.
 14. Ganesalingam J, Pizzo E, Morris S, Sunderland T, Ames D, Lobotesis K. Cost-utility analysis of 
mechanical thrombectomy using stent retrievers in acute ischemic stroke. Stroke. 2015;46:2591–
2598.
 15. Gascou G, Lobotesis K, Machi P, Maldonado I, Vendrell JF, Riquelme C, et al. Stent retrievers in 




 16. Curtis L, Burns A. Units Costs of Health and Social Care 2017. Personal Social Services Research 
Unit, University of Kent, Canterbury. https:// www.pssru.ac.uk/project-pages/unit-costs/unit-
costs-2017/. Accessed March 15, 2018.
 17. Wardlaw J, Brazzelli M, Miranda H, Chappell F, McNamee P, Scotland G, et al. An assessment of the 
cost-effectiveness of magnetic resonance, including diffusion-weighted imaging, in patients with 
transient ischaemic attack and minor stroke: a systematic review, meta-analysis and economic 
evaluation. Health Technol Assess. 2014;18:1–368, v-vi.
 18. Biesbroek JM, Niesten JM, Dankbaar JW, Biessels GJ, Velthuis BK, Reitsma JB, et al. Diagnostic 
accuracy of CT perfusion imaging for detecting acute ischemic stroke: a systematic review and 
meta-analysis. Cerebrovasc Dis. 2013;35:493–501.
 19. Pizzo E, Dumba M, Lobotesis K. Cost-utility analysis of mechanical thrombectomy between 6 and 
24 hours in acute ischemic stroke. [published online February 14, 2019]. Int J Stroke. Accessed 
May, 14, 2019.
 20. Lobotesis K, Veltkamp R, Carpenter IH, Claxton LM, Saver JL, Hodgson R. Cost-effectiveness of 
stent-retriever thrombectomy in combination with IV t-PA compared with IV t-PA alone for acute 
ischemic stroke in the UK. J Med Econ. 2016;19:785– 794.
 21. Leppert MH, Campbell JD, Simpson JR, Burke JF. Cost-effectiveness of intra-arterial treatment as 
an adjunct to intravenous tissue-type plasminogen activator for acute ischemic stroke. Stroke. 
2015;46:1870–1876.
 22. Programme, SSNAP Sentinel Stroke National Audit. Thrombectomy Report for April 2016 - March 
2017. https://www.strokeaudit.org/results/ Clinical-audit/National-Results.aspx. Accessed March 
15, 2018.
 23. Allen M, Pearn K, James M, Ford GA, White P, Rudd AG, et al. Maximising access to thrombectomy 
services for stroke in England: a modelling study. Eur Stroke J. 2019;4:39–49.
 24. Luengo-Fernandez R, Yiin GS, Gray AM, Rothwell PM. Populationbased study of acute- and long-
term care costs after stroke in patients with AF. Int J Stroke. 2013;8:308–314.
 25. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the 
United States. Stroke. 1996;27:1459–1466.
101
4
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table II. Hazard ratios for mortality
Table from Slot et al. study [10].
mrS lothian (n=2054)
0 1; N=283
1 0.98 (0.63, 1.54); N=404
2 1.74 (1.16, 2.61); N=455
3 2.58 (1.73, 3.87); N=360
4 3.89 (2.48, 6.12); N=122
5 4.98 (3.15, 7.88); N=122
6 0
A weighted average of these values gives 1.29 for mRS012 and 3.33 for mRS345.
Table III. Intermediate outcomes of late MT according to advanced imaging accuracy (as modelled in 
the AIelMT strategy of the decision tree)
Truth
(late MT will be beneficial)
Truth
(late MT will not be beneficial)
Positive test
(AdvImg informs that late 
MT will be beneficial)
TP rate (patients with LAO moderate 
or severe receiving late MT)
= prior probability * sensitivity
fP rate (patients with LAO mild or 
small occlusions receiving late MT)
= 1 – TP – FN – TN
Negative test
(AdvImg informs that late 
MT will not be beneficial)
fn rate (patients with LAO moderate 
or severe not receiving late MT)
= prior probability - TP
Tn rate (patients with LAO mild or 
small occlusions not receiving late MT)





TP: true positive; FP: false positive; FN: false negative; TN: true negative
MT: mechanical thrombectomy
Table Iv. Outcomes for fP AIS patients after correction for embolic and hemorrhagic complications 
after standalone MT (AIelMT strategy)







Death after embolic and
hemorrhagic complications
after standalone MT
Total patients 50 94 -
Embolic complications 8 (16%) 10 (10.6%) 38.9% 16% * 38.9% = 6.2%
Hemorrhagic complications 9 (18%) 20 (21.3%) 45.5% 45.5% * 18% = 8.2%
6.22% + 8.19% = 14.4%
b) Outcomes for FP AIS patients after correction for periprocedural complications
Outcome for Tn
(no MT)
Outcome for fP (MT) 
in the AIelMT strategy 
after correction for 
complications after MT
mRS 0 after mild stroke and beyond 6 hours from onset 18.3% 16.5%
mRS 1-2 after mild stroke and beyond 6 hours from onset 42.5% 40.7%
mRS 3-5 after mild stroke and beyond 6 hours from onset 30.2% 28.4%
mRS 6 after mild stroke and beyond 6 hours from onset 9% 14.4%
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Table va. Inflated 2016/17 resource use costs for administration of Iv-tPA from Sandercock et al. [15]
extra staffing 
requirements












PSSRU 2011 (staff nurse 
24hr ward)
Nurse (Band 5) 
(Section 14 of PSSRU 
2017)









PSSRU 2011 (registrar 
group)
Registrar (Section 15 
of PSSRU 2017).






PSSRU 2011 (medical 
consultant costs)
Medical consultant 
(Section 15 of PSSRU 
2017)
Cost per working 
hour
£106 £107.89 £89.91
5 min routine 
observation by 
senior nurse in 
place of more 
junior nurse
It has been assumed 
that observations are 
carried out by a senior 
nurse, and that each 
observation takes 5 
minutes
PSSRU 2011 (ward 
manager 24hr ward and 
staff nurse 24hr ward)
Nurse advanced 
(band 7) (Section 14 
of PSSRU 2017)










at 5 min each
It has been assumed 
that routine 
observations take 5 
minutes to be carried 
out 
PSSRU 2011 (ward 
manager 24hr ward)
Nurse advanced 
(band 7) (Section 14 
of PSSRU 2017)







5 hours 1:1 
senior nurse 
care
PSSRU 2011 (ward 
manager 24hr ward)
Nurse advanced 
(band 7) (Section 14 
of PSSRU 2017)











PSSRU 2011 (foundation 
house officer 1)
Foundation doctor 
(FY1) (Section 15 of 
PSSRU 2017)















900 micrograms required per kg [16];
75kg/patient; 67.5mg per patient
£259.20 for 20mg pack + £432 for 50mg pack =>£691.20 per patient
Lower
60kg/patient; 54mg per patient
£172.80 for 10mg pack + £432 for 50mg pack => £604.80
Upper
85kg/patient; 76.5mg per patient




Average: 691.2 + 1052 = £1,743.2
Lower: 604.8 + 965 = £1,569.8
Upper: 864 + 1052 = £1,916
Assuming an average patient weight of 75kg, based on an indication of 900 micrograms per kg [17], the 
average drug acquisition cost was estimated to be £691.20. Assuming alternative weights of 60kg and 85kg 
led to required doses of 54mg and 76.5mg, respectively. We then assumed a lower estimate of drug acquisi-
tion costs to be £604.80 (assuming between 50mg and 60mg are required per patient), and £864 (assuming 
between 70mg and 80mg are required per patient).
The administration costs, that were based on those from Sandercock et al. study (2004) [15] and inflated for 
2018, amount for £1,051.6. Discussion with a clinical expert regarding general changes in the care of stroke 
patients over time suggests that the difference in care between patients receiving IV-tPA and those not 
receiving IV-tPA may not anymore be as important as the estimates that Sandercock suggested for the year 
2004. In particular, less administrative (145 minutes) and consultant (20 minutes) time should be assumed 
for patients receiving IV-tPA compared to 2004. Based on this, we estimated a lower estimate of the costs of 
administration of patients receiving IV-tPA of £965.
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Table vI. Distribution of ischemic patients across the mrS scale at three months per prior probability 


















no late MT 
strategy
NA 10% 15% 36% 35% 13%
NA 20% 14% 34% 36% 15%
NA 30% 13% 32% 38% 17%
AdvImg 
followed 





10% 16% 39% 33% 12%
20% 15% 38% 33% 14%
30% 14% 38% 32% 16%
sensitivity: 80%  
specificity: 100%
10% 16% 38% 34% 12%
20% 15% 38% 34% 14%
30% 14% 37% 34% 15%
sensitivity: 100%  
specificity: 70%
10% 15% 38% 33% 13%
20% 15% 38% 33% 14%
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Table vIII. ICerS at 90 days and lifetime horizon for the nine investigated scenarios (results of the 
model)
ICer (cost per ly gained) lifetime ICer (cost per QAly gained) lifetime




3 months 3 months 3 months 3 months 3 months 3 months
$240.245 $245.411 $805.037 $131.805 $134.640 $322.752
lifetime lifetime lifetime lifetime lifetime lifetime




3 months 3 months 3 months 3 months 3 months 3 months
$250.578 $258.328 $1.811.967 $137.474 $141.726 $494.846
lifetime lifetime lifetime lifetime lifetime lifetime




3 months 3 months 3 months 3 months 3 months 3 months
$281.579 $297.079 -$4.280.241 $154.482 $162.986 $1.258.398
lifetime lifetime lifetime lifetime lifetime lifetime
$8.221 $8.586 $115.077 $8.199 $8.566 $49.515
Methods and sources used to calculate the probabilities of the decision tree
Calculation of the probability that the ischemic patient imaged within 4,5 hours 
receives Iv-tPA:
We assumed that 70% of the ischemic stroke patients managed within 4,5 hours were 
eligible to IV-tPA (in reference to the fact that 80+ patients should be considered on 
individual basis).
The percentage of all stroke patients (all stroke types) given thrombolysis (April 
2016-March 2017) is 11.6%.
The percentage of eligible patients (according to the Royal College of Physicians guide-
line minimum threshold) given thrombolysis (April 2016-March 2017) is 86.9%.
Based on these proportions, we calculated the probability that the ischemic patient 






































































Based on the above data:
Probability that the ischemic patient imaged within 4,5 hours receives IV-tPA
= (86.9*70/100)/100
= 0.608
This app ared to be consistent with the study by Mc Meekin et al. [18]. They reported that:
- the early presenters (within 4 hours) were 15350.
- those who received IV-tPA if eligible were 10130
This leads to a pro ability to re eive IV-tPA of 10130/15350= 65.9%.
Calculation of the probability that the ischemic patient is being imaged within 4.5 hours after symp-
tom onset and calculation of the probability that the ischemic patient is being imaged between 4.5 
and 6 hours after symptom onset
1. The distribution of onset to hospital times is known (figure below)
2. The probability to receive a scan within 1 hour once the patient is in the hospital is known (51.3%)
based on these, we es imated he distr bution from onset to CT time
3. Assumptions:
3a. the distribution of patients with known and unkno n onset time is the same among ischemic and 
hemorrhagic patients.
3b. we found in the literature the proportion of patients per hour range from onset to hospital arrival (for 
patients with known onset). In each hour range, we assumed that the proportion of patients in the first half 
hour equals the proportion of patients in the second half hour.
3c. finally, we assumed that the probability for a patient to receive a scan within 1 hour is related to the 
time from symptom onset to arrival at hospital. Patients that have a shorter time since onset are more likely 
to receive a scan within 1 hour than those who had their onset a longer time ago. Therefore, we assumed 
that the probability to receive a scan within 1 hour when the time from onset is below 3.5 hours was 60%.
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Table Ix. Data
values reference
Percentage of patients scanned within 1 hour of 
arrival at hospital: 2016/2017: 51.3%
The Fourth SSNAP Annual Report https://www.
strokeaudit.org/Documents/AnnualReport/2016-
17-SSNAP-Annual-Report.aspx
32% of patients had an unknown stroke onset





Distribution of onset to arrival at hospital time
Time from onset to arrival < 3.5 hours: 59%
Time from onset to arrival known and >3.5 hours: 
41%




figure 4: Symptom onset time to arrival at hospital, 
for patients with known or estimated onset time
Calculation:
probability that the ischemic patient is being imaged within 4.5 hours after symptom onset
= probability that the time from onset is known * probability that the time from onset is less than 
3.5 hours * probability that the patient receives a scan within 1 hour of hospital admission
= 0.68 * 0.59 *0.6
= 0.24
probability that the ischemic patient is being imaged between 4.5 and 6 hours after symptom 
onset
= 0.68 * 0.085 * 0.6
= 0.034
Calculation of the conditional probabilities that the ischemic patient receives MT
The calculation of the probabilities to have a thrombectomy within and beyond 4.5 hours and with or 
without IV-tPA (among all thrombectomies) was based on some known proportions and complemented 
by assumptions.
1. The total number of thrombectomies from April 2016 to March 2017 was 580. The number of thrombec-
tomies with IV t-PA is known (369 per year, 63.6% of all thrombectomies). It was assumed that thrombec-
tomies performed after IV t-PA were administered either right after thrombolysis or in a delay of maximum 
6 hours.
2. It was assumed that 75% of the thrombectomies performed without IV t-PA happened between 4.5 and 
6 hours from symptom onset. The remaining 25% of the thrombectomies performed without IV t-PA hap-








Thrombectomies 580 100% https://www.strokeaudit.org/results/
Clinical-audit/National-Results.aspx
Thrombectomy Report for April 2016 - 
March 2017
Thrombectomies after IV t-PA 369 63.6%
Thrombectomies without IV t-PA 211 36.4%
Thrombectomies without IV t-PA 
beyond 4.5 hours (and within 6 
hours)
158 27.3% Assumed









with and without Iv 
t-PA










Total thrombectomies within and 
after 4.5 hours
369 (63.6%) 211 (36.4%) 580 (100%)
Table xII: Data
Probability among all thrombectomies
Thrombectomies without IV t-PA within 4.5 hours 9.1%
Thrombectomies without IV t-PA between 4.5 and 
6 hours
27.3%
Thrombectomies after IV t-PA 63.6%
Table xIII: Data
all strokes (England, Wales, Northern Island) 85122
ischemic stroke patients 74216
hemorrhagic stroke patients 10906
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3. The 3 conditional probabilities of interest used in the decision tree were back-calculated using the condi-
tional probabilities in the related branches.
3a. Probability that the ischemic patient imaged within 4.5 hours receives MT any time after IV t-PA:
Probability to be imaged within 4.5 hours * Probability to receive IV t-PA * Probability to have a MT after IV 
t-PA = percentage of ischemic stroke patients receiving MT after IV t-PA
Hence:
Probability to have a MT after IV t-PA
= percentage of ischemic stroke patients receiving MT after IV t-PA / (Probability to be imaged within 4.5 
hours * Probability to receive IV t-PA)
= (369/74216)/(0.24*0.60)
= 0.034
3b. Probability that the ischemic patient imaged within 4.5 hours receives MT alone (without IV t-PA):
Probability to be imaged within 4.5 hours * Probability to receive MT within 4.5 hours = percentage of isch-
emic stroke patients receiving MT within 4.5 hours without IV-tPA
Hence:
Probability to have a MT within 4.5 hours from onset (without IV t-PA)
= percentage of ischemic stroke patients receiving MT within 4.5 hours without IV-tPA /
Probability to be imaged within 4.5 hours
= (53/74216)/0.24
= 0.0029
3c. Probability that the ischemic patient imaged beyond 4.5 hours receives MT between 4.5 and 6 hours 
from symptom onset (without IV t-PA):
Probability to be imaged beyond 4.5 hours * Probability to receive care between 4.5 and 6 hours * Probabil-
ity to receive MT between 4.5 and 6 hours = percentage of ischemic stroke patients receiving MT beyond 
4.5 hours without IV t-PA
Hence:
Probability to have a MT between 4.5 and 6 hours from onset (without IV t-PA)
= percentage of ischemic stroke patients receiving MT beyond 4.5 hours without IV t-PA/
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Question:  Is mechanical thrombectomy in the extended treatment window cost-
effective across patient subgroups in the United States?
findings: This economic evaluation study found that mechanical thrombectomy pro-
vides good value for money in all the defined subgroups the 2 randomized clinical trials 
evaluated. Sensitivity analyses revealed a wide range of probabilities for late mechanical 
thrombectomy to be cost-effective at the willingness-to-pay threshold of $50 000 per 
quality-adjusted life-year.
Meaning: The results of this study suggest that attention should be placed on increas-
ing access to mechanical thrombectomy rather than on developing subgroup-specific 
guidelines unless workforce and budget constraints require prioritization.
Abstract
Importance
Two 2018 randomized controlled trials (DAWN and DEFUSE 3) demonstrated the clini-
cal benefit of mechanical thrombectomy (MT) more than 6 hours after onset in acute 
ischemic stroke (AIS). Health-economic evidence is needed to determine whether the 
short-term health benefits of late MT translate to a cost-effective option during a life-
time in the United States.
Objective
To compare the cost-effectiveness of 2 strategies (MT added to standard medical care 
[SMC] vs SMC alone) for various subgroups of patients with AIS receiving care more than 
6 hours after symptom onset.
Design, Setting, and Participants
This economic evaluation study used the results of the DAWN and DEFUSE 3 trials to 
populate a cost-effectiveness model from a US health care perspective combining a 
decision tree and Markov trace. The DAWN and DEFUSE 3 trials enrolled 206 interna-
tional patients from 2014 to 2017 and 182 US patients from 2016 to 2017, respectively. 
Patients were followed until 3 months after stroke. The clinical outcome at 3 months 
was available for 29 subgroups of patients with AIS and anterior circulation large vessel 
occlusions. Data analysis was conducted from July 2018 to October 2019.
125
5
Cost-effectiveness of MT beyond 6 h based on the DAWN and DEFUSE 3 results in the US
exposures
MT with SMC in the extended treatment window vs SMC alone.
Main Outcomes and Measures
Expected costs and quality-adjusted life-years (QALYs) during lifetime were estimated. 
Deterministic results (incremental costs and effectiveness, incremental cost-effective-
ness ratios, and net monetary benefit) were presented, and probabilistic analyses were 
performed for the total populations and 27 patient subgroups.
results
In the DAWN study, the MT group had a mean (SD) age of 69.4 (14.1) years and 42 of 107 
(39.3%) were men, and the control group had a mean (SD) age of 70.7 (13.2) years and 51 
of 99 (51.5%) were men. In the DEFUSE 3 study, the MT group had a median (interquartile 
range) age of 70 (59-79) years, and 46 of 92 (50.0%) were men, and the control group 
had a median (interquartile range) age of 71 (59-80) years, and 44 of 90 (48.9%) were 
men. For the total trial population, incremental cost-effectiveness ratios were $662/
QALY and $13 877/QALY based on the DAWN and DEFUSE 3 trials, respectively. MT with 
SMC beyond 6 hours had a probability greater than 99.9% of being cost-effective vs SMC 
alone at a willingness-to-pay threshold of $100 000/QALY. Subgroup analyses showed a 
wide range of probabilities for MT with SMC to be cost-effective at a willingness-to-pay 
threshold of $50 000/QALY, with the greatest uncertainty observed for patients with a 
National Institute of Health Stroke Scale score of at least 16 and for those aged 80 years 
or older.
Conclusions and relevance
The results of this study suggest that late MT added to SMC is cost-effective in all sub-
groups evaluated in the DAWN and DEFUSE 3 trials, with most results being robust in 
probabilistic sensitivity analyses. Future MT evidence-gathering could focus on older 




The randomized clinical trials DAWN and DEFUSE 3 demonstrated superior functional 
outcomes of mechanical thrombectomy (MT) at 90 days among patients with acute 
ischemic stroke (AIS) treated 6 to 24 hours after they were last known well (eAppendix 
in the Supplement) [1-2]. Health-economic evidence is needed to determine whether 
the short-term functional benefit of late MT translates to cost-effectiveness in the 
United States over a lifetime. A prolonged MT window implies advanced neuroimaging 
selection of patients and greater neurology and endovascular staff, which are costly and 
potentially critical resources. Furthermore, factors such as time from symptom onset, 
patient characteristics, National Institutes of Health Stroke Scale (NIHSS) score, mode 
of presentation, imaging criteria, and localization of the occlusion might influence the 
long-term value of late MT. Analyzing the magnitude of the long-term cost-effectiveness 
of late window MT per patient subgroup could expand the evidence and help inform al-
location of critical resources. The aim of this study was to compare the cost-effectiveness 
of MT with standard medical care (SMC) vs SMC alone by patient subgroup in the late 
window in the United States.
5.2 MeTHOD
Study design
We framed, structured, populated and dealt with uncertainty, according to the formal 
steps of cost-effectiveness modeling [3,4]. A short-run decision tree model (3-month 
time horizon) and a lifetime Markov state-transition model were designed in Microsoft 
Excel version 2002 to analyze and compare the costs and outcomes of 2 care pathways, 
ie, MT with SMC vs SMC alone, in patients with AIS 6 to 24 hours after symptom onset 
in the United States. We defined SMC as antiplatelet therapy and supportive care ac-
cording to local guidelines. Subgroup analyses were performed based on the subgroup 
data published for the 2 trials [1,2]. A hypothetical US cohort of 1000 patients with AIS 
was modeled using the same age characteristics and criteria as defined in the trials. The 
efficacy data from the 2 trials were used as 3-month input parameters in our short-run 
model. Other input parameter values, such as costs, utilities, and transition probabili-
ties, were drawn from the literature. Costs and quality-adjusted life-years (QALYs) were 
calculated for each care strategy for a lifetime time horizon. Costs and outcomes were 
discounted at 3% annually, and the US health care perspective was used. Per our insti-
tutional policy, ethical approval is not required for this study type. This study followed 
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Model structure
Decision tree model
We built a short-run decision model to estimate the costs and clinical outcomes at 
90 days after the first AIS (Figure 5.1). Patients with AIS in a hypothetical cohort were 
distributed at 90 days into 1 of 7 possible modified Ranking Scale (mRS) scores [6]. 
Treatment outcomes were assumed to occur during the acute phase. The probabilities 
for a patient to be allocated to the different mRS states at 90 days were obtained from 
the DAWN and DEFUSE 3 results for both the total study populations and for patient 
subgroups (eTable 1 in the Supplement). The group of patients in the combined mRS 5 
and 6 group in the DAWN results was split into 2 groups (mRS 5 and mRS 6) according 
to the relative proportions of these 2 groups in the DEFUSE 3 trial. The mean age of the 
modeled cohort of AIS patients was customized based on the mean age per trial, per 
strategy (MT with SMC or SMC alone) and per patient subgroup. The ages modeled in 
our different analyses can be found in eTable 2 in the Supplement.
Markov model
We included AIS patients who survived the initial 3-month acute phase in a long-run 
Markov state-transition model (Figure 5.1) built to estimate lifetime costs and health 
outcomes. The model was composed of 3-month cycles, which were repeated until all 
patients theoretically died to reflect a lifetime time horizon. Every 3 months, patients 
could remain in their current mRS state, experience a recurrent stroke, or die from 
nonstroke-related cause. Patients experiencing a recurrent stroke could either die or 
transition to a worse mRS state (with an equal risk of transitioning to a worse state). 
Because previous studies indicated an increased mortality for dependent patients (ie, 
patients with mRS 3, 4, or 5) compared with independent patients (ie, patients with mRS 
0, 1, or 2) [7, 8], we used mRS state-specific hazard ratios (Table 5.1) [8-19]. We used US 
life tables for age-adjusted and sex-adjusted all-cause mortality rates applied from the 
end of month 3 onward [20].
Patients experiencing a recurrent stroke were managed with the same treatment strat-
egy (ie, MT with SMC or SMC only) as their initial treatment strategy. Based on previous 
studies, the risk of stroke recurrence was assumed to be equal across mRS states [11, 21]. 
We assumed that patients could experience only 1 recurrent stroke per 3-month cycle. 
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Costs and resource inputs
All costs were calculated in US dollars for the fiscal year 2019. We inflated costs origi-
nating from previous years based on the general Consumer Price Index [22]. Costs and 
resource used in the model are presented in Table 5.1.
For SMC alone, patients were assumed to have received computed tomography (CT) 
and CT angiography (CTA). For MT with SMC, patients were assumed to have received 
CT and CTA or magnetic resonance angiography (MRA) and CT perfusion (CTP) or MR 
imaging (MRI). We assumed that CTA was used as often as MRA and that CTP was used 
as often as MRI. The cost of the software used to assess the infarct volume with MRI 
and CTP was added (eTable 3 in the Supplement). The cost of intravenous thrombolysis 
included acquisition and administration [14]. This cost was included in both the MT with 
SMC and SMC strategies proportionally to the frequency of use in each group of the 
DAWN and DEFUSE 3 trials (eTable 4 in the Supplement). The cost of MT included the 
cost of the devices, nonphysician room personnel, and operating room overhead [15]. 
The physician costs related to the delivery of MT were added [15].
Based on the literature, the mean acute costs of the first 90 days after AIS and the mean 
3-month long-term costs were dependent on the severity of the outcome (ie, on mRS 
state). The acute costs reflected the mean payment per patient with ischemic stroke 
older than 65 years discharged to home after hospitalization with an mRS score of less 
than 2, discharged to any destination except home with an mRS score of 3 to 5, and 
dying at the hospital with an mRS score of 6, based on original data from the 2010 to 
2013 MarketScan Commercial Claims and Encounters Inpatient Database and Medicare 
Supplemental and Coordination of Benefits Database [16, 23]. Long-term mRS state-
specific poststroke costs were based on observed data from a prospective economic 
study conducted alongside the SWIFT-PRIME trial [24]. The long-term costs were based 
on Medicare inpatient and outpatient claims 3 months after the initial hospitalization 
and until death for 958 patients treated in 2 stroke centers in the United-States between 
2010 and 2014 [15]. Nursing home costs were included. The cost of a recurrent stroke 
was derived from the findings of the decision tree and assumed to be specific to the 
MT with SMC strategy or SMC strategy alone. As such, it represents the cost estimate 
to identify and treat a typical AIS according to the strategy defined in the decision tree.
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Table 5.1 List of input parametersa
Model input 
parameters
Base-Case value Distribution range Source
3-monthly transition probabilities in the Markov model
State after recurrence of 














Fagan et al. for 
probability of death 
and assumption 
that the patient 
has an equal risk of 
transitioning to one 
of the worse states
State after recurrence of 












State after recurrence of 










State after recurrence of 
a patient in mRS 3
mRS 4
mRS 5





State after recurrence of 
a patient in mRS 4
mRS 5





Death hazard ratios for
mRS 0 / mRS 1 / mRS 2 / 
mRS 3 / mRS 4 / mRS 5
1 / 1 / 1.11 / 1.27 / 
1.71 / 2.37
Log normal
SE: 0.076 / 0.46 / 
0.46 / 0.46 / 0.46 
/ 0.46
[8]
Samsa et al., 1999
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Table 5.1 List of input parametersa (continued)
Model input 
parameters
Base-Case value Distribution range Source
Costs and resource use
Costs and resource use in the decision tree
CT $198 β Pert $168-$228 [12] CMS 2015
CTA $774 β Pert $658-$890
MRI $625 β Pert $531-$718
MRA $1023 β Pert $870-$1.176
CTP $836 β Pert $711-$961 [13] Jackson et al., 
2010
Software $89 β Pert ($44 – 520) eTable 3 in the 
Supplement
Frequency of CTA vs 
MRA
0.5 Uniform 0-1 Assumed
Frequency of CTP vs 
MRI
0.5 Uniform 0-1 Assumed
IV-tPA acquisition and 
administration













[15] Shireman et al., 
2017






























[16] Joo et al., 2017
(No IV-tPA group, 
weighted mean of 
costs for the group 
aged 65-80 years 
and the group aged 
above 80 years)
Costs and resource use in the Markov model
3-monthly long-term 


























[15] Shireman et al., 
2017




Table 5.1 List of input parametersa (continued)
Model input 
parameters
Base-Case value Distribution range Source
Cost of recurrent stroke 
(90 days following 
stroke recurrence)
In the MT+SMC strategy
In the SMC alone 
strategy


















Based on the 95% 









mRS 0 0.85 β 0.8 - 1 [18] Gage et al., 1998
mRS 1 0.8 β 0.8 - 0.95
mRS 2 0.7 β 0.68 - 0.9 [19] Nelson et al., 
2016mRS 3 0.51 β 0.45 - 0.65
mRS 4 0.3 β 0.1 - 0.4 [17] Earnshaw et al., 
2009 for the range.mRS 5 0.15 β 0 - 0.32
mRS 6 or dead 0 NA NA
Recurrent stroke (90 
days following stroke 
recurrence)
In the MT+SMC strategy
In the SMC alone 
strategy
















utility) of the 
decision tree.
Based on the 95% 








a Input parameters related to efficacy of MT with SMC and SMC alone, used in the decision tree, can be 
found in eTable 1 in the supplemental.
Abbreviations:
CT, computed tomography; CTA, CT angiography; CTP, CT perfusion; IV-tP, intravenous tissue plasminogen 
activator; MRA, magnetic resonance angiography; MRI, MR imaging; mRS, modified Ranking Scale; MT, me-
chanical thrombectomy; SMC, standard medical care.
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utilities and quality of life
Utilities were assigned to each mRS state based on survey data from a large sample of 
individuals at increased risk of stroke using the time trade-off method to value hypo-
thetical health states. We chose this because of its methods and its use in recent US 
cost-effectiveness models [18, 19].
Utility values (ranges) were defined as 0.85 (0.80-1.00) for mRS 0; 0.80 (0.80-0.95) for 
mRS 1; 0.70 (0.68-0.90) for mRS 2; 0.51 (0.45-0.65) for mRS 3; 0.30 (0.10 to 0.40) for mRS 4; 
and 0.15 (0-0.32) for mRS 5. The utility of a recurrent stroke was assumed to be specific 
to each pathway and derived from the outcomes of the short-run model. Utilities were 
varied according to a β distribution (Table 5.1).
Subgroup analyses
The published results of the DAWN and DEFUSE 3 trials allowed for 29 subgroup analy-
ses. The mean ages reported for the total study population from the trials (control and 
intervention groups) were used by default except for subgroups defined by age (eTable 
2 in the Supplement). The sample size for each subgroup was modeled according to 
the trial subgroups (eTable 1 in the Supplement). Cost-effectiveness analyses were 
conducted for the total study populations and patient subgroups defined by time from 
stroke onset, age, NIHSS score, mode of presentation, clinical infarct mismatch (group A, 
aged ≥80 years, NIHSS score ≥10, and infarct volume <21 mL; group B, aged <80 years, 
NIHSS score ≥10, and infarct volume <31 mL; group C, aged <80 years, NIHSS score ≥20, 
and infarct volume 31-51 mL), occlusion location, time of symptom first observed, and 
trial eligibility criteria.
Statistical analysis
No statistical tests were conducted. No hypothesis testing nor level of statistical signifi-
cance was relevant to our analysis. We estimated the credibility intervals (CI) surround-
ing the mean values when relevant (Table 5.2).
We performed a probabilistic sensitivity analysis (PSA) in Excel to assess how parameter 
uncertainty affected the cost-effectiveness results. In this process, we assigned a distribu-
tion to each parameter according to the level of uncertainty regarding its deterministic 
value. A random value was drawn from each distribution, and the set of drawn values was 
used to calculate the results of interest. This process was repeated in 2000 simulations 
to generate 2000 estimates of the costs and QALYs for each strategy. The proportion 
of simulations when MT with SMC had a higher net monetary benefit (NMB) than SMC 
alone was calculated for different values of the willingness-to-pay (WTP) threshold for a 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































each curve represented the probability that MT with SMC was cost-effective compared 
with SMC alone at different WTP thresholds.
5.3 reSulTS
In the DAWN study, the MT group had a mean (SD) age of 69.4 (14.1) years and 42 of 107 
(39.3%) were men, and the control group had a mean (SD) age of 70.7 (13.2) years and 51 
of 99 (51.5%) were men. In the DEFUSE 3 study, the MT group had a median (interquartile 
range) age of 70 (59-79) years, and 46 of 92 (50.0%) were men, and the control group had 
a median (interquartile range) age of 71 (59-80) years, and 44 of 90 (48.9%) were men.
Table 5.2 shows the base-case cost-effectiveness results of MT with SMC vs SMC alone 
per trial inputs. Based on the total population from either trial, MT with SMC generated 
higher costs and more QALYs compared with SMC alone. The resulting incremental cost-
effectiveness ratios (ICERs) were $662/QALY and $13 877/QALY based on the DAWN and 
DEFUSE 3 trial inputs, respectively. The incremental costs and QALYs for the total popula-
tions and all subgroups are plotted in eFigure 1 in the Supplement. In all subgroups, MT 
with SMC led to better health outcomes than SMC alone. In 8 of 18 DAWN subgroups 
(44.4%), MT with SMC was cost saving and more effective (ie, dominant) compared with 
SMC alone. Based on the DEFUSE 3 trial results, $3555 was the minimum cost to gain 
1 QALY and was observed in patients with baseline NIHSS scores of less than 16. The 
maximum cost to gain 1 QALY was $19 994, based on the DAWN results and observed 
for patients older than 80 years and those in clinical infarct mismatch group A. Based on 
the DEFUSE 3 results, the maximum cost to gain 1 QALY was $42 635 for patients with 
baseline NIHSS score of 16 or greater (Table 5.2).
Figure 5.2 presents the results of the deterministic 1-way sensitivity analysis based on the 
DAWN inputs. The ICER is particularly sensitive to the cost of MT. Additionally, an increase 
in the long-term cost of mRS 4 and 5 led to a more favorable ICER. The same analysis based 
on the DEFUSE 3 inputs led to similar results (eFigure 2 in the Supplement).
The uncertainty surrounding the base-case estimates for the total population per trial is 
shown in Figure 5.3A. The PSA demonstrated that MT with SMC had either a 100% (based 
on the DAWN results) or a 99.9% (based on the DEFUSE 3 results) probability of being 
cost-effective at the WTP threshold of $100 000 per QALY. At a threshold of $50 000 per 
QALY, the probability of MT with SMC to be cost-effective was 100% and 97.5% based 
on the DAWN and DEFUSE 3 results, respectively. Scatter plots of incremental costs and 
incremental QALYs for all subgroups per trial can be found in eTable 5 in the Supplement.
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Figure 5.3B shows the probability that MT with SMC is cost-effective at different WTP 
thresholds for a QALY for the total populations and the 3 subgroups characterized by 
the most extreme results. At the threshold of $100 000/QALY, the probability for MT 
with SMC to be cost-effective was among the 2 lowest for patients aged 80 years or 
older (DEFUSE 3) (83.3%). At this threshold, the lowest probability (79.8%) was observed 
for patients with a middle cerebral artery M2 occlusion (DAWN), but given the small 
sample size for this group, its curve is reported only in eFigure 3 in the Supplement. At 
$50 000/QALY, the probability for MT with SMC to be cost-effective was less than 60% 
for patients with a baseline NIHSS score of 16 or greater in the DEFUSE 3 trial. At a low or 
no WTP for a QALY, the probability of MT with SMC being cost-effective was the highest 
among patients younger than 80 years (DAWN). eFigure 3 in the Supplement presents 
the consolidated results for all groups and subgroups.
5.4 DISCuSSIOn
Our main finding was that MT with SMC, compared with SMC alone, for patients with 
AIS and anterior large vessel occlusion in the late window is cost-effective in the United 
States. We performed model-based cost-effectiveness analyses of MT with SMC com-
pared with SMC alone based on the DAWN and DEFUSE 3 trial results and found that 
MT with SMC met conventional standards for cost-effectiveness in all subgroups. Based 
on the American College of Cardiology and American Heart Association (ACC/AHA) 
policy statement defining cost-effectiveness levels to inform value-based policies, ICERs 
below $50 000/QALY suggest high-value care, while ICERs between $50 000/QALY and 
$150 000 suggest intermediate value [25]. All the point estimates in the various sub-
groups suggest that MT with SMC provides high-value care (per the ACC/AHA standard) 
compared with SMC alone. The PSA results indicated that the minimum probability for 
MT with SMC to be cost-effective was approximately 80% at a threshold of $100 000/
QALY across subgroups. Increased uncertainty regarding whether MT with SMC was 
cost-effective at $50 000/QALY appeared among patients with NIHSS scores of 16 or 
greater in the DEFUSE 3 trial and patients aged 80 years and older in both trials.
Our findings are consistent with previous studies but also push the boundary of knowl-
edge regarding the cost-effectiveness of late MT. Kunz et al [14] performed a model-
based cost-effectiveness analysis of MT with SMC vs SMC in the early treatment window. 
Their calculated ICER ($3110/QALY) was similar to our findings in the late treatment 
window ($662/QALY and $13 877/QALY for the DAWN and DEFUSE 3 trials, respectively). 
Although their analysis was limited by the number of subgroups, their results were 
robust in most patient profiles. In another analysis in the early window, Kunz et al [26] 
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figure 5.3 Monte Carlo simulations of incremental cost and incremental quality-adjusted life-years (QALY) 
of mechanical thrombectomy with standard medical care for the full population
A. Monte Carlo simulations of incremental cost and incremental QALY
B. Cost-eff ectiveness acceptability curves
A, The results are shown as scatterplots of incremental costs and incremental QALYs of mechanical throm-
bectomy with standard medical care vs standard medical care alone per patient with acute ischemic stroke 
for the full population per trial. Each dot represents 1 simulation run. The black lines indicate 3 diff erent 
willingness-to-pay thresholds per QALY. The number of dots below a specifi c line represent the probability 
for mechanical thrombectomy with standard medical care to be cost-eff ective at the related WTP threshold.
B, Each curve shows the probability that mechanical thrombectomy with standard medical care is cost-
eff ective at diff erent values of willingness to pay for a QALY for the full population and diff erent subgroups. 





found that MT with SMC was cost-effective in all age groups analyzed (ie, 50-100 years 
at stroke onset), with increased cost-effectiveness observed in younger patients, which 
is also consistent with our findings. In contrast, Pizzo et al [27] and Peultier et al [28] 
demonstrated that MT with SMC vs SMC alone was cost-effective in the late window 
in the United Kingdom. However, by targeting the UK market, their studies may not be 
generalizable to the US cost structure and did not include subgroups.
Given that they demonstrated the cost-effectiveness of MT across all clinical subgroups, 
our findings have latent policy and clinical implications. Acute stroke treatment guide-
lines and quality measures should focus on increasing access to MT for all eligible US 
patients rather than on tailoring policies that prioritize specific subgroups. Specifically, 
policies are needed to improve stroke recognition and transportation to comprehensive 
stroke centers (providing MT) in light of the cost-effectiveness of MT, which does not 
depreciate significantly by stroke severity or age. Should additional MT trials be con-
ducted, our results suggest potential value in reducing the uncertainty regarding the 
cost-effectiveness of MT in certain subgroups (ie, patients with NIHSS scores of 16 or 
greater and those aged 80 years and older). However, this is only important to improve 
the certainty that MT represents high-value care (ie, ICER <$50 000/QALY), as opposed to 
MT being cost-effective at the conventional thresholds of $100 000/QALY to $150 000/
QALY used in the United States [29].
Beyond the cost-effectiveness considerations, the evidence regarding the clinical effec-
tiveness of MT in the extended time window presents challenges for fast and widespread 
implementation. Complex and transversal care by ambulance or air and personnel in 
emergency, neurology, radiology, and neuro-intervention might sometimes be limited 
and might not guarantee access to MT for all eligible patients. Local and national policies 
to increase staffing in these professions may be necessary to meet this burgeoning clini-
cal demand. Another short-term way to address potential critical limitations might be to 
prioritize the delivery of MT according to the degree and certainty of cost-effectiveness 
per patient subgroup.
Finally, in a country characterized by regions with low population density and large 
medically underserved areas and many individuals at increased risk of cardiovascular 
diseases, the delivery of MT in the late window might face organizational challenges 
[30]. Access to MT for remote patients will probably require more investments in systems 
such as telemedicine and infrastructures both within and between states. Given that 
air transportation of patients will decrease time to treatment but increase costs, the 
optimal organization of stroke care will need to be investigated.
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5.5 lIMITATIOnS
This study has limitations. First, our analyses are limited by the sample sizes of each 
subgroup included in the trials. However, we included sample size when estimating the 
probability of cost-effectiveness and found that there was a high probability that MT 
with SMC was cost-effective for most subgroups. Second, our analyses were limited by 
the selections of subgroups reported in the DAWN and DEFUSE 3 trial results. Thus, it is 
possible that MT with SMC might not be cost-effective in other subgroups. Third, while 
the DAWN trial included patients from multiple countries, we performed our analyses 
for the US setting. However, the DEFUSE 3 trial was restricted to 38 stroke centers in 
the United States, and our findings did not substantially differ between the 2 trials. 
Fourth, the quality-of-life estimates that we used were obtained from a study from 1998. 
However, these estimates have been used in recent studies. Fifth, although the cost of 
acquisition of software was included, it is important to highlight that this cost will de-
pend on the number of patients diagnosed per facility per year. Further research might 
be needed to assess the cost-effectiveness of MT in the extended window at hospital 
level. Sixth, given the specifics (including the high costs) of the health care system in the 
United States, these results are not generalizable to other health care settings, where 
late MT might be more or less cost-effective.
5.6 COnCluSIOnS
In conclusion, MT with SMC was generally cost-effective in all the subgroups evaluated 
in the DAWN and DEFUSE 3 trials. Future MT evidence-gathering is needed with a focus 
on older ages (ie, 80 years) and NIHSS scores of 16 and higher to reduce the uncertainties 
regarding these findings. More attention should be placed on increasing access to MT 
rather than on developing subgroup specific guidelines, unless workforce and budget 
constraints require prioritization.
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eAppendix. Source Data
In the DAWN trial, patients with an anterior circulation large vessel occlusion, NIHSS 
>10, and favorable imaging profiles were randomized to either MT (N=107) or medical 
management (N=99) between 6 to 24 hours after time last known well at centers in the 
United States, Canada, Europe, and Australia. In DEFUSE 3, patients with anterior circula-
tion large vessel occlusions, NIHSS > 6, and favorable imaging profiles were randomized 
to MT (N=92) versus medical therapy (N=90) 6 to 16 hours after last known well. Patients 
were recruited from 38 centers located in the United States.
Informed consent was obtained from all participants or their legal representatives. MT 
was performed with the Trevo device by Stryker in DAWN and with any FDA-approved 
device in DEFUSE 3. Intravenous tissue plasminogen activator (IV-tPA) was allowed 
before randomization, if begun within 4.5 hours from symptom onset.



































































































































































































































































































Cost-effectiveness of MT beyond 6 h based on the DAWN and DEFUSE 3 results in the US
eTable 1. Short-run model input parameters: distribution of patients on the mRS scale at 3 months after 






Distribution at 3 months on the mrS scale
Patient 















6 ≤ 24 hours (total population)
SMC 4,1% 5,1% 4,1% 16,1% 34,1% 13,6% 22,6% 99
MT + SMC 9,1% 22,1% 17,1% 13,1% 13,1% 9,5% 15,8% 107
6 ≤ 12 hours
SMC 6,9% 6,9% 5,9% 10,9% 36,9% 12,2% 20,5% 46
MT + SMC 14% 22% 18% 10% 6% 11,3% 18,8% 50
>12 hours
SMC 1,9% 3,9% 1,9% 20,9% 31,9% 14,9% 24,9% 53




SMC 6% 6% 5% 17% 40% 9,8% 16,3% 70
MT + SMC 8,9% 25,9% 18,9% 11,9% 14,9% 7,4% 12,4% 82
≥ 80 years
SMC 0% 3,8% 0% 13,8% 20,8% 23,1% 38,6% 29





SMC 9,1% 9,1% 6,1% 18,1% 33,1% 9,1% 15,1% 45
MT + SMC 16,9% 24,9% 28,9% 7,9% 7,9% 5,1% 8,6% 52
≥ 17
SMC 2% 0% 2% 15% 35% 17,3% 28,8% 54













SMC 5% 4% 2% 17% 38% 12,8% 21,3% 47
MT + SMC 11% 22% 16% 15% 12% 9% 15% 67
unwitnessed
SMC 3% 5% 5% 18% 29% 15% 25% 38
MT + SMC 7% 24% 10% 7% 17% 13,1% 21,9% 29
Witnessed
SMC 7% 7% 7% 7% 36% 13,5% 22,5% 14
MT + SMC 9% 18% 37% 18% 9% 3,4% 5,6% 11
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eTable 1. Short-run model input parameters: distribution of patients on the mRS scale at 3 months after 






Distribution at 3 months on the mrS scale
Patient 


















) CIM group A
SMC 0% 3,8% 0% 13,8% 20,8% 23,1% 38,6% 29
MT + SMC 12% 12% 8% 16% 8% 16,5% 27,5% 25
CIM group B
SMC 7% 7% 6% 20% 39% 7,9% 13,1% 61
MT + SMC 10% 26% 21% 12% 15% 6% 10% 73
CIM group C
SMC 0% 0% 0% 0% 44% 21% 35% 9










Internal Carotid Artery (ICA)
SMC 0% 0% 0% 21% 21% 21,8% 36,3% 19
MT + SMC 4,9% 26,9% 13,9% 13,9% 4,9% 13,4% 22,4% 22
Middle Cerebral Artery M1 Segment
SMC 5% 7% 5% 14% 38% 11,6% 19,4% 77
MT + SMC 10,9% 20,9% 17,9% 12,9% 15,9% 8,1% 13,6% 83
Middle Cerebral Artery M2 Segment
SMC 0% 0% 0% 33,3% 33,3% 12,7% 20,9% 3

















Symptom first Observed ≤ 6 hours
SMC 2% 6% 5% 20% 32% 13,1% 21,9% 54
MT + SMC 10% 23% 13% 14% 16% 9% 15% 74
Symptom first Observed > 6 hours
SMC 7% 4% 2% 11% 38% 14,3% 23,8% 45













6 ≤16 hours (total population)
SMC 7,9% 3,9% 3,9% 15,9% 26,9% 15,9% 25,9% 90
MT + SMC 10,1% 16,1% 18,1% 15,1% 18,1% 8,1% 14,1% 92
6 ≤11 hours
SMC 11,9% 5,9% 5,9% 15,9% 24,9% 17,9% 17,9% 51
MT + SMC 12,3% 14,3% 16,3% 12,3% 20,3% 8,3% 16,3% 49
>11 hours
SMC 2,9% 2,9% 2,9% 14,9% 27,9% 12,9% 35,9% 39
MT + SMC 6,9% 18,9% 20,9% 18,9% 15,9% 6,9% 11,9% 43
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eTable 1. Short-run model input parameters: distribution of patients on the mRS scale at 3 months after 














SMC 10,9% 5,9% 4,9% 19,9% 23,9% 14,9% 19,9% 66
MT + SMC 12,7% 15,7% 22,7% 15,7% 18,7% 5,7% 8,7% 70
≥ 80 years
SMC 0% 0% 4% 4% 33% 17% 42% 24





SMC 15,9% 8,9% 8,9% 21,9% 17,9% 15,9% 10,9% 45
MT + SMC 18,9% 22,9% 20,9% 11,9% 11,9% 6,9% 6,9% 43
≥16
SMC 0% 0% 0% 8,8% 35,8% 15,8% 39,8% 45












SMC 5% 0% 2% 17% 26% 19% 31% 42
MT + SMC 8,3% 16,3% 18,3% 14,3% 16,3% 6,3% 20,3% 49
Time known
SMC 8,9% 5,9% 8,9% 10,9% 28,9% 16,9% 19,9% 35












a not DAWn eligible
SMC 8,9% 5,9% 8,9% 8,9% 23,9% 11,9% 31,9% 34
MT + SMC 11% 19% 25% 6% 17% 8% 14% 36
DAWn eligible
SMC 6,9% 3,9% 1,9% 19,9% 28,9% 17,9% 20,9% 56
MT + SMC 9,1% 14,1% 14,1% 21,1% 20,1% 7,1% 14,1% 56
Clinical infarct mismatch: mismatch between the severity of the clinical deficit and the infarct volume de-
fined according to the following groups:
Group A: age ≥80, NIHSS ≥10, infarct volume <21ml
Group B: age< 80, NIHSS ≥10, infarct volume <31ml
Group C: age< 80, NIHSS ≥20, infarct volume <31-51ml
Time of symptom first observed to randomization
ICA: Internal carotid artery
MCA M1: middle cerebral artery M1 segment
NIHSS: National Institutes of Health Stroke Scale
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eTable 2. Reported age of randomized patients in the DAWN and DEFUSE 3 trials and parameterized age 
of patients in our model
Total study 
population
SMC + MT SMC alone
Data from the trial Data used in our 
model*
Data from the trial Data used in our 
model*
DAWN 69.4 (SD=14.1) 69 70.7 (SD=13.2) 71
DEFUSE 3 70 70 71 71
Age ≥80 year SMC + MT SMC alone
Data from the trial Data used in our 
model (mean age 
of the patients 
≥80)*
Data from the trial Data used in our 
model (mean age 
of the patients 
≥80)*
DAWN 23% 86.3 rounded to 86 29% 86.2 rounded to 86
DEFUSE 3 23.9%** 86.6 rounded to 87 26.6%** 86
Age <80 year SMC + MT SMC alone
Data from the trial Data used in our 
model (mean age 
of the patients 
<80)*
Data from the trial Data used in our 
model (mean age 
of the patients 
<80)*
DAWN 77% 65.4 rounded to 66 71% 66.6 rounded to 67
DEFUSE 3 76.1%** 65.7 rounded to 66 73.3%** 66.7 rounded to 67
*estimated assuming a normal distribution around the mean age of the full randomized population (tool: 
http://davidmlane.com/hyperstat/z_table.html)
** calculated from the data provided in the DAWN and DEFUSE 3 studies
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Cost-effectiveness of MT beyond 6 h based on the DAWN and DEFUSE 3 results in the US
eTable 3. Calculations methods for the cost of software per ischemic stroke patient
Mean (range) Comments Reference
Thrombectomy-
capable centers





Annual stroke patients 795,000 [2]
Annual ischemic stroke 
patients (87%)
691,650
Annual ischemic stroke 
patients in the 6-23-
hour onset-to-door 
window
(those likely to receive 
advanced-imaging and 




Of all ischemic stroke patients:
3.0% presented >24 hours 53.0% did not 
have exact time of onset documented
Of the 44% remaining, 25.4% were in 
the 6 to 24-hour onset-to-door window. 
Assuming linearity, this is 24% in the 
6-23-hour window.
(1 hour is assumed between arrival at 
hospital and imaging assessment).
44%*24%=10.5%
(probably an overestimate if there are 
other contraindications or obstacles to 
MT for patients within this time window)
[3]
Annual ischemic stroke 








Annual cost per facility
$26,250 ($17,500 
-52,000)
depending on configuration (1 scanner 
or unlimited)
feedback from 
RAPIDAI (VP sales 
contact)
and from one 
hospital in the 






$89 ($44 – 520)
eTable 4. Reported frequencies of use of intravenous thrombolysis in the DAWN and DEFUSE 3 trials
DAWn DefuSe 3
Intervention (MT+SMC) 5% 11%
Control (SMC alone) 13% 9%
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eTable 5. PSA results - Monte Carlo simulations of incremental cost and incremental QALY per AIS patient 
of MT+SMC (versus SMC alone)
Probabilistic sensitivity analysis per patient group and all subgroups of the DAWN and DEFUSE 3 trials.
TIMe frOM SyMPTOM OnSeT
when performed within 6 to 24 hours (DAWn) and when performed within 6 to 16 hours 



















TIMe frOM SyMPTOM OnSeT
when performed within 12 hours compared to 
b y nd 12 hours (DAWn)
when performed within 11 hours compared to 







































Cost-effectiveness of MT beyond 6 h based on the DAWN and DEFUSE 3 results in the US
eTable 5. PSA results - Monte Carlo simulations of incremental cost and incremental QALY per AIS patient 
of MT+SMC (versus SMC alone) (contined)
Age





































when performed in patients with a baseline 
nIHSS of 10 to 17 versus beyond (DAWn)
when performed in patients with a baseline 












































































when performed in patients with wake-up 
stroke versus unwitnessed stroke (DAWn)
when performed in patients with wake-up stroke 













































































eTable 5. PSA results - Monte Carlo simulations of incremental cost and incremental QALY per AIS patient 
of MT+SMC (versus SMC alone) (contined)
ClInICAl InfArCT MISMATCH (DAWn)







































































Cost-effectiveness of MT beyond 6 h based on the DAWN and DEFUSE 3 results in the US
eTable 5. PSA results - Monte Carlo simulations of incremental cost and incremental QALY per AIS patient 
of MT+SMC (versus SMC alone) (contined)
TIMe Of SyMPTOM fIrST OBServeD (DAWn)
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rationale, Aims, and Objectives
While different imaging and treatment options are available in acute coronary syn-
drome (ACS) care, there is a lack of data regarding their use across Europe. We examined 
the diagnostic and treatment strategies in patients with known or suspected ACS as 
reported by physicians and identified variations in responses across European countries 
and geographical areas.
Method
A web‐based clinician survey focusing on ACS imaging and revascularization treatments 
was circulated through email distribution lists and websites of European professional 
societies in the field of cardiology. We collected information on respondents’ clinical 
setting and specialty. Reported percentages of patients receiving imaging or treatment 
modalities and percentages of clinicians reporting to use modalities in a range of clinical 
scenarios were analyzed. Statistical comparisons were performed.
results
In total, 69 responses were received (Sweden [n = 20], United Kingdom [n = 16], Northern/
Western Europe [n = 17], Southern Europe [n = 9], and Central Europe [n = 7]). Consider-
able variations between geographical areas were seen in terms of reported diagnostic 
modalities and treatment strategies. For example, when presented with the scenario of 
a theoretical 45‐year‐old smoking female with a suspected ACS, 56% of UK clinicians 
reported to use coronary computed tomography angiography, compared to only 10% of 
Swedish clinicians (P = .002). Large variations were observed regarding the reported use 
of fractional flow reserve by physicians for non‐culprit lesions during invasive manage-
ment of myocardial infarction patients (44% in Sweden, 31% in the United Kingdom, and 
30% in Northern/Western Europe vs non‐use in Central and Southern Europe).
Conclusions
In this survey, respondents reported different diagnostic and treatment strategies in 
ACS care. These variations seem to have geographic components. Larger studies or real 
world data are needed to verify these observations and investigate their causes. More 
research is needed to compare the quality and efficiency of ACS care across countries 
and explore pathways for improvement.
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7.1 InTrODuCTIOn
Acute coronary syndrome (ACS) refers to conditions where the blood supplied to the 
heart muscle gets suddenly blocked leading to the death of cells in the heart tissues. In 
patients with suspected ACS, several imaging or functional testing modalities may be 
used to establish the diagnosis and to identify patients who should undergo myocardial 
revascularization. As different imaging and treatment options are currently available in 
the field, this variety might leave room for clinical practice variation at the European 
level.
Evidence suggests differences in ACS care and outcomes within Europe [1]. However, 
variations in clinical practice and outcomes in ACS care have mainly been analyzed at 
a national level, providing information about the relative patterns and performance of 
different hospitals within individual countries [2]. Although this information is crucial 
to assess the performance of hospitals and identify inequalities in care at the national 
level, between‐country comparisons have received little attention and would provide a 
complementary opportunity for learning from foreign health care systems and improv-
ing national performances [2]. Furthermore, given the lack of reliable data, establishing 
the status of the use of cardiovascular imaging in Europe has been a priority for influen-
tial European associations in the field [3].
While both surveys and registries are needed to verify whether clinical practice is in line 
with guidelines [4], surveys offer the advantage to present specific clinical cases and 
obtain detailed information about diagnostic and management strategies.
In this context, we developed and used a web‐based clinician survey to examine the 
diagnostic and treatment strategies reported by respondents and to identify potential 
variations in responses between countries or geographical areas within Europe. The 
focus was made on diagnostic tests (including coronary imaging and functional assess-
ment) and revascularization treatment, in a range of clinical scenarios encompassing 





In order to assess clinical practice in ACS in Europe, we conducted an online clinician 
survey. The survey questions were formulated based on expert opinion and feedback 
collected from a European expert panel, which included five cardiologists and three 
radiologists.
A pilot phase was conducted before the survey was launched in March 2017. The survey 
was conducted using the online software “Google form” and was made available online. 
The target population for dissemination included non‐invasive and interventional 
cardiologists, radiologists, and emergency physicians (including those completing their 
specialization).
No financial incentive was offered to participants and survey completion was voluntary. 
An ethics committee (EMC Rotterdam) reviewed the protocol and survey questions and 
concluded that this work was not subject to the Dutch law of medical research (WMO).
7.2.2 Structure
A closed and structured format in English was chosen to enable clinicians to select their 
responses among multiple predefined choices. First, an introduction provided the frame-
work of the study and was followed by general questions regarding the respondents’ 
work setting. Subsequently, respondents were asked about the diagnostic workup and 
the proportions of high‐risk and low‐ to intermediate‐risk patients suspected with ACS 
who would receive different imaging modalities in the respondent’s practice setting. 
Section 5 contained questions about the treatments used for ST‐elevation myocar-
dial infarction (STEMI) and non‐ST segment elevation myocardial infarction (NSTEMI) 
patients while Section 6 focused on follow‐up imaging. Questions related to specific 
patient cases and clinical scenarios were disseminated throughout the survey and are 
summarized in Table 7.1. The survey questions can be found in Supporting Information. 
A pilot‐test phase was conducted after which the number of questions was reduced.
7.2.3 Dissemination
The online survey link was circulated through email distribution lists and websites of 
national and European professional societies. The Swedish Society of Cardiology, the 
British Society of Cardiovascular Imaging, and the Radcliffe Cardiology group invited 
their members to participate in the survey through personal emails. The survey was 
circulated via the website of the Bulgarian Society of Cardiology, the Czech Nuclear 
Medicine Society, the European Society of Cardiovascular Radiology, and the Hungarian 
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Society of Cardiology, which complemented this action with an announcement in their 
newsletter.




Patient case Procedure surveyed
1 45-year-old female woman suspected with ACS, admitted in the 
emergency department. She had no cardiovascular risk factor 
except for smoking during 20 years. She presents with an atypical 
chest pain, her ECG is normal and her troponin result is low.
Further examination
2 65-year-old NSTEMI patient who received PCI of the culprit lesion 
and presents a relatively good clinical status
Strategy for dealing 
with suspected non-
culprit lesions
3 Patient over 50 y-o, admitted to the health centre with chest pain 
and an ACS has been ruled out
Usual diagnostic 
strategy after an ACS 
was ruled out
Abbreviations: ACS, acute coronary syndrome; ECG, electrocardiogram; NSTEMI, non‐ST segment elevation 
myocardial infarction; PCI, percutaneous coronary intervention.
7.2.4 Statistical analysis
Reported percentages of patients receiving imaging or treatment modalities and 
percentages of respondents reporting to use different invasive or non‐invasive diag-
nostic tests or treatments were extracted from the clinicians’ responses. Non‐invasive 
diagnostic tests comprise anatomical imaging such as coronary computed tomography 
angiography (CTA) or functional (or stress) tests, including exercise electrocardiogram 
(ECG), stress echocardiography, and scintigraphic or magnetic resonance (MR) perfu-
sion imaging. In ACS care, functional imaging is used to assess the haemodynamic 
characteristics of the heart. Invasive assessments require insertion of cardiac catheters 
and include invasive coronary angiography and fractional flow reserve (FFR) assessment 
during an interventional procedure.
Mean percentages were calculated for two countries (Sweden and the United Kingdom) 
and three clusters of countries (Central Europe, Northern/Western Europe, and Southern 
Europe) that were created based on the geographic location of the respondents and 
expected commonalities in their health care system. Given the breakdown of partici-
pants per country, Sweden and the United Kingdom were extracted from the Northern/
Western Europe cluster and isolated for more detailed analyses. Our statistical analyses 
rely on the assumption that respondents can be considered to be independent obser-
vations. Based on background information of the hospital (city, academic centre, and 
number of MI diagnosed), the maximum possible number of respondents coming from 
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the same centre is very low, which means that the potential influence of this possibility 
on the results is low.
The 95% confidence intervals (CIs) surrounding the mean estimates were computed 
using bootstrapping [5]. This involved randomly resampling the original samples with 
replacement 500 times, which corresponded to the number of replications needed to 
ensure stability and accuracy. Each bootstrapped sample yielded a bootstrap statistic 
(eg, mean frequency). The bootstrap distribution was computed from the 500 bootstrap 
statistics, per geographic area. Between‐country and between‐cluster comparisons of 
imaging and treatments were conducted using one‐way ANOVA tests in SPSS (version 
23). Statistical significance of the results was tested using a .05 level.
7.2.5  general background regarding the availability and use of 
imaging modalities in the european union
Previous studies reported considerable variation in the availability and use of imaging 
equipment in the European Union (EU). In 2015, Luxembourg recorded the highest 
number of angiography units per capita, followed by Italy and Sweden (Table 7.2) [6]. 
Germany and Italy reported more than 2.8 magnetic resonance imaging (MRI) units per 
100 000 inhabitants, in contrast to 0.4 MRI units per 100 000 inhabitants in Hungary. In 
2016, Luxembourg and France had the highest number of CT scans per capita in the EU 
(21 100 scans and 20 400 scans per 100 000 inhabitants). Furthermore, while Sweden, 
and Northern Europe in general, are known for their early adoption of medical technolo-
gies, Eastern European countries tend to be late adopters [7,8].
Table 7.2 Availability and use of imaging equipment in a set of selected EU countries [6]













France 0.7 1.7 1.4 20 439 11 385
Germany 1.1 3.5 3.5 14 310 a 13 616 a
Hungary 0.6 0.9 0.4 11 619 4 224
Italy 1.4 1.3 a 2.8 a 8 129 6 710
Luxembourg 1.6 1.7 1.2 21 064 8 340
Spain 0.6 1.8 1.6 10 870 8 245
Sweden 1.3 2.2 1.6 NA NA
UK NA 1 0.7 8 470 5 676
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7.3 reSulTS
We received responses from 74 clinicians. Of those, four non‐European clinicians and 
one non‐interpretable response set were excluded from the analysis. Among the 69 
remaining respondents, 20 were from Sweden, 16 from the United Kingdom, 7 from 
Central Europe, 17 from Northern/Western Europe, and 9 from Southern Europe. Given 
that the survey was distributed by national professional societies, it was not possible 
to calculate the response rate. We acknowledge the fact that the response rate might 
be small. Details about the respondents’ characteristics and work environment can be 
found in Table 7.3.
Table 7.3 Respondents’ characteristics
number %




Central europe (Czech Republic, Hungary, Romania, Serbia)
northern and Western europe (Finland, France, Germany, Ireland, Luxembourg, 
Netherlands)













Cardiologist and emergency physician
Cardiologist and PCI operator
































Abbreviation: PCI, percutaneous coronary intervention.
7.3.1 Initial diagnostic workup
On the basis of all answers, ECG combined with biochemical tests was reported as the 
mainstay of the first‐line diagnostic workup for both high‐risk patients (79%; 95% CI: 
70%, 87%) and low‐ to intermediate‐risk patients (68%; 95% CI: 58%, 78%) admitted to a 
health centre in Europe with chest pain and suspected ACS. Across the different investi-
gated areas, non‐invasive test appears to respondents to play a greater role to establish 
or rule out the diagnosis of an ACS in low‐ to intermediate‐risk patients than in high‐risk 
222
Chapter 7
patients. Indeed, while an average of 64% of the low‐ to intermediate‐risk patients were 
reported to receive non‐invasive imaging (with ECG plus biochemical tests, with ECG 
only and with biochemical tests only), only 48% of the high‐risk patients were reported 
to receive it (see Figure S1).
7.3.2 Diagnosis of a low risk patient
The first patient case described a 45‐year‐old woman suspected with ACS admitted in 
the emergency department with no cardiovascular risk factors except for smoking for 
20 years, atypical chest pain, a normal ECG, and a low troponin result. The respondents 
were asked to indicate what further investigations they would perform. In this hypo-
thetical clinical case, the vast majority of the clinicians responded they would opt for 
a combination of coronary CTA and/or echocardiogram and/or stress tests (see Figure 
7.1). The combination of tests reported by the respondents can be found in Figure S2. 
On the basis of the responses, stress tests (including treadmill, scintigram, stress echo-
cardiogram, or stress MRI) would be obtained by 43% to 65% of the respondents in each 
of the five investigated areas. The use of coronary CTA was reported to be the highest 
among UK respondents (56%) and lowest among Swedish respondents (10%) (P = .002). 
Swedish and Southern Europe respondents strongly favoured stress tests in this context.
Significantly more UK respondents (56%) than Swedish respondents (10%) reported 
they would use coronary CTA (P = .002). Large variations were also observed regarding 
the use of echocardiogram: while 71% of the respondents from Central Europe reported 
they would perform an echocardiogram, this was only 22% in Southern Europe and 25% 
in the United Kingdom. Interestingly, throughout the different geographic areas, a vary-
ing proportion of respondents (0%‐22%) reported they would not perform any further 
examination.
7.3.3  Imaging modality guiding treatment decision for patients with a 
high probability of ACS after biochemical tests
Overall, European respondents reported that an average of 60% of their patients pre-
senting with a high probability of ACS after biochemical tests receive echocardiogram 
(see Figure S3). Furthermore, European respondents reported that an estimated 54% 
of their patients receive invasive coronary angiography without FFR compared to 37% 
receiving invasive coronary angiography with FFR.
Southern European respondents reported the lowest frequencies of FFR combined with 
invasive coronary angiography. While UK respondents reported using coronary CTA for 
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7.3.4 Diagnosis after ruling out ACS
Figure 7.2 shows the frequencies of diagnostic tests for patients over 50 years of age 
admitted with chest pain and after an ACS was ruled out, based on the proportion of pa-
tients per test reported by each respondent (patient case 3). For these typical patients, 
UK respondents reported using bicycle ECG less often than the other European respon-
dents. The difference between British and Swedish respondents was statistically signifi-
cant (4.5% vs 57%; P = .00). Interestingly, UK respondents appear to be almost equally 
figure 7.1 Percentages of clinicians reporting to use different examinations in the diagnosis of a low risk 
patient (patient case 1)
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divided between performing stress echocardiogram, coronary CT scan, and invasive 
coronary angiography, with frequency rates close to 20% for each test. UK respondents, 
together with Northern/Western Europe respondents, reported the highest frequencies 
of stress MRI: 15% and 15.5%, respectively. On average, English respondents estimated 
that 15% of their patients matching the hypothetical case 3 description receive stress 
MRI, which means that this imaging modality is significantly more often reported in the 
United Kingdom than in Sweden, Central Europe, and Southern Europe (P  < .05), in the 
described context. The reported use of stress MRI also appears to be significantly greater 
in London than in other UK cities (P  < .01).
figure 7.2 Reported percentages of patients receiving different diagnostic strategies after an ACS was 
ruled out (patient case 3). ACS, acute coronary syndrome
7.3.5  Average time between diagnosing a nSTeMI patient and 
performing invasive coronary angiography
The reported time between diagnosing an NSTEMI patient and performing invasive 
coronary angiography appear to vary substantially between and within the investigated 
areas. While 18% of the whole group of respondents (12/69) estimated an average time 
of 24 hours between diagnosis and invasive coronary angiography, 52% (36/69) of 
these respondents reported a delay of more than 24 hours. Of these 36 respondents, 13 
estimated a delay of at least 72 hours, hence a total of 19% (13/69) of the whole group. 
Interestingly, while 45% (9/20) of the Swedish respondents reported performing coro-
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7.3.6  reperfusion treatment method for patients presenting with 
a STeMI and revascularization treatment method for patients 
presenting with a primary nSTeMI
Figure 7.3 shows the reported frequencies of reperfusion treatments and revasculariza-
tion treatments given to STEMI patients (A) and NSTEMI patients (B), respectively, who 
were not contra‐indicated for any treatment. Percutaneous coronary intervention (PCI) 
was reported as the primary treatment modality for both STEMI and NSTEMI patients. 
This was the case in all geographical areas, although the actual percentage varied some-
what between geographical areas, with ranges of 77% to 96% for STEMI patients and 
67% to 91% for NSTEMI patients. For the two categories of patients, the lowest rates of 
PCI were reported in the United Kingdom. The UK respondents also reported the highest 
rate of intravenous thrombolysis, with nearly 14% of their STEMI patients receiving it, 
compared to an average of 2% to 6% reported in the other geographic areas. Regarding 
the NSTEMI group, UK respondents reported the highest rate of coronary artery bypass 
grafting (CABG) (19%) across the investigated areas.
7.3.7 Treatment of non‐culprit lesions
In a second patient case, respondents were asked about how they would treat suspected 
non‐culprit lesions in a 65‐year‐old NSTEMI patient presenting with a relatively good 
clinical status following the PCI of the culprit lesion. For this typical patient, slightly more 
than one‐quarter of the whole group of European respondents (19/69 = 28%) reported 
they would opt for conservative management with PCI only in the case of symptoms or 
reversible ischemia on stress tests (see Figure 7.4). Despite this trend, large variations are 
observed between responses across geographical areas: while this strategy was chosen 
by 56% and 57% of the respondents in Southern Europe and Central Europe, respec-
tively, it was selected by only 16% to 25% of the respondents in the United Kingdom, 
Sweden, and Northern/Western Europe. The strategy of FFR was chosen by 26% (18/69) 
of the total group: 16% (11/69) of the whole European respondents opted for an im-
mediate FFR‐guided PCI during index catheterization, 9% (6/69) for a staged FFR‐guided 
PCI during index hospitalization, and one respondent opted for a staged FFR‐guided 
PCI between 4 and 8 weeks. Among the respondents reporting PCI, the strategy of im-
mediate PCI was most prevalent in the United Kingdom and Sweden (67% and 36%, 
respectively) (Figure 7.4B). No clinician from Southern Europe reported FFR‐guided PCI 
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figure 7.4. A, Percentages of clinicians reporting their most common strategy in treating non‐culprit le-
sions (patient case 2). B, Percentages of clinicians reporting different approaches when performing PCI of 
the non‐culprit lesion (patient case 2). PCI, percutaneous coronary intervention
Totals per country do not sum up to 100% due to respondents who reported a “I do not know” answer.
7.4 DISCuSSIOn
To the best of our knowledge, this study presents the first online survey aimed at de-
scribing and analyzing reported diagnostic and treatment practices in ACS care across 
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European regions and countries. This study also provides detailed data related to a range 
of clinical scenarios that focus on strategies for specific patients.
Considerable variations in the respondents’ answers were observed in both the diag-
nostic and treatment phases of patients with known or suspected ACS. In addition, 
comparative analyses revealed significant differences between the responses from 
Swedish and UK clinicians.
7.4.1 Availability and reimbursement of diagnostic tests
The survey results showed that significantly lower frequencies of CTA use were reported 
by the Swedish respondents compared to the UK respondents. This may be explained by 
the facts that CTA is increasingly but not widely available in Sweden and that CTA was 
incorporated into the UK NICE guidelines for patients at low risk of CAD [9,10]. By means 
of the specific patient cases presented in the survey, MRI was significantly more often 
reported by UK respondents than by Swedish respondents. Furthermore, respondents 
from London reported MRI to be more frequently used than respondents from other UK 
cities. These studies showed a rapid increase in use of cardiac MRI in patients with ACS 
and striking variations in use between high volume centres, in and around London, and 
the rest of the country [11]. A major factor that might explain the wide availability and 
the increased use of MRI scanners in the United Kingdom is the fact that cardiac MRI is 
funded for assessment of ischaemic heart disease (including suspected ACS) and other 
heart diseases. The situation is different in many other European countries where differ-
ent reimbursement schemes are in place and issues regarding reimbursement may need 
to be solved [12]. Further research would be needed to assess whether the geographical 
imbalance observed in the responses within and between countries reflects an over-
use in the United Kingdom, and especially in London, or underuse patterns outside of 
London and in other European countries. As cardiac MRI is an accepted modality for 
assessment of suspected coronary disease, the question of potential overuse mainly 
relates to the cost‐effectiveness of the test.
Although the value of FFR to evaluate intermediate lesions or guide selection of lesions 
for revascularization in patients with multi‐vessel disease is widely accepted [13], modest 
rates were reported in this survey. This observation might reflect a low use or even a low 
implementation of FFR in Europe. It might also relate to the fact that the prognostic role 
of FFR in guiding myocardial revascularization in patients with an ACS needs additional 
clarification [14,15]. Although FFR‐guided PCI has been proven to reduce mortality and 
MI compared to angiography‐guided PCI in patients with stable angina, considerable 
differences were observed in the survey responses between regions and countries [16]. 
In that case again, reimbursement remains a major constraint preventing FFR from being 
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widely utilized in Europe: differences remain between countries that have allowed their 
hospitals to cover the costs of FFR procedures (like the United Kingdom and Germany) 
and other European countries where this is not reimbursed [17].
7.4.2 guidelines
Our findings showed that the reported time between diagnosing an NSTEMI patient and 
performing invasive coronary angiography varied substantially between and within the 
geographical areas of the respondents.
Although the European Society of Cardiology (ESC) guidelines recommend revas-
cularization within 24 hours in high‐risk patients and within 2 hours in very high‐risk 
patients, this can be a challenge in contemporary cardiac care in Europe [15]. Achiev-
ing revascularization within 24 hours was reported as a major challenge for Sweden 
in the SWEDEHEART Annual report of 2017 [9]. National Institute for Health and Care 
Excellence (NICE) guidelines recommend coronary angiography within 72 hours for 
intermediate or higher risk patients [18]. We think that the influence of NICE guidelines 
in the United Kingdom might partly explain why the times reported by UK respondents 
show a shift towards later intervention compared to the times reported by the Swedish 
respondents.
7.4.3 Treatments
The relatively high reported rates of PCI for reperfusion in STEMI patients and for revascu-
larization in NSTEMI patients might reflect a widespread access to PCI throughout Europe. 
Despite this trend, lower rates of PCI were reported by UK respondents and variations 
in the answers were seen between all geographical areas; these two observations are 
consistent with previous studies [19]. European respondents reported PCI as the most 
common invasive treatment for STEMI and NSTEMI patients, although the efficacy and 
durability of CABG over PCI (for different groups of patients) was largely demonstrated 
[20,21]. CABG remains highly recommended in patients characterized by multi‐vessel 
disease, diabetes, or lesion complexity. In Sweden, the volume of CABG procedures has 
been declining over the past 35 years but considerable differences in the proportion of 
CABG and PCI out of the total of revascularization exist across hospitals [9]. This large 
variability might indicate that some patients do not receive the optimal treatment and 
highlight that further studies would be needed to investigate the optimal rates of CABG 
and PCI. Comprehensive research is needed on barriers to implementation, and more 
generally, on factors and structure that determine the diffusion, implementation, and 
variations in use of PCI within and between European countries.
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Finally, we analyzed clinicians’ responses regarding whether and when non‐culprit le-
sions are treated and intended to identify possible geographic trends. While guidelines 
recommend a staged approach in the treatment of patients with STEMI and multi‐vessel 
disease, there is no evidence supporting the superiority of a staged over an immediate 
approach and no evidence regarding the best approach for NSTEMI patients [13,22].
By means of a survey, this study investigated clinical situations where evidence might 
remain uncertain or lacking. Indeed, the survey guaranteed that respondents answer 
to the exact same case, which allows preliminary international comparisons in clinical 
areas where registry data might not exist, capture limited details, be poor in quality, or 
not be available to third parties.
7.5 lIMITATIOnS
As a main limitation of our study, we acknowledge that a limited number of responses 
was received, implying a risk of selection bias and constraining generalizability of our 
results. Further research would be needed to ascertain and generalize our findings. 
However, our results are consistent with previous studies in the field and identify con-
siderable differences in the reported strategies between areas.
7.6 COnCluSIOnS
Our study revealed considerable variation in the reported modalities of diagnostic and 
treatment strategies in patients with suspected or established ACS across Europe. We 
have discussed potential causes for the reported differences in the utilization of these 
techniques that range from evidence regarding availability of techniques, guidelines, 
and reimbursement. Such differences may indicate that some patients do not receive 
the best available care and may have an important impact on the quality of health care 
and patient outcomes across geographical areas.
Complementary research might be possible to gather generalizable data and confirm 
these variations, investigate their causes and assess how much they reflect health care 
inefficiency and result in inequalities in patient outcomes. This could be done by either 
exploiting existing high-quality registries or setting them up with a specific scope in 
terms of patient population. The latter might require considerable resources though.
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Further research investigating the country‐specific cost‐effectiveness of diagnostic and 
treatment strategies in ACS care might be needed to define the most cost‐effective way 
for diagnosing and treating patients per country. Such studies would inform national 
policy makers and help them decide what cardiovascular technologies to promote and 
reimburse in order to maximize health gains and/or minimize costs, in the context of 
their local specificities and constraints. While large European studies such as the SPCCT 
(Spectral Photon Counting CT) project aim at developing new technologies, stronger 
evidence regarding current local care, by means of surveys or alternative methods, 
might be needed before the role and value of new imaging modalities in the clinical 




 1. André R, Bongard V, Elosua R, et al. International differences in acute coronary syndrome patients’ 
baseline characteristics, clinical management and outcomes in Western Europe: the EURHOBOP 
study. Heart. 2014;100(15):1201-1207.
 2. Chung SC, Sundström J, Gale CP, et al. Comparison of hospital variation in acute myocardial 
infarction care and outcome between Sweden and United Kingdom: population based cohort 
study using nationwide clinical registries. BMJ. 2015;351:h3913.
 3. Lancellotti P, Płonska-Go  sciniak E, Garbi M, et al. Cardiovascular imaging practice in Europe: a 
report from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 
2015;16(7):697-702.
 4. Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary 
syndromes in patients presenting without persistent ST-segment elevation: task force for 
the Management of Acute Coronary Syndromes in patients presenting without persistent ST-
segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315.
 5. Calmettes G, Drummond GB, Vowler SL. Making do with what we have: use your bootstraps. Br J 
Pharmacol. 2012;167(2):233-237.
 6. Healthcare Resource Statistics – Technical Resources and Medical Technology. Eurostat statistics 
explained. 2018. Accessed 26 November 2019. https://ec.europa.eu/eurostat/statisticsexplained/
index.php/Healthcare_resource_statistics_-_technical_ resources_and_medical_technology.
 7. Bergman E, Iversen Flateland L, Handegård Dyrstad E, et al. Strongholds and Qualities of the 
Nordic Health Tech Ecosystem. 2018. Accessed 26 November 2019. https://norden.diva-portal.
org/ smash/get/diva2:1293369/FULLTEXT01.pdf.
 8. Suriñach J, Autant-Bernard C, Manca F, et al. The Diffusion/Adoption of Innovation in the Internal 
Market. 2009. Accessed 26 November 2019. https://ec.europa.eu/economy_finance/publica-
tions/pages/ publication15826_en.pdf.
 9. SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based 
care in Heart disease Evaluated According to Recommended Therapies). SWEDEHEART Annual 
report 2017; 2018. Accessed 30 October 2018. https://www.ucr.uu.se/ swedeheart/dokument-sh/
arsrapporter-sh/aeldre-arsrapporter-olderreports/arsrapport-2017.
 10.  NICE. National Institute for Health and Care Excellence. CT Coronary Angiography; 2012. Accessed 
30 October 2018. https://www.nice. org.uk/sharedlearning/ct-coronary-angiography.
 11. Antony R, Daghem M, McCann GP, et al. Cardiovascular magnetic resonance activity in the United 
Kingdom: a survey on behalf   of the British Society of Cardiovascular Magnetic Resonance. J 
Cardiovasc Magn Reson. 2011;13(1):57.
 12. Knobelsdorff-Brenkenhoff F, Schulz-Menger J. Role of cardiovascular magnetic resonance in the 
guidelines of the European Society of Cardiology. J Cardiovasc Magn Reson. 2016;18:6.
 13. Windecker S, Alfonso F, Collet JP, et al. ESC/EACTS guidelines on myocardial revascularization: the 
Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the 
European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2014;35:2541-2619.
 14. Zimmermann FM, van Nunen LX. Fractional flow reserve-guided percutaneous coronary inter-
vention: standing the test of time. CVIA J. 2016;1(3):225-232.
 15. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascular-
ization. Eur Heart J. 2019;40:87-165.
 16. Pijls NH, Fearon WF, Tonino PA, et al. Fractional flow reserve versus angiography for guiding 
percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year 
233
7
European survey on acute coronary syndrome diagnosis and revascularisation treatment
follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) 
study. J Am Coll Cardiol. 2010;56(3):177-184.
 17. Pinto F, Fraser AG, Kautzner J, et al. Barriers to cardiovascular device innovation in Europe. Eur 
Heart J. 2016;37(2):140-144.
 18. NICE. National Institute for Health and Care Excellence. Acute Coronary Syndromes in Adults; 
2014. Accessed 30 October 2018. https://www. nice.org.uk/guidance/qs68/chapter/Quality-
statement-3-Coronaryangiography-and-PCI-within-72-hours-for-NSTEMI-or-unstable-angina.
 19. Widimsky P, Wijns W, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarc-
tion in Europe: description of the current situation in 30 countries. Eur Heart J. 2010;31(8):943-
957.
 20. Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C. Coronary artery bypass grafting vs percutaneous 
coronary intervention and long-term mortality and morbidity in multivessel disease: meta-
analysis of randomized clinical trials of the arterial grafting and stenting era. JAMA Intern Med. 
2014;174:223-230.
 21. Deb S, Wijeysundera HC, Ko DT, Tsubota H, Hill S, Fremes SE. Coronary artery bypass graft sur-
gery vs. percutaneous interventions in coronary revascularization: a systematic review. Jama. 
2013;310(19):2086-2095.
 22. Ong P, Sechtem U. Controversies in the treatment of patients with STEMI and multivessel disease: 
is it time for PCI of all lesions? Clin Res Cardiol. 2016;105(6):467-470.






Q1a: In what COUNTRY is your health centre located?
Q2: In what CITY is your health centre located?
Q3: What is your exact function?
Q4: What is the teaching category of your health centre?
Q5: Is your health centre publicly or privately funded?
Q6: How many myocardial infarction diagnosed patients does your health centre receive annually?
DIAgnOSTIC WOrKuP
Q7a: What is the diagnostic workup when a high risk patient is admitted to your health centre with chest 
pain and an ACS is suspected? Please also precise for what proportion of high risk patients the modality 
is used?
ECG + biochemical tests
ECG + biochemical tests + non-invasive imaging
ECG + non-invasive imaging (no biochemical test)
Biochemical tests + non-invasive imaging (no ECG)
Other
Q7b: If you marked ‘’other imaging test’’ in the previous question, please describe the modality used.
Q8a: What is the diagnostic workup when a low to intermediate risk patient is admitted to your health 
centre with chest pain and an ACS is suspected? Please also precise for what proportion of these patients 
the modality is used?
ECG + biochemical tests
ECG + biochemical tests + non-invasive imaging
ECG + non-invasive imaging (no biochemical test)
Biochemical tests + non-invasive imaging (no ECG)
Other
Q8b: If you marked ‘’other’’ in the previous question, please describe the modality used.
Q9b: If you marked ‘’other imaging test(s)’’ in the previous question, please describe the modality used.
Q9a: What is the usual strategy when a patient over 50 y-o is admitted to your health centre with chest 












Q9b: If you marked ‘’other’’ in the previous question, please describe the modality used.
Q10a: About troponin assays as serial testing, please indicate when the first test and subsequent tests (if 
any) are performed (more than one answer is expected)
In the ambulance
At admission in the hospital
1 hours after symptom onset
2 hours after symptom onset
3 hours after symptom onset
4 hours after symptom onset
5 hours after symptom onset
6 hours after symptom onset
12 hours after symptom onset
Other
Don’t know
Q10b: If you marked ‘’other’’ in the previous question, please describe the modality used.
IMAgIng MODAlITIeS
Q11a: Among all patients presenting with a high probability of ACS after biochemical tests, what are 
the imaging modalities used to make the treatment decision? For each imaging modality used, please 
indicate the proportion of the patients that undergo that modality (more than 1 answer is possible).
Echocardiogram
Coronary computed tomography angiography (CCTA)
Invasive coronary angiography with Fractional Flow Reserve (FFR)









Q11b: If you marked ‘’other’’ in the previous question, please describe the modality used.
Q12a: Among all patients presenting a low or intermediate probability of ACS, what are the imaging 
modalities used to establish the diagnosis? For each imaging modality used, please indicate the propor-
tion of the patients that undergo that modality (more than 1 answer is possible).
Echocardiogram
Coronary computed tomography angiography (CCTA)
Invasive coronary angiography with Fractional Flow Reserve (FFR)







Q12b: If you marked ‘’other’’ in the previous question, please describe the modality used.
Q13a: A 45-year-old female woman suspected with ACS was admitted in the emergency department. She 
had no cardiovascular risk factor except for smoking during 20 years. She presents with an atypical chest 
pain, her ECG is normal and her troponin result is low. In this specific case, what further examination(s) 





Stress tests (treadmill/scintigram/stress echo/stress MRI)
MRI
Other
Q13b: If you marked ‘’other» in the previous questions, please describe the modality used.
Q14a: What proportion of patients presenting with NSTEMI receives invasive coronary angiography? 
(leave blank if you do not know)
Q14b: What is the average time between diagnosing an NSTEMI patient and performing invasive coro-
nary angiography? (leave blank if you do not know)
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TreATMenT
Q15a: Which reperfusion treatment method do you use for patients presenting with a STEMI and no 
contra indication of treatment? Please also precise the proportion of patients treated with each method.
Percutaneous coronary intervention (PCI)
IV thrombolysis
PVI and IV thrombolysis
Other treatment
Q15b: If you marked ‘’other treatment” in the previous questions, please describe the modality used.
Q16a: Which revascularization treatment method do you use for patients presenting with a primary 




Q16b: If you marked ‘’other treatment” in the previous questions, please describe the modality used.
Q17: Following PCI of the culprit lesion, what is THE MOST COMMON STRATEGY for dealing with sus-
pected non-culprit lesions in a 65-year-old NSTEMI patient presenting a relatively good clinical status?
Conservative management and PCI only if symptoms or reversible ischemia on stress test
Elective stress-test (stress Echo/scintigram/threadmill/stress MRI)
Coronary computed tomography angiography (CCTA)
Immediate PCI during index catheterization
Immediate FFR-guided PCI during index catheterization
Staged PCI during index hospitalization
Staged FFR-guided PCI during index hospitalization
Staged elective PCI within 4-6 weeks
Coronary Artery Bypass Graft surgery
Other
fOllOW-uP IMAgIng
Q18a: Do you routinely perform follow-up imaging immediately after interventional therapy and within 
4 days after symptom onset? (answers c and d can be combined)
Yes, for all patients
Yes, for STEMI patients only
Yes, for patients presenting clinical deteriorations




Q18b: What are the main imaging modalities used as follow-up imaging after revascularization and 
within 24 hours?
Echocardiogram








Q18c: If you marked ‘’other’’ in the previous question, please describe the modality used.
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Supplementary fi gure 3. Reported percentages of patients receiving diff erent imaging modalities when 
presenting with a high probability of ACS after biochemical tests.
Respondents were asked about the imaging modalities used to make the treatment decision
Timing of troponin assays
Regarding troponin assays used as serial testing, of the 56 respondents who indicated 
that the fi rst test was performed upon hospital admission, 12 reported no subsequent 
test, 10 reported a subsequent test at 3 hours after symptom onset and 7 reported a test 
at both 3 hours and 6 hours. Besides these main trends in serial testing, other respon-
dent reported various combinations of timing, with answers including testing at 2, 4, 5 
and 12 hours after symptom onset.
follow-up imaging after revascularization treatment
In the phase of follow-up imaging used up to 24 hours after revascularization treatment, 
echocardiogram was reported to be used for an average of 74% of the patients across 
Europe, far ahead of MRI and myocardial perfusion scan (each modality being reported 
to be used for 6% of the patients).
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Cardiovascular diseases cause a high humanistic and economic burden worldwide [1-3]. 
Imaging diagnostic tests have been increasingly used in this field over the past decades, 
which has transformed the landscape of cardiovascular care but also raised concerns 
about potential overuse of diagnostics [4,5]. CEAs of diagnostic tests and treatments 
may inform appropriate clinical use of these techniques while improving medical deci-
sion making in a context of limited resources. The aim of this thesis was to assess the 
potential cost-effectiveness of a currently developed advanced imaging diagnostic 
technology (SPCCT), for supporting health care decision making in cardiovascular 
diseases, taking into account international variation. This chapter presents an overview 
of the main findings of this work, the implications of the results, the challenges encoun-
tered, the limitations of our approach and some recommendations for further research.
9.1 MAIn fInDIngS
In a context of variety of imaging and treatment options in stroke care, little was known 
regarding the diagnostic and treatment workup for patients presenting with a suspected 
stroke in Europe. Therefore, we conducted a systematic literature review (Chapter 2) 
and a clinician survey (Chapter 3) to identify the patterns of stroke diagnostic imaging 
and acute revascularisation treatments in routine clinical practice. We also examined 
practice variation across European countries. Our systematic review showed that CT was 
the most widely used imaging modality for diagnosing stroke in Germany, Sweden and 
the UK. Furthermore, our review highlighted potential variations in the imaging workup 
of stroke patients, depending on the category of hospital, on timeslots of the day and 
week and on geographic areas. No evidence regarding the optimal imaging strategy to 
diagnose stroke patients could be found. Our clinician survey confirmed the pivotal role 
of CT as the first-line imaging modality to diagnose stroke and revealed CTA as one of 
the common second-line modalities for ischaemic patients throughout Europe. This in-
formation was used to define the comparator (i.e. current care) in our CEAs of advanced 
imaging. In contrast to these diagnostic-specific findings, considerable variation in the 
revascularisation treatment for ischaemic strokes was observed across countries, in 
terms of percentage of eligible patients treated and treatment used (MT or intravenous 
thrombolysis). Similarly, our second clinician survey (Chapter 7), focusing on clinical 
practice in ACS, suggested large variations in the diagnostic modalities and acute treat-
ment used across geographical areas in Europe. In both disease areas of stroke and ACS, 
current care appears to be heterogeneous and little evidence is available to accurately 
identify and quantify practice variation across countries. Gaining insight into the clinical 




The potential cost-effectiveness of SPCCT in the diagnostic work-up of ischaemic stroke 
patients was investigated in different healthcare systems: the UK, the US, Germany, Hun-
gary and Sweden (Chapters 4, 5 and 6, respectively). Our CEAs suggest that advanced 
imaging (such as SPCCT) to select patients for late MT was cost-effective in the UK 
(£6,164 to £37,229 per QALY, depending on imaging accuracy and prior probability) and 
in the US ($662 to $13,877 per QALY, depending on trial data used). A reduced specificity 
of SPCCT reduced its cost-effectiveness; this effect decreased as the prior probability 
for patients to benefit from late MT decreased. Moreover, we investigated the cost-
effectiveness of SPCCT followed by late MT in 27 subgroups of US ischaemic patients 
with a large occlusion (i.e. those who are eligible for late MT). Our findings suggest 
that SPCCT and late MT are cost-effective in all subgroups in the US setting. However, 
increased uncertainty about the cost-effectiveness was observed for some subgroups 
(patients with NIHSS**≥16 and patients of 80 years or older). Both our UK-based and US-
based models suggest that although it is worth investing in SPCCT, in combination with 
treatment, more research is needed regarding the (prior) probability that patients will 
benefit from late MT. Despite the general conclusions regarding the cost-effectiveness 
of SPCCT in the US and in the UK, we highlighted that the country-specific findings were 
not generalisable to other countries.
The topic of generalisability of cost-effectiveness models to other settings was addressed 
in a subsequent step (Chapter 6). More concretely, we combined two frameworks and 
applied a four-step approach to assess the validity of transferring a decision analytic 
model from the UK to Germany, Hungary and Sweden. Large variations were observed in 
the country-specific cost-effectiveness estimates of SPCCT across countries. Although the 
exact value of SPCCT is country-dependent, this new technology was found to be cost-
effective in all investigated countries. Based on our method to assess the process of trans-
ferring an original model, we showed different levels of validity of our cost-effectiveness 
results, mainly related to the quality of the country-specific input data that we used.
Finally, we investigated the potential cost-effectiveness of SPCCT in selecting patients 
with NOCAD for statin treatment, based on the imaging identification of vulnerable 
plaques in the UK (Chapter 8). We modelled four different comparators in order to reflect 
variation in current care and explore the impact of different imaging accuracy levels on 
the cost-effectiveness of SPCCT. Based on our findings, an improved imaging test with 
higher sensitivity in identifying vulnerable plaques in patients with NOCAD provides 
good value for money.





9.2 IMPlICATIOnS Of Our reSulTS
The results of our analyses have latent implications at different levels of the healthcare 
system and for various stakeholders.
early-cycle health economic evaluations for test developers
Early CEAs and, more generally speaking, early economic evaluations provide key infor-
mation that manufacturers of the medical industry may use to optimise their product 
development [6,7]. More precisely, early cycle health economic evidence has been 
shown to support strategic research and development decisions (including portfolio 
management), preliminary market assessment and preliminary pricing and reimburse-
ment estimates [8]. The contribution of our early-HTA work to manufacturers is mainly 
valuable in guiding the research development phase of SPCCT and in providing some 
preliminary estimates of the market potentials in two disease areas. First, in the initial 
phase of the SPCCT project, expert panels were conducted that engaged radiologists, 
neurologists, cardiologists, physicists and health economists from academia and the 
industry, both internal and external to the project, in early dialogues. These ‘’scoping’’ 
meetings gave birth to a preliminary inventory of the potential uses of an improved 
photon-counting imaging test in clinical practice. The most promising use of that 
inventory was ascertained through a process of external and independent validation 
with clinicians in different countries. As such, we elicited the most likely use of SPCCT 
in terms of disease area (acute ischaemic stroke and NOCAD), the potential sequence 
(single replacement test) and application (diagnostic, prognostic and/or companion 
diagnostic test to decide on a therapy). These elicitations were also refined according 
to the results of our systematic literature reviews and clinician surveys (Chapters 2, 3 
and 7). In that respect, it is interesting to note that the findings described in Chapter 7 
(survey of current care in ACS) led to a shift in the potential use of SPCCT in cardiac care, 
namely from ACS to NOCAD area. Second, we investigated the impact of the diagnostic 
performance (sensitivity and specificity) of SPCCT on the cost-effectiveness results 
(Chapter 4 and 8). Our results showed that specificity should be favoured over sensitivity 
in the diagnosis of stroke patients, while sensitivity should take priority in the diagnosis 
of NOCAD patients. These findings are concrete elements that should determine the 
technical features and specifications related to the performance of SPCCT. With this 
information at hand, manufacturers are better equipped to anticipate and mitigate the 
risk of developing a new complex technology and can thereby maximise their return on 
investment. In Chapter 4, we also investigated the impact of the prior probability to ben-
efit from late MT on the cost-effectiveness of SPCCT. By doing so, we also provided pre-
liminary indications of the market potential for SPCCT in stroke care. We highlighted the 
multi-level uncertainty around our cost-effectiveness estimates: parameter uncertainty, 
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structural uncertainty but also heterogeneity caused by patients’ characteristics. Given 
this uncertainty, the complexity and high cost of advanced imaging test development, a 
dynamic and iterative process of integration of the newest evidence and adjustment of 
the product specificities is recommended [7]. This iterative process should also capture 
other important stakeholders’ perspectives, among which the clinician’s perspective is 
essential.
Clinicians
As previously mentioned, internal and external clinicians are continuously involved 
along the development phase of a medical product. They provide feedback and advise 
on the indications and applications that a new technology could have in clinical prac-
tice. In addition, clinicians may influence the trade-off level between sensitivity and 
specificity of a new diagnostic test. As such, clinicians make an explicit bridge between 
the industrial and clinical worlds, which is essential to guarantee the applicability and 
relevance of industrial products in the healthcare setting. Their contribution in all phases 
of our early-HTA work (framing, structuring, making assumptions, analysing the results) 
was also essential to articulate the medical and health economic concepts and ensure 
the clinical validity and relevance of our models. In the absence of RCTs, results of early 
decision-analytic models provide preliminary evidence for medical decision making 
that needs to be ascertained by clinicians. In addition to this continuous consultancy 
role to the manufacturer and health economists, clinicians are key opinion leaders at 
the hospital level who play a substantial role during the selection and implementation 
process of a new diagnostic test. The acquisition of a diagnostic imaging device is a 
large and potentially risky financial investment in an equipment expected to have a 
long economic life in the hospital. Therefore, it is essential that clinicians understand 
how a new medical product addresses concrete clinical needs, in terms of both health 
outcomes and process outcomes. Furthermore, the implementation of a new imaging 
diagnostic tool might have extensive implications in the organisation of care at local 
and regional levels. If the choice was made to implement stroke advanced imaging in 
only a few hospitals countrywide, these hospitals would certainly become regional hubs 
for the diagnosis and triage of suspected stroke patients. This would have consequences 
in terms of the human and material resources needed in these hospitals to absorb the 
incoming flow of patients from a vast region. On a more practical note, it is important to 
keep in mind that clinicians are the end users of diagnostic devices in their daily work. 
Reluctance to change and bias towards more traditional, gold standard or expert-driven 
modalities might play an important role in the way clinicians and opinion leaders in-





Policy makers and national payers: reimbursement, clinical guidelines 
and future research
The assessment of diagnostics in Europe is untransparent and often relies on a reim-
bursement review at the local or regional level, which contrasts with the national process 
generally applied to drug reimbursement decisions [10]. In addition, diagnostic tests are 
often reimbursed through a DRG payment in Europe. In this context and given the early 
HTA nature of our analyses, it is unlikely that our work can directly be used to inform 
reimbursement decisions by the payer (i.e. government or insurer). However, our analy-
ses clearly showed that advanced imaging, used to inform MT treatment, provides high 
value for money across the different investigated countries (UK, US, Germany, Hungary 
and Sweden) (Chapter 4, 5 and 6). In a universe where cancer drugs and drugs for rare 
genetic illnesses are being paid for at millions of dollars or euros per QALY gained, the 
ICERs that we presented in our results imply that major public investments should be 
made in MT, and therefore, in prerequisite diagnostics to this treatment. Given the mag-
nitude of the effects of MT and the likelihood that interventions improving functional 
outcomes in stroke are highly cost-effective, our results might influence future positive 
reimbursement decisions. Most importantly, our results provide an understanding of 
the science that relates to particular clinical decisions and might encourage healthcare 
authorities to revise clinical guidelines both in the field of stroke (time of treatment since 
onset, explicit imaging criteria required for treatment) and NOCAD (systematic imaging-
based decision to select patients for statin therapy). Our work might also stimulate 
healthcare authorities to commission additional research that will be needed to achieve 
future reimbursement decisions. Major parameters driving decision uncertainty were 
identified (e.g., prior probability to benefit from MT, long-term post-stroke costs, test 
accuracy), which might serve as a basis to set the research agenda, preferably based 
on explicit value of information analyses. Future policy questions might address the 
magnitude of the cost-effectiveness across heterogeneous subgroups or the maximum 
number of endovascular treatments that the annual budget can bear, for example.
early health economic evaluations for research and beyond, gaining 
international insight
Our model-based analyses in the area of stroke essentially confirm the existing health-
economic knowledge regarding the value of MT while pushing the boundaries of 
evidence further, with an emphasis on the impact of advanced imaging and patient 
heterogeneity on the ICER (Chapters 4 and 5). Our model-based analysis in the field of 
NOCAD presents new evidence regarding the potential value of an improved test on 
plaque assessment for selection of patients for statin treatment (Chapter 8). Given the 
fact that no model is perfect, there is a necessity to compare the results of different 
models investigating similar research questions and scrutinise their methodology in the 
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quest for convergence validity. In that respect, our work contributes to the scientific 
understanding of the link between disease progression, disease-related cost structure 
and the positioning, requirements and usefulness of a new imaging technology in 
stroke and NOCAD care. Based on evidence synthesis, our early-HTA work converted 
raw numbers into results and information that are relevant to the scientific commu-
nity. Finally, in spite of the heterogeneity in the role of HTA across European countries, 
our country comparison (Chapter 6) demonstrated, through a unique methodology 
(early cost-effectiveness), that the exact value of SPCCT is country-dependent. Although 
SPCCT has a country-specific value, it appeared to be uniformly cost-effective across the 
countries that we investigated. In that respect, our country comparison provides valu-
able international insights and may contribute to lowering barriers to market access for 
advanced imaging in countries that have a slower rate of adoption of new technologies, 
such as Hungary. Based on recent evidence, countries that are ‘’recent’’ adopters of HTA 
(such as Hungary and, more generally, Central and Eastern Europe) consider the decision 
made in ‘’early HTA adopter’’ countries (such as England, Germany, Sweden, or France) to 
inform their own final decision regarding the reimbursement of drugs [11]. Anchoring 
a Hungarian decision on the use of the appraisal decision of another European country 
might not reflect the local conditions, priorities and values. Our analysis (Chapter 6) 
highlights the need to use local data as input for final decision making while providing 
strong preliminary evidence of the value of SPCCT in Hungary.
9.3 CHAllengeS enCOunTereD
Assessing current care
Three chapters of this thesis were dedicated to the assessment of current care in routine 
clinical practice (Chapters 2 and 3 related to stroke care, and Chapter 7 related to ACS 
care). In this attempt to gain insight into current care, we faced major challenges caused 
by the lack or unavailability of data. On the one hand, literature reviews tend to be 
generated late which introduces a time mismatch between the availability of evidence 
and the moment data are needed to perform HTA analysis. On the other hand, while 
surveys offer the advantage of their flexibility and specificity to a topic of interest, their 
results may not be representative or generalisable. Finally, registries are often exclusive 
to rare diseases or cancer care and present various limitations. In this context, and due 
to the international scope of our analyses, the assessment of current care turned out to 





Choosing a unique comparator in a context of healthcare variation
Given the incremental concept that forms the backbone of the methodology in CEAs, 
the choice of a relevant comparator was essential to determine the value of the health 
technology being assessed. Given the substantial practice variation across countries in 
terms of diagnostic imaging techniques used in stroke care, the choice of a comparator 
was challenging. Based on the results of our European clinician survey, CT + CTA was 
identified as a general, widespread and most likely comparator to be used in our Europe-
an-based CEAs (Chapters 4 and 6). In contrast, in Chapter 5, our comparator was chosen 
based on the imaging modalities used in the DAWN and DEFUSE 3 trials (CT+ CTA or 
MRA + CTP or MRI). Large practice variation in diagnostic techniques used in the field of 
stroke care exists, which suggests that the value of SPCCT should be assessed against 
that of multiple comparators (including relevant combinations of imaging tests) or 
against a realistic mix of diagnostic technologies. We could have adjusted the structure 
of our stroke model (Chapter 4 and 6) and included more comparison arms to reflect 
variation in current care, which would have reduced the structural uncertainty. However, 
for feasibility reasons, for the sake of obtaining findings that are useful at healthcare 
system level and in line with clinicians’ inputs, we simplified our research to a single 
comparator (stroke analyses). Given the lack of evidence regarding the standard assess-
ment and selection of NOCAD patients for statin therapy, we decided to model more 
comparison arms in the related model (Chapter 8). In the case of large practice variation, 
hospital-level CEAs might be particularly relevant as part of the evidence needed to 
inform decisions made at hospital level (such as buying a new imaging device).
early HTA: modelling the unknown and dealing with uncertainty
Given the early phase of development of SPCCT, the most likely clinical indications 
where this new imaging technology could add value was uncertain. Scoping meetings 
with clinicians highlighted different viewpoints and a lack of consensus regarding the 
potential use (diagnostic, prognostic, screening, follow-up) of SPCCT and the patient 
populations most likely to benefit from this new technology. Specifically, while the 
diagnosis of ACS initially appeared to be a prospective area where SPCCT could add 
value, a final decision was made to center our CEA on NOCAD. Furthermore, for feasibil-
ity reasons, we limited the value assessment of SPCCT to two disease areas (ischaemic 
stroke and NOCAD) while in reality, SPCCT could have increased value in various other 
indications, and even in other disease areas. Most importantly, once implemented in 
clinical practice, SPCCT will not be limited to one indication but will rather serve a range 
of diseases, clinical applications and patient populations, which will influence its aver-
age cost-effectiveness. Furthermore, at the time of our analyses, the accuracy of SPCCT 
per medical condition was unknown, which was addressed by different methodologies. 
Concretely, different pairs of sensitivity and specificity were simulated in a scenario-
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based analysis in Chapter 4, a perfect test was modelled in Chapter 6 and two SPCCT-
based strategies were modelled in Chapter 8. Finally, a substantial part of our work was 
dedicated to measuring uncertainty around our results. The uncertainty around the 
current care estimates (Chapters 3 and 7) was explored by means of the non-stochastic 
simulation method of bootstrapping. Multivariate parameter uncertainty was addressed 
by means of stochastic simulations in PSAs (Chapters 4, 5, 6 and 8). In addition to the 
CEAC(s) presented in these four chapters, confidence intervals around the determin-
istic results and deterministic 1-way sensitivity analyses were introduced in Chapter 5. 
These various methods were chosen to address the dual challenge of dealing with and 
efficiently communicating uncertainty to different stakeholders. Although we primarily 
focused on the impact of parameter values, structural uncertainty, resulting from the 
model design and the various structural assumptions, is probably a major source of 
uncertainty worthy of further investigation [12]. While our modelling work in the field of 
stroke care benefitted from relatively mature research, with available models and data, 
modelling NOCAD involved greater structural uncertainty, mostly driven by the lack of 
robust evidence regarding current care and treatment efficacy. Future research will be 
needed to more specifically address the joint structural and non-structural uncertainty, 
especially in the field of NOCAD. ‘’Disease-specific model standardisation’’ might be an 
approach to decrease structural uncertainty [12,13].
Simplifying reality
A model is a simplification, and therefore an approximation, of reality, based on framing, 
assumptions and the input data (e.g., cost data, disease progression, quality of life data). 
There is a tradeoff between accuracy (adequation between the model and the reality) 
and feasibility, which, as such, presented a first challenge. In the phase of structuring the 
model, it can be difficult to assess which level of precision and complexity is needed to 
obtain accurate results without making the data collection exercise impossible. Another 
major structural simplification lay in the fact that we modelled the crude discrete prob-
abilities to benefit from late MT (stroke care, Chapter 4) (probabilities of 10%, 20% and 
30%). Ideally, we would have modelled the explicit clinical imaging markers (volume of 
infarcted tissue, volume of salvageable brain tissue or penumbra, for example) used to 
predict patients’ outcome and referral to treatments [14-16]. Given the lack of evidence 
regarding these concepts, in terms of imaging thresholds or prevalence, these physi-
ological findings were not explicitly modelled. In addition, a second challenge inherent 
to any modelling exercise related to the limited data available. Specifically, in our work, 
cost data for SPCCT were not available and were based on assumptions. In addition, the 
paucity of available and existing stroke data in Germany and Hungary, respectively, ham-
pered the accuracy and the validity of these countries’ estimates (Chapter 6). While the 




is relatively mature, we encountered an extreme paucity of data in the area of NOCAD 
and our modelling work had to rely on numerous assumptions (Chapter 8). Finally, we 
presented deterministic results that essentially are costs per average patient, which is a 
concept that does not exist in the real world. On the contrary, between-patient variation 
might be substantial and the impact of this variation on the ICER could be addressed by 
means of alternative research methods (such as discrete event simulations).
Assessing diagnostics
Given the indirect and uncertain effects of a test on patient’s outcomes (via treatment), 
the value appraisal of diagnostics is more complex than that of drugs and requires ex-
tensive knowledge of the post-diagnosis care pathways [17]. Due to this indirect effect, 
it can be challenging to disentangle the value of an imaging test from the value of the 
treatment or procedure delivered based on the test’s results. The value assessment can 
be even more challenging when, in combination to the treatment, the patient modifies 
his lifestyle (smoking or exercise, for example) based on the information provided by the 
test, which would typically be the case for NOCAD patients selected for statin therapy. 
Furthermore, the benefit of a correct diagnosis, the potential harm of a false-positive 
diagnosis and the loss of benefit in a false-negative case, in the short- or long-term, are 
strong drivers of the value of diagnostic tests that go beyond the technical performance 
(sensitivity and specificity) [18]. The value of a diagnostic test also depends on the pre-
test probability of the disease or condition, which may not be precisely known [18]. In 
case additional tests are used in clinical practice, they will change the prior probability 
before the subsequent test, which will impact the value of the diagnostic technology 
being assessed. Finally, there may be adverse effects of performing the test, caused by 
the toxicity of the contrast agent used or the exposure to radiation [18]. The clinical and 
economic value of diagnostics is therefore the result of many variables that all need to 
be taken into consideration during the value assessment.
9.4 lIMITATIOnS Of Our APPrOACH
We acknowledge different methodological limitations in our work.
narrow classical approach: CeA
Besides the limitations of the individual studies described in the Chapters, the main 
limitations of our work come from the narrow classical approach to determining the 
value of a health technology for the purpose of its reimbursement at healthcare system 
level. With this approach, we fail to capture the comprehensive value that SPCCT might 
offer to various stakeholders in the healthcare and societal arenas. The results that we 
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provided (ICER) represent the general healthcare cost per QALY gained per patient. At 
hospital level, these results might be heavily impacted by local factors, ranging from the 
volume of patients scanned per year, the patient case-mix (in terms of age, disease or 
comorbidities) and the human and material capacity to deliver acute treatments follow-
ing diagnosis. We touched upon the impact that the cost of RAPID software (needed in 
addition to CTP or MRI, to inform treatment decisions beyond 6 hours from stroke onset) 
might have on the cost-effectiveness of advanced imaging at hospital level (Chapter 5). 
The annual cost of the software per hospital varies substantially per institution ($17,500 
to $52,000 in the US), depending on the use and configuration (for one scanner or un-
limited software license). Considering that the annual software cost would be divided 
among the annual number of patients scanned, the cost-effectiveness of advanced im-
aging might considerably vary across hospitals. In addition to the software costs, critical 
capital equipment investment is involved when it comes to acquiring imaging diagnos-
tics. Cost-effectiveness evidence at hospital-level is needed to inform hospital managers 
regarding their investment decisions. Furthermore, hospital-specific cost-effectiveness 
estimates might be needed to optimise the organisation of stroke care, based on the 
number and localisation of diagnostic- and/or treatment-capable hospitals at country 
level. While reimbursement of the patient scans is a key criterion for investment, budget 
considerations are also essential in the strategic investment choices that hospital man-
agers are responsible for. As such, the approach used to inform decisions applicable at 
a healthcare system level may not be suitable for decisions applicable at a healthcare 
provider level where complementary decision tools might be needed.
relevance of hospital-based HTA or mini-HTA
Compared to CEA, mini-HTA provides a broader HTA approach to decision making. Mini-
HTA is a comprehensive management and decision support tool targeted at hospital 
managers and clinicians which aims at a strong role for healthcare providers [19,20]. The 
tool is intended to promote informed decision making regarding the acquisition (i.e. 
purchase) of a new health technology, taking into consideration scientific evidence (for 
patient benefit) combined to the impact on the hospital in the context of its organisation, 
culture and economic considerations [19, 20]. The dimension of value at hospital level 
may be captured through safety, patient impact and benefit, cost-effectiveness, quality 
of evidence and level of innovation [21]. The dimension of risk may be broken down 
into the impact on staff and space, incremental and net costs and the investment effort 
required [21]. Most of these variables were not incorporated in our cost-effectiveness-
based value appraisal. Various initiatives of mini-HTA or hospital-based HTA have been 
developed in recent years [22]. Although their approaches seem unharmonised, these 
initiatives reflect a clear general need for hospital-based evidence when medical tech-




approaches, a tool combining mini-HTA and multi-criteria decision analysis (MCDA) was 
developed, also reflecting the growing need to incorporate the opinion of end-users (i.e. 
clinicians) into the hospital decision making process [23].
Beyond CeAs: MCDA and budget impact
We touched upon some of the limitations of the cost-effectiveness framework with 
regards to its general implications at healthcare system level. Fortunately, HTA is a much 
more comprehensive discipline which offers complementary methods addressing other 
important concepts than value, such as equity or affordability.
MCDA is a potential contributor to decision making that involves a broader and flexible 
set of criteria or benefits, compared to the restricted cost per QALY gained (captured by 
the ICER). MCDA allows for a systematic, explicit, transparent trade-off between various 
relevant criteria in the decision-making process [24]. This method offers the advantage 
to account for multiple stakeholders’ perspectives [24]. The included criteria vary widely 
and include disease prevalence, disease severity, life expectancy of a patient left un-
treated, effectiveness of intervention and whether the condition is related to patient 
risk behavior. Noteworthy is the fact that the ICER can be part of the MCDA. In line with 
this approach, a recent comprehensive benefit-risk framework specifically assessing the 
value of imaging diagnostics identified 36 criteria classified into three domains: test or 
device attributes, clinical management or provider experience and patient experience 
(Table 9.1) [25]. These criteria are subject to trade-offs across diseases and patients’ or 
providers’ preferences. Furthermore, the choice of criteria depends on the disease or 
indication. While the missed cases, the examination time or the patient preparation re-
quirements might be essential criteria in acute stroke care where ‘’time is brain’’, criteria 
related to patient experience (radiation, toxicity of contrast agent) may be more relevant 
in the area of NOCAD.
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Table 9.1 Benefit-risk criteria for the assessment of diagnostic imaging, categorised into 3 domains [25]
Test-specific features Patient Management and Provider 
experience
Patient experience
Missed cases Therapeutic/procedural success Value of knowing





Potential for incidental finding 
management




Net unnecessary treatment (test prescribed 
or averted treatment)
Patient comfort
Depth/breadth of anatomy 
visualisation
Access to test Patient future compliance 
and behaviour
Invasiveness/risk of adverse 
events
Time to diagnosis Radiation-induced cancers
Contrast reaction potential Inpatient/outpatient healthcare visits Length/quality of life
Ionising radiation dose Time to discharge
Patient-specific exclusions Provider utility










Finally, while we have clearly showed that advanced imaging for referral to MT provides 
high value (in terms of cost per health outcome), we have not assessed the affordability 
of the intervention (diagnosis + treatment) at country level. Affordability can be evalu-
ated by means of a budget impact analysis which is generally conducted in addition to 
the ‘’companion’’ CEA [26]. A budget impact analysis accounts for the number of patients 
who need the intervention (stroke incidence for instance) multiplied by the cost of the 
intervention at a short time-horizon (a few years). This analysis allows national payers 
to quantify how using the technology in clinical practice will affect their budget and is 
often used for resource planning and budget allocation. Affordability is a key element 
determining patient access to treatment. In the case of stroke, in spite of the high value 
of advanced imaging and MT, it is likely that some governments cannot afford to cover 
the costs of diagnostic and treatment for all clinically eligible patients. An intervention 
might be highly cost-effective but unaffordable at population level, which suggests 




ences (younger patients, patients with the greatest needs or patients most likely to 
benefit from treatment, for example). Finally, a budget impact analysis, incorporated 
as an element of mini-HTA, could be highly relevant to decision makers. Budget impact 
analyses performed at hospital level might support the idea that high-cost diagnostic 
technologies should be concentrated in a few specific hospitals or clinics rather than 
widely spread.
One method does not fit all countries
We provided international insight into the value of SPCCT in the UK (Chapter 4 and 8), in 
the US (Chapter 5) and in Germany, Hungary and Sweden (Chapter 6). Our country-specific 
results are based on the single methodology of cost-effectiveness, which might not equally 
be suited to the different investigated countries. While the UK, Germany and Sweden strive 
for a better quality and equal access to care combined with an efficient use of resources, 
Hungary places increased attention on budget considerations during the pricing and 
reimbursement decision-making process [11]. In contrast, the US has historically been 
less inclined to financial constraints in healthcare [27]. Germany follows the principle of 
added therapeutic benefit and requires health economic evidence (cost-benefit analyses) 
for reimbursement decisions only when no agreement on the reimbursed price is reached 
[11]. These different uses of HTA across European countries show that country-specific 
methods should be used to assess the country-specific value of healthcare technologies, 
especially if the value appraisal is intended for reimbursement.
To a certain extent, and in the interest of patients across countries, our work questions 
the necessity of a more harmonised international HTA system to ensure timely and eq-
uitable access to new high value healthcare technologies. EUnetHTA (European network 
for HTA) has the mission ‘’to support collaboration between European HTA organisations 
that brings added value to healthcare systems at the European, national, and regional 
level’’ [28]. Despite the EUnetHTA achievements, concern has been raised regarding 
the untransparent and heterogeneous reimbursement decisions across countries for a 
similar drug-indication [29]. To date, despite growing efforts focused on the assessment 
of medical devices by EUnetHTA and other HTA organisations, no evidence regarding 
the appraisal process for expensive imaging diagnostics is available. The challenges and 
specificities related to the reimbursement of diagnostics suggest rather more heteroge-
neity than less, compared to pharmaceuticals.
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9.5 reCOMMenDATIOnS fOr fuTure reSeArCH
We have provided an early insight into the potential value of SPCCT. Further research 
is needed to confirm our cost-effectiveness estimates. First, real world data are needed 
to understand what imaging modalities are currently used in clinical practice for the di-
agnosis of stroke and NOCAD patients at hospital level, national level and international 
level. Real world data based on registries, patient electronic dossiers or big healthcare 
data might be ways to obtain high quality data, especially in countries characterised by 
less research capacities. Value of information analyses using our models could be help-
ful to set the research agenda and priorities regarding data collection. Second, clinical 
studies of SPCCT (trials and observational studies) should be conducted to provide solid 
evidence regarding the clinical efficacy. The potential harms of testing should also be 
investigated. More generally speaking, the value assessment of SPCCT from a patient 
perspective might be relevant. Third, structural uncertainty related to the framing of our 
CEAs should receive additional attention. This particularly needs to be addressed in the 
area of NOCAD, where more robust evidence regarding long-term statin efficacy is nec-
essary. Disease-specific standards for modelling might contribute to a higher quality of 
the health-economic evidence. Fourth, further research should investigate the optimal 
deployment of advanced imaging diagnostic based on the organisation of acute stroke 
care at country level. Since the value of advanced imaging operates via treatment, it is 
necessary to optimise the network of care according to the country-specific practical 
constraints, in terms of budget, manpower, geography, infrastructures and culture. Fifth, 
there is a limit to the price of advanced imaging per patient beyond which the country-
specific conventional cost-effectiveness threshold, if any, will not be met. Headroom 
analyses should be conducted to determine the maximum price of an advanced imag-
ing scan per stroke patient and NOCAD patient according to the national willingness-
to-pay threshold. Headroom analyses could also inform value-based pricing and should 
be conducted for each indication of SPCCT. Finally, international harmonisation of the 
HTA process for reimbursement might be needed to promote fairness and equitable 
access to care for patients across countries. The relevance and mandate of international 
organisations such as EUnetHTA to promote HTA harmonisation throughout European 
countries in favour of equal access to care should be determined.
generAl COnCluSIOn
Despite a lack of data and considerable practice variation across countries, we have used 
modelling techniques to assess the cost-effectiveness of complex diagnostic strategies 




effectiveness of the currently developed SPCCT modality in stroke and NOCAD care and 
identified the technical drivers of the value per disease area. We explained the relevance 
of our early HTA findings to the manufacturer and highlighted the necessity to sharpen 
our cost-effectiveness estimates once more evidence and (quality) data become avail-
able. The evidence of value of SPCCT might be required by decision makers or payers at a 
later time. Although CEAs form a solid pillar in value assessment regardless of the level of 
decision making, they present limitations that complementary methods incorporating 
different stakeholder perspectives may overcome. Depending on the stage of diffusion 
and implementation of SPCCT, later in its life cycle, a more comprehensive approach 
including mini-HTA, MCDA and budget impact analyses might become relevant. In the 
current phase, our economic analyses present strong and useful evidence of how SPCCT 
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Worldwide, in a context of diffusion of medical technologies and increasing healthcare 
costs, there in a strong need for scientific evidence to support the decision-making 
process regarding the use and financing of new technologies. Health technology as-
sessment (HTA) is the systematic evaluation of the direct and intended effects of a health 
technology, as well as its indirect and unintended consequences. Economic evaluations 
are the core of HTA and provide insight into the costs and effects of a new technology 
compared with another one, which, in many occasions, is current care. The methods 
of cost-effectiveness analysis and cost-utility analysis are commonly used, leading to 
the generic efficiency outcome of cost per quality-adjusted life year (QALY). Framing 
is a crucial initial step of a cost-effectiveness/utility analysis, which includes defining 
the patient population, the intervention, the comparator, and the perspective. Framing 
also is required when evidence from various sources is mathematically synthesised in 
a decision analytic model. The key purpose of decision modelling in healthcare is to 
provide evidence for decision-making under the conditions of uncertainty. Decision 
model uncertainty is threefold: it includes the uncertainty related to the values of the 
parameters used, to patient heterogeneity and to the structural choices that are be-
hind the model, such as the clinical events and statistical methods used. Making these 
concepts of uncertainty explicit, early HTA can also be used alongside the research and 
development phase of a new technology to inform the manufacturer and other relevant 
stakeholders about the potential value of the technology. This is especially relevant 
for diagnostic technologies since early decision analytic modelling may encourage 
developers to adjust the technical features to improve the value of new diagnostics for 
treatment decisions, patients, healthcare providers, manufacturers, and more generally, 
society. A positive value assessment might lead to favourable decisions regarding pur-
chase and/or reimbursement by healthcare providers and healthcare authorities. Finally, 
since the value of a health technology is highly dependent on the healthcare system 
context, transferring health economic evidence from one country to another might be a 
fast and efficient method to inform decision makers in various jurisdictions.
Diseases
Leading cause of death and associated with a high humanistic and economic burden 
globally, cardiovascular diseases (CVD) are a group of disorders of the heart and blood 
vessels, that include coronary heart diseases and cerebrovascular diseases. The large 
majority of CVD cases is caused by atherosclerosis, which is the deposit of fatty mate-
rials (or plaques) on the inner wall of arteries. Plaques and plaque rupture or erosion 
can cause vessel occlusion and lead to cardiovascular events, such as acute coronary 
syndrome (ACS) (including myocardial infarction (MI)), stroke and/or death. The new 
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emerging and innovative imaging technology spectral photon-counting computed 
tomography (SPCCT) could potentially add value in the diagnostic workup of patients 
experiencing or being at risk of a cardiovascular event.
This thesis focuses on two major cardiovascular disorders: ischaemic stroke and coronary 
artery disease (CAD), with ACS and non-obstructive coronary artery disease (NOCAD). 
First, acute patients presenting with stroke-like symptoms need to receive a timely as-
sessment of the cause and nature of brain damage before clinicians can decide on the 
type of acute treatment. SPCCT is expected to improve acute stroke treatment decision-
making by a better quantification of brain perfusion impairment. Second, patients 
presenting with chest pain or discomfort require an assessment of the cause of their 
complaints before treatment can be determined. By its higher sensitivity to calcification 
and increased spatial resolution, SPCCT is expected to improve the accuracy of coronary 
stenosis measurement and the characterisation of atherosclerotic plaques in terms of 
their structure and biology. With this level of information, SPCCT is expected to identify 
plaques that are at risk of rupture and to guide the decision of preventive treatment in 
CAD.
This thesis
The overall objective of this thesis is to assess the potential cost-effectiveness of the cur-
rently developed advanced diagnostic imaging technology SPCCT, to support health-
care decision-making, taking international variation into account. Four main research 
questions are covered. First, what is known about current care and its variation in four 
European countries regarding the diagnostic workup and therapeutic interventions for 
patients presenting with a suspected stroke and patients presenting with ACS? Second, 
what is the cost-effectiveness of SPCCT in ischaemic stroke patients in the United King-
dom (UK) and the United States of America (USA)? Third, is there international variation 
in the cost-effectiveness of SPCCT for patients with ischaemic stroke and is the transfer 
of an economic model a valid method to obtain country-specific estimates? Fourth, 
what is the cost-effectiveness of SPCCT in patients with NOCAD in the UK?
The studies
In Chapter 2, a description of the currently used stroke imaging technologies and prac-
tice variation across Germany, Hungary, Sweden and the UK is provided. This information 
is needed to reflect current clinical practice in our subsequent cost-effectiveness analy-
ses. In a systematic literature review, original studies reporting the imaging workup used 
in acute stroke care were identified. Following the design of a de novo search strategy, 
five databases were consulted, and fifteen studies were included in the final analysis. 
Most of the selected articles were observational studies based on national registries. 
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No study was identified for Hungary. Computed tomography (CT) was reported as the 
main diagnostic imaging modality used in stroke care. Evidence regarding the optimal 
imaging approach to diagnose stroke patients is lacking. Furthermore, evidence was 
insufficient to make an accurate between-country comparison of the imaging workup 
used in stroke care.
A variety of imaging and treatment options for stroke treatment exists. In order to 
complement the findings of Chapter 2 and examine current practice, we developed a 
web-based survey that was distributed to clinicians throughout Europe. Despite a low 
response rate, we presented responses from Sweden (21), the UK (16), Hungary (15), 
Germany (12) and Europe (47) in Chapter 3. Variation in acute stroke diagnosis across 
European countries appeared to be limited regarding the first-line imaging test (CT 
used for 81% to 93% of patients). However, variation increases at later stages of the 
imaging workup and in the choice of treatment. German and UK respondents reported 
that 81% and 12%, respectively, of their patients with a large vessel occlusion diagnosed 
within 4.5 hours received intravenous thrombolysis and thrombectomy. For patients 
diagnosed with an extensive ischaemic stroke within 2 hours from onset, 75% of the UK-
respondents stated thrombectomy as their preferred revascularisation treatment, but 
only 13% reported to use it. We conclude that further research is needed to compare the 
quality of stroke care across countries and determine the most cost-effective second-
line imaging workup to diagnose stroke patients.
In Chapter 4, we compared the cost-effectiveness of two care pathways for acute 
ischaemic stroke patients in the UK: mechanical thrombectomy (MT) limited to 6 hours 
after symptom onset based on conventional imaging versus MT within and beyond 6 
hours based on selection by advanced imaging. For this purpose, we developed a deci-
sion tree (representing the short-term diagnostic and treatment phase) and a Markov 
trace (representing the long-term post-stroke evolution until death) and modelled the 
progression of a hypothetical UK-cohort of patients aged 71. Various scenarios based 
on different values of prior probability to benefit from late thrombectomy and imaging 
accuracy were evaluated. In addition, probabilistic sensitivity analyses were conducted. 
Incremental cost-effectiveness ratios varied from $8,199 (£6,164) to $49,515 (£37,229) 
per QALY gained. Our analyses showed that advanced imaging accuracy impacted 
the incremental cost-effectiveness ratio mainly when its specificity decreased. Over a 
lifetime horizon, all scenarios including late MT improved QALYs. Depending on the sce-
nario, the probabilistic sensitivity analyses showed probabilities varying between 46% 
and 93% for the late MT pathway to be cost-effective at a willingness to pay threshold 
of $39,900 (£30,000) per QALY. We show that, in principle, late MT up to 12 hours from 
symptom onset may be good value for money. However, additional data are needed 
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regarding the implementation of advanced imaging and prior probability for patients 
with an ischaemic stroke to benefit from late MT before the cost-effectiveness can be 
fully assessed.
Recent evidence (DAWN and DEFUSE 3 trials) regarding the functional benefit of late 
MT at a 3-month follow-up showed that MT might be beneficial up to 24 hours from 
stroke onset. Delivering MT in the late treatment window (between 6 and 24 hours from 
symptom onset) requires advanced neuroimaging selection of patients. In Chapter 5, 
we presented whether the short-term functional benefit of late MT based on advanced 
imaging and standard medical care (SMC) translates into cost-effectiveness in the USA 
over a lifetime, compared to SMC only. Adopting a US healthcare perspective, a cost-
effectiveness model combining a decision tree and Markov trace was designed and 
populated with the results of the DAWN and DEFUSE 3 trials. For the total trial popula-
tions, the ICERs were $662/QALY and $13,877/QALY, respectively. Late MT+SMC (versus 
SMC only) has a 99.9% probability of being cost-effective at the willingness to pay of 
$100,000/QALY. Subgroup analyses revealed a wide range of probabilities for MT+SMC 
to be cost-effective at $50,000/QALY, with the greatest uncertainty observed for patients 
with NIHSS≥16 (National Institutes of Health Stroke Scale) and patients of 80 years or 
older.
Chapter 6 presented the international variation in the value of SPCCT for ischaemic 
stroke patients and a methodology to assess the validity of transferring cost-effectiveness 
evidence from a country to another. A 4-step approach combining the framework by Mc-
Cabe and Welte was developed and implemented to assess the validity of transferring 
the decision analytic model of Chapter 4 from the UK to Germany, Hungary and Sweden. 
The UK model appeared to be relevant for the 3 decision countries. Transferability 
limiting factors were identified which led to the localisation of input data per decision 
country. A step was dedicated to the quality assessment of the local data. Model-based 
results were compared across countries. Lifetime incremental cost-effectiveness ratios 
per QALY gained varied across countries: €4,525 (UK), €7,506 (Germany), €12,749 (Hun-
gary), €-11,242 (healthcare perspective) and €-16,362 (societal perspective) for Sweden. 
Despite variation, advanced imaging, followed by late MT, is cost-effective in the 4 
countries. Transferring the original model based on a 4-step approach appeared to be 
an efficient method to provide a preliminary assessment of the cost-effectiveness of late 
MT in different countries. We showed high validity of the cost-effectiveness estimates for 
Sweden. Moderate validity was shown for Germany and Hungary, with the quality of the 
local data being the main validity-limiting factor.
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Chapter 7 presents the findings of our European web-based survey regarding the diag-
nostic and treatment strategies in patients with known or suspected ACS, as reported by 
respondents. The survey focused on ACS imaging and revascularisation treatments and 
on a range of clinical scenarios. Given the limited number of respondents, we clustered 
the responses for Sweden (20), the UK (16), Northern/Western Europe (17), Southern 
Europe (9), and Central Europe (7). Considerable variations between geographical areas 
were observed in terms of reported diagnostic modalities and treatment strategies. The 
differences reported may indicate that some patients do not receive the best available 
care and may experience different health outcomes across geographical areas. Larger 
studies and real-world data are needed to verify these observations and investigate 
their causes.
Patients with NOCAD are at a higher risk of cardiovascular events than patients with 
normal coronary arteries and may benefit from statin therapy. Chapter 8 presented 
the potential cost-effectiveness of SPCCT (versus coronary CT angiography (CCTA)) in 
diagnosing and selecting patients with NOCAD for statin treatment in the UK, based 
on the identification of vulnerable coronary plaques. A de novo decision tree and a 
Markov trace were developed to model the expected outcomes for a hypothetical UK 
cohort of 50-year-old male patients with stable chest pain and no history of CAD. Our 
deterministic and probabilistic results showed that an imaging test providing increased 
sensitivity in detecting vulnerable plaques would add value compared to CCTA. Never-
theless, accurate data regarding the efficacy and adverse events of statin treatment are 
needed before the cost-effectiveness of SPCCT can be estimated more precisely in this 
population.
Discussion
In Chapter 9, an overview of the main findings of the studies is presented together with 
the implications of our results, the challenges encountered and the limitations of our ap-
proach. In light of our research questions, our findings are fourfold. First, despite limited 
data, there is a clear indication of considerable variation between European countries 
regarding the diagnostic workup and therapeutic interventions for patients suspected 
with stroke and patient presenting with ACS. Second, SPCCT is cost-effective in patients 
with ischaemic stroke in the UK and in the USA. A reduced specificity of SPCCT reduced 
its cost-effectiveness. Third, despite variation in country-specific cost-effectiveness esti-
mates, advanced imaging, followed by late MT, appeared to be good value for money 
in Germany, Hungary and Sweden. However, based on a 4-step approach, we showed a 
suboptimal validity of our German and Hungarian cost-effectiveness estimates derived 
from the transfer of a cost-effectiveness model. Fourth, SPCCT is cost-effective in pa-
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tients with NOCAD in the UK, provided increased sensitivity compared to competing 
technologies.
Our results have implications for test-developers, clinicians, policy makers and payers, 
and beyond, for scientific purposes. The definition of current care, the lack of data, the 
necessity to deal with uncertainty and the specific complexity of assessing diagnostics 
were the main challenges that we faced throughout our work. We highlighted the limi-
tations of the narrow approach of cost-effectiveness analyses. Those limitations could 
be overcome by complementary methods such as mini-HTA, multi-criteria decision 
analysis (MCDA) and budget impact analyses. In order to confirm our cost-effectiveness 
estimates, further research is needed to collect real-world data, assess the clinical ef-
ficacy of SPCCT, address structural uncertainty, investigate the optimal deployment of 
advanced imaging in clinical practice and determine its maximum price.
general conclusion
Despite a lack of data and considerable practice variation across countries, we have used 
modelling techniques to assess the cost-effectiveness of complex diagnostic strategies 
in cardiovascular diseases. More specifically, we estimated the country-specific cost-
effectiveness of the currently developed SPCCT modality in stroke and NOCAD care and 
identified the technical drivers of the value per disease area. We explained the relevance 
of our early HTA findings to the manufacturer and highlighted the necessity to sharpen 
our cost-effectiveness estimates once more evidence and (quality) data become avail-
able. The evidence of value of SPCCT might be required by decision makers or payers at a 
later time. Although CEAs form a solid pillar in value assessment regardless of the level of 
decision-making, they present limitations that complementary methods incorporating 
different stakeholder perspectives may overcome. Depending on the stage of diffusion 
and implementation of SPCCT, later in its life cycle, a more comprehensive approach 
including mini-HTA, MCDA and budget impact analyses might become relevant. In the 
current phase, our economic analyses present strong and useful evidence of how SPCCT 




Wereldwijd, in de context van introductie van medische technologie en stijgende kos-
ten van de gezondheidszorg, is er een sterke behoefte aan wetenschappelijk bewijs om 
besluitvorming te ondersteunen betreffende het gebruik en de financiering van nieuwe 
technologieën. Health technology assessment (HTA) is de systematische evaluatie van 
de directe en bedoelde effecten van een technologie, als mede de indirecte en onbe-
doelde consequenties. Economische evaluaties zijn de kern van HTA en geven inzicht in 
de kosten en de effecten van een nieuwe technologie in vergelijking met een alternatief, 
in veel gevallen de huidige zorg. De onderzoeksmethoden kosteneffectiviteitsanalyse 
en kostenutiliteitsanalyse worden veel gebruikt en deze leiden vaak tot de generieke 
uitkomst van de kosten per voor kwaliteit gecorrigeerd levensjaar (Quality Adjusted 
Life Year, QALY). Een cruciale stap van een kosteneffectiviteitsanalyse of kostenutili-
teitsanalyse is het vaststellen van de uitgangspunten, en dit betreft het definieren van 
de patiëntenpopulatie, de interventie, het vergelijkingsalternatief (comparator) en het 
perspectief van analyse. Het definieren van dergelijke uitgangspunten is ook noodzake-
lijk in het geval wetenschappelijke data uit verschillende bronnen mathematisch in een 
besliskundig model worden samengevoegd. Het belangrijkste doel van besliskundig 
modelleren in de context van de gezondheidzorg is om wetenschappelijk bewijs ten 
behoeve van besluitvorming te leveren, waarbij onzekerheid centraal staat. Onzeker-
heid in relatie tot besliskundige modellen bestaat uit drie onderdelen: onzekerheid 
betreffende de specifiek waarden van rekenparameters in het mathematisch model, 
verscheidenheid (heterogeniteit) in patiëntenpopulaties en ten derde de keuzen die ten 
grondslag liggen aan het model, zoals klinische gebeurtenissen en de gebruikte statisti-
sche methoden. Door deze concepten van onzekerheid expliciet te maken kan vroege-
HTA tijdens de onderzoek- en ontwikkelingsfasen van een nieuwe technologie gebruikt 
worden om de fabrikant en andere belanghebbenden te informeren over de potentiele 
waarde van de technologie. Dit is vooral relevant voor diagnostische technologie omdat 
besliskundig modelleren tijdens de ontwikkelingsfase ontwikkelaars kan stimuleren 
technische mogelijkheden aan te passen om zodoende de waarde van de diagnostische 
technologie voor behandelbeslissingen, patiënten, zorgprofessionals, producenten, en 
de samenleving als geheel te verbeteren. Een positieve waardering kan dan leiden tot 
positieve beslissingen betreffende aankoop en/of vergoeding door zorgaanbieders en 
zorgautoriteiten. Ten slotte, omdat de waarde van een gezondheidstechnologie erg 
afhankelijk is van het gezondheidszorgsysteem waar deze ingezet gaat worden, is de 
aanpassing van gezondheidseconomisch bewijs van het ene naar het andere land mo-





Cardiovasculaire ziekten (cardiovascular diseases, CVD) ofwel hart- en vaatziekten zijn 
de belangrijkste doodsoorzaken en gaan gepaard met wereldwijd aanzienlijke men-
selijke en economische consequenties. Deze ziekten betreffen aandoeningen van het 
hart en de bloedvaten, waaronder aandoeningen aan de kransslagaders, ofwel coro-
naire hartziekten en aandoeningen aan de bloedvaten in en naar de hersenen, ofwel 
cerebrovasculaire ziekten. Het merendeel van de CVD-gevallen wordt veroorzaakt door 
atherosclerose waarbij vet- of andere lichaamscellen zich ophopen in de binnenwand 
van de slagader en daar een plaque vormen. De plaque zelf en ook het scheuren of 
eroderen van de plaque kan leiden tot afsluiting van een bloedvat en zodoende car-
diovasculaire incidenten veroorzaken zoals acuut coronair syndroom (waaronder myo-
cardinfact ofwel hartaanval), ischemisch cerebrovasculair accident (ofwel beroerte) en/
of overlijden. De nieuwe en innovatieve beeldvormende technologie, genaamd spectral 
photon counting computed tomography (SPCCT), heeft de potentie van waarde te zijn 
in het diagnostische traject van patiënten die een cardiovasculair incident doormaken 
of daar risico op lopen.
Dit proefschrift richt zich op twee belangrijke cardiovasculaire aandoeningen: ische-
misch cerebrovasculair accident (ICVA) en de coronaire vaataandoeningen acuut coro-
nair syndroom (ACS) en non-obstructief coronaire vaataandoeningen (non-obstructive 
coronary artery disease, NOCAD). Ten eerste richten we ons op acute patiënten met 
CVA-achtige symptomen. Deze moeten zo snel mogelijk onderzocht worden om de 
oorzaak en de kenmerken te bepalen van mogelijke hersenschade voordat de arts kan 
beslissen welke behandeling het beste is. SPCCT zal naar verwachting de besluitvor-
ming in deze situatie verbeteren doordat de doorbloeding van de hersenen beter kan 
worden gequantificeerd. Daarnaast concentreert dit proefschrift zich op patiënten met 
pijn of druk op de borst. Hier moet de oorzaak van deze klachten worden vastgesteld 
voordat een behandeling kan worden bepaald. Door de hogere gevoeligheid van SPCCT 
voor calcificaties en betere beeldkwaliteit door een hoger aantal pixels kan worden 
verwacht dat de nauwkeurigheid van de meting van vernauwing van kransslagaders 
toeneemt. Daarnaast kan SPCCT de structuur en samenstelling van eventuele plaque 
beter vaststellen. Hierdoor kan SPCCT plaques identificeren die risico lopen te scheuren 
en zodoende kan besloten worden tot preventieve behandeling bij CAD.
Dit proefschrift
Het doel van dit proefschrift is om de potentiele kosteneffectiviteit van de in ontwikke-
ling zijnde diagnostische beeldvormende technologie SPCCT vast te stellen en hiermee 
gezondheidszorgbeslissingen te informeren, rekening houdend met internationale 
variatie. Vier onderzoeksvragen worden behandeld. 1) Wat is er bekend over de huidige 
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zorg en de variatie tussen vier Europese landen betreffende het diagnostisch traject en 
behandelbeleid voor patiënten verdacht een van cerebrovasculair accident, dan wel 
patiënten met klachten die wijzen op ACS? 2) Wat is de kosteneffectiviteit van SPCCT 
bij patiënten met ICVA in het Verenigd Koninkrijk (UK) en in de Verenigde Staten van 
America (USA)? 3) Is er internationale variatie in de kosteneffectiviteit van SPCCT bij 
patiënten met ICVA en is het valide om een economisch rekenmodel aan te passen om 
te komen tot land-specifieke schattingen? 4) Wat is de kosteneffectiviteit van SPCCT bij 
patiënten met NOCAD in de UK?
De studies
In hoofdstuk 2 wordt een beschrijving gegeven van de momenteel bij cerebrovasculair 
accident (CVA) toegepaste beeldvormende technologieën en de variatie in de CVA-zorg 
tussen Duitsland, Hongarije, Zweden en de UK. Deze bevindingen zijn nodig om de 
huidige zorgpraktijk in onze kosteneffectiviteitsanalyses weer te geven. In een syste-
matisch literatuuronderzoek werden originele onderzoeksstudies opgenomen waarin 
de diagnostische trajecten werden gepresenteerd in de zorg voor patiënten met CVA. 
Gebaseerd op een gericht ontwikkelde zoekstrategie werden vijf literatuur databases 
doorzocht en op basis hiervan werden 15 originele studies in het literatuuroverzicht 
opgenomen. De meeste van deze studies betroffen observationele studies op basis 
van nationale registers. Voor Hongarije werd geen enkele studie gevonden. Computed 
tomografie (CT) werd gerapporteerd als de belangrijkste beeldvormende technologie 
bij de zorg voor CVA-patiënten. Eenduidig bewijs van het optimale diagnostische traject 
voor deze patiënten ontbreekt. Verder bleek dat er onvoldoende bewijs is om een nauw-
keurige vergelijking tussen de vier landen te maken betreffende dit diagnostisch traject.
Er is een veelheid van beeldvormende technologieën en behandelopties voor CVA. Om 
de bevindingen zoals gepresenteerd in hoofdstuk 2 aan te vullen en de huidige zorg-
praktijk te bestuderen werd een online enquête ontwikkeld en verstuurd naar clinici in 
Europa. Ondanks een lage response rapporteren we in hoofdstuk 3 de antwoorden uit 
Zweden (21), de UK (16), Hongarije (15), Duitsland (12) en overige Europese landen (47). 
De variatie tussen Europese landen met betrekking tot diagnostiek van acute CVA bleek 
beperkt wat betreft de eerst toegepaste beeldvormende technologie: CT werd gebruikt 
in 81% tot 93% van de patiënten. Echter, praktijkvariatie nam toe in de latere stadia van 
het beeldvormende diagnostische traject en in de keuze van de behandeling. Duitse en 
Britse respondenten rapporteerden dat respectievelijk 81% en 12% van de patiënten 
waarbij binnen 4,5 uur na aanvang van symptomen een grote arteriele vernauwing werd 
gediagnostiseerd, behandeld werd met intraveneuze bloedverdunning (trombolyse) en 
verwijdering van het bloedstolsel (trombectomie). Betreffende patiënten die binnen 
2 uur gediagnostiseerd werden met een uitgebreid herseninfarct rapporteerde 75% 
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van de Britse respondenten dat zij trombectomie als behandeling prefereerden, maar 
tegelijkertijd deed slechts 13% dit daadwerkelijk. We concluderen dat nader onderzoek 
nodig is om de kwaliteit van CVA-zorg tussen landen te kunnen vergelijken en om te 
bepalen welke 2e-lijns beeldvormende technologie het meest kosteneffectief is om 
CVA-patiënten te diagnostiseren.
In hoofdstuk 4 vergelijken we de kosteneffectiviteit van twee zorgpaden voor acute 
ICVA-patiënten in de UK: mechanisme trombectomie (MT) tot 6 uur na aanvang van 
symptomen op basis van conventionele beeldvorming versus MT tot, maar ook na 6 
uur na aanvang van symptomen op basis van geavanceerde beeldvorming. Hiertoe ont-
wikkelden wij een beslisboom (die het korte termijn diagnostische en behandeltraject 
weergaf ) en een Markov-model (die de lange termijn voortgang na CVA weergaf, tot 
overlijden) en we modelleerden hiermee de voortgang van een hypothetisch UK-cohort 
van 71-jarige patiënten. Verschillende scenario’s gebaseerd op verschillende waarden 
van zowel de a priori-kans om baat te hebben van late MT als de accuraatheid van 
geavanceerde beeldvorming werden doorgerekend. Daarnaast werden probabilistische 
gevoeligheidsanalyses uitgevoerd. Incrementele kosteneffectiviteitsratio’s (IKER) vari-
eerden van $8.199 (£6.164) tot $49.515 (£37.229) per gewonnen QALY. Onze analyses 
lieten zien dat de accuraatheid van geavanceerde beeldvorming vooral invloed heeft 
op de incrementele kosteneffectiviteitsratio wanneer de specificiteit verlaagd wordt. Bij 
een levenslange tijdhorizon resulteerde late MT in alle scenario’s tot gezondheidswinst 
(meer QALY’s). Afhankelijk van het scenario lieten de probabilistische gevoeligheidsana-
lyses zien dat de kans dat het late MT-traject kosteneffectief was bij een kosteneffecti-
viteitsdrempelwaarde van $39.000 (£30.000) per gewonnen QALY varieerde tussen 46% 
en 93%. We lieten zien dat, in principe, late MT tot 12 uur na aanvang van symptomen 
een goede investering kan zijn. Echter, additionele gegevens zijn nodig betreffende de 
implementatie van geavanceerde beeldvorming en de a priori-kans van ICVA-patiënten 
om baat te hebben van late MT voor de kosteneffectiviteit kan worden vastgesteld.
Twee recente klinische trials (DAWN en DEFUSE 3) lieten zien dat er 3 maanden na 
behandeling positieve functionele effecten waren van late MT, tot 24 uur na aanvang 
van symptomen. Behandeling door middel van MT in het late tijdsbestek na aanvang 
van symptomen (tussen 6 en 24 uur) vereist selectie van patiënten op basis van geavan-
ceerde beeldvorming. In hoofdstuk 5 presenteren we hoe de korte termijn functionele 
effecten van late MT op basis van geavanceerde beeldvorming en standaard medische 
zorg (SMZ) zich lieten vertalen in kosteneffectiviteit in vergelijking met louter SMZ in de 
USA, uitgaande van een levenslange tijdshorizon. Op basis van een Amerikaans gezond-
heidszorg perspectief, werd een kosteneffectiviteitsmodel ontwikkeld, gebaseerd op de 
combinatie van een beslisboom en een Markov model en dit model werd ingevuld met 
299
Samenvatting
de bevindingen uit de DAWN en DEFUSE 3 studies. Voor de studiepopulaties waren de 
IKERs respectievelijk $662/QALY en $13.877/QALY. Late MT+SMZ (versus louter SMZ) had 
een kans van 99,9% om kosteneffectief te zijn bij een kosteneffectiviteitsdrempel van 
$100.000/QALY. Subgroep analyses lieten zien dat bij een kosteneffectiviteitsdrempel-
waarde van $50.000/QALY deze kans een breed bereik kende, waarbij de belangrijkste 
onzekerheid gold voor patiënten met een NIHSS-score ≥ 16 (National Institutes of Health 
Stroke Scale) en patiënten van 80 jaar en ouder.
In hoofdstuk 6 wordt de internationale variatie betreffende de waarde van SPCCT voor 
ICVA-patiënten gepresenteerd, als ook een methode om te beoordelen wat de validiteit 
is van het transfereren van kosteneffectiviteitsbevindingen van het ene naar het andere 
land. Een vier-stappen benadering werd ontwikkeld die de principes van McCabe en 
Welte combineerde en deze werd toegepast om de validiteit van het transfereren van 
het model zoals gepresenteerd in hoofdstuk 4 van de UK naar Duitsland, Hongarije en 
Zweden te bepalen. Het UK-model bleek passend voor de beslissingscontext van deze 
drie landen. Beperkende factoren voor het transfereren van de UK-bevindigen werden 
vastgesteld en hiervoor werden steeds lokale gegevens verkregen. Ook werd van deze 
gegevens de kwaliteit bepaald. De resultaten gebaseerd op de kosteneffectiviteitsmo-
dellen van de landen werden met elkaar vergeleken en hierbij bleek er variatie in de 
resultaten wat betreft de incrementele kosteneffectiviteit in gewonnen QALY op basis 
van een levenslange tijdhorizon: €4.525 (UK), €7.506 (Duitsland), €12.749 (Hongarije) 
en voor Zweden gebaseerd op een gezondheidsperspectief en een maatschappelijke 
perspectief, respectievelijk -€11.242 en -€16.362. Ondanks deze variatie bleek geavan-
ceerde beeldvorming gevolgd door late MT kosteneffectief in de vier landen. Transfe-
reren van het originele model door middel van de vier-stappen benadering bleek een 
efficiënte methode om een voorlopige analyse van de kosteneffectiviteit van late MT 
in verschillende landen uit te voeren. We lieten zien dat er een hoge validiteit is van de 
kosteneffectiviteitsuitkomsten voor Zweden. Een beperkte betrouwbaarheid bleek het 
geval te zijn voor Duitsland en Hongarije, waarbij de kwaliteit van lokale gegevens de 
beperkende factor was.
In hoofdstuk 7 worden de resultaten gepresenteerd van een online enquête betreffende 
de diagnostische- en behandelstrategieën van patiënten bekend met of verdacht van 
ACS, zoals gerapporteerd door patiënten. De vragenlijst richtte zich op beeldvorming 
en behandelingen voor revascularisatie en daarnaast ook op enkele klinische scenario’s. 
Gegeven het beperkte aantal respondenten werden de antwoorden gegroepeerd van 
Zweden (20), de UK (16), Noord-/West-Europa (17), Zuid-Europa (9) en Centraal-Europa 
(7). Aanzienlijke variatie werd gevonden tussen de verschillende geografische gebie-
den betreffende diagnostische trajecten en behandelstrategieen. De gerapporteerde 
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verschillen gaven mogelijk aan dat sommige patiënten niet de best gangbare zorg 
ontvingen en dat er gezondheidsverschillen waren tussen gebieden. Grotere studies en 
data uit de dagelijkse zorgpraktijk zijn noodzakelijk om onze bevindingen te verifiëren 
en achterliggende oorzaken aan het licht te brengen.
NOCAD-patiënten hebben een hoger risico op cardiovasculaire incidenten dan patiën-
ten met normale kransslagaders waardoor zij mogelijk baat hebben bij behandeling met 
statines. Hoofdstuk 8 presenteert de potientiele kosteneffectiviteit van SPCCT (versus 
coronair CT angiografie, CCTA) in de diagnostiek en selectie van NOCAD-patiënten voor 
statinebehandeling in de UK, gebaseerd op de aanwezigheid en samenstelling van 
arteriele plaque. Een beslisboom en Markov model werden ontwikkeld om hiermee de 
verwachte uitkomsten voor een hypothetisch cohort van 50-jarige mannelijk patiënten 
met stabiele angina pectoris (pijn op de borst), zonder voorgaande CAD. Onze determi-
nistische en probabilistische resultaten lieten zien dat beeldvorming met een hogere 
sensitiviteit om instabiele plaques te detecteren van waarde is ten opzichte van CCTA. 
Desalniettemin zijn preciese gegevens nodig inzake de werkzaamheid en bijwerkingen 
van statinebehandeling voordat de kosteneffectiviteit van SPCCT bij deze populatie 
nauwkeurig kan worden vastgesteld.
Discussie
In hoofdstuk 9 wordt het overzicht van de belangrijkste bevindingen van de studies 
gegeven met daarbij de implicaties van onze resultaten, de uitdagingen die we zijn 
tegengekomen en de beperkingen van onze aanpak. Gegeven onze onderzoeksvragen 
kunnen we de bevindingen in vier punten samenvatten. Ten eerste kan, ongeacht de 
beperkte gegevens, worden gesteld dat er een duidelijke aanwijzing is voor aanzienlijke 
variatie tussen Europese landen wat betreft het diagnostisch traject en behandelbeleid 
voor patiënten verdacht van een cerebrovasculair accident en patiënten met klachten 
die wijzen op ACS. Ten tweede blijkt dat SPCCT kosteneffectief is bij patiënten met 
ICVA in de UK en de USA. Een lagere specificiteit van SPCCT (de kans op een negatieve 
testuitslag bij personen zonder de aandoening) vermindert de kosteneffectiviteit. Ten 
derde werd aangetoond dat ondanks variatie in de kosteneffectiviteit tussen landen 
geavanceerde beeldvorming gevolgd door late MT de investering waard is in Duitsland, 
Hongarije en Zweden. Echter, middels de vier-stappen benadering laten we zien dat 
het transferen van een kosteneffectiviteitsmodel naar Duitsland en Hongarije leidt tot 
beperkte validiteit van resultaten. Ten vierde stellen we vast dat SPCCT bij patiënten 
met NOCAD in de UK kosteneffectief is zolang de sensitiviteit (de kans op een positieve 




Onze resultaten hebben implicaties voor de ontwikkelaars van diagnostische tests, 
zorgverleners, beleidsmakers, financiers en verzekeraars en bovendien de wetenschap. 
De definitie van huidige zorg, de schaarste aan gegevens, de noodzaak om rekening te 
houden met onzekerheid en de specifieke complexiteit van de evaluatie van diagnos-
tisch technologie waren de belangrijkste uitdagingen die we in de totstandkoming van 
dit proefschrift tegenkwamen. We hebben de beperkingen van de gerichte benadering 
van kosteneffectiviteitsanalyses laten zien. Dergelijke beperkingen kunnen worden 
gepareerd door toepassing van complementaire onderzoeksmethoden zoals mini-HTA, 
multi-criteria beslissingsanalyse (MCDA) en budget impact analyses. Om onze kostenef-
fectiviteitsschattingen te bevestigen is verder onderzoek noodzakelijk naar gegevens 
uit de dagelijkse zorgpraktijk, als ook het vaststellen van de klinische werkzaamheid 
van SPCCT, de structurele onzekerheid van onze modellen, en bovenal het onderzoeken 
van de optimale toepassing van geavanceerde beeldvorming in de zorgpraktijk en het 
vaststellen van de maximaal acceptabele prijs.
Algemene conclusie
Ongeacht de schaarste aan gegevens en aanzienlijke zorgpraktijkvariatie tussen landen 
hebben we modelleringsmethoden toegepast om de kosteneffectiviteit van complexe 
diagnostische strategieen bij cardiovasculaire aandoeningen te schatten. Hiermee heb-
ben we de landspecifieke kosteneffectiviteit van de in ontwikkeling zijnde technologie 
SPCCT berekend ten behoeve van zorg voor patiënten met CVA en NOCAD en hierbij 
hebben we per aandoening de technische kenmerken vastgesteld die deze waarde in 
grote mate bepalen. Hiermee laten we de relevantie van onze vroege HTA-bevindingen 
aan mogelijke fabrikanten zien en geven de noodzaak aan de kosteneffectiviteitsbe-
vindingen te actualiseren in het geval er betere gegevens beschikbaar komen. In een 
later stadium wordt wellicht dergelijk bewijs over de waarde van SPCCT vereist door 
beleidsmakers of financiers. Alhoewel kosteneffectiviteitsanalyses ongeacht de beslis-
singscontext een belangrijke basis vormen voor de waardebepaling van een technolo-
gie, hebben deze beperkingen die door complementaire onderzoeksmethoden vanuit 
het perspectief van diverse belanghebbenden kunnen worden gecompenseerd. Afhan-
kelijk van de mate van toepassing en implementatie gerelateerd aan de levenscyclus 
van SPCCT kan een bredere benadering, waaronder mini-HTA, MCDA en budget impact 
analyses, relevant worden. In de huidige fase van de levenscyclus van SPCCT geven 
onze economische analyses desalniettemin sterk en nuttig bewijs van hoe SPCCT een 




It is with relief and other mixed emotions that I am putting my final thoughts into words.
It is also with immense pleasure that I am expressing my appreciation for the help and 
support of those who, in one way or another, have contributed in making this journey 
possible.
To my supervisors, Professor Hans Severens and Doctor Ken Redekop,
These lines will surely not be sufficient to express all my gratitude. You followed an open 
recruiting process and took the risk to give her chance to a stranger. You taught me that, 
while it strives for prediction and control, research can be conducted under all degrees 
of freedom. I greatly appreciated four years of trust, the complementary and serene 
team that you formed, your involvement, expertise and constructive approach to work.
Hans, thank you for your energy, your vision, for many inspirational conversations.
Ken, thank you for showing me weekly what kindness and patience mean.
To the coauthors of this work, to the clinicians and professionals who provided inputs 
and feedback, to the members of the SPCCT project,
This product is the fruit of an extensive collaboration between experts from multiple 
disciplines, across seven countries, within and beyond the SPCCT boundaries. I highly 
valued your academic and scientific faith and relied on your critical insight into this work.
I also witnessed that short or unexpected encounters can be the birthplace of inspira-
tion for substantial progress. In particular, I am thankful to Professor Daniel Bereczki 
(Semmelweis University, Hungary), Doctor Dimitrios Venetsanos (Karolinska Institute, 
Sweden) and Doctor James Burke (University of Michigan, USA), for their availability and 
kindness.
I would also like to thank the members of my evaluation committee, Professor Silvia 
Evers, Professor Job van Exel and Professor Gabriel Krestin, for their critical assessment.
Dear Kinga, this work only shows that you have been an invaluable source of inspiration 
ever since we met in Mexico, more than 13 years ago. Thank you for your support.
Christian, thank you for your remote but close presence and for letting me sense the 
world through your magical ears and compassionate eyes.
Vanessa, thank you for mastering the art of repainting life in yellow when all the colors 
look black.
Damien, how fascinating the world is, mountain summits beneath our feet. Thank you 
for some stormy adventures and many breathtaking hikes. 
303
Acknowledgements
To my PhD-sceptic friends from France, for their genuine guidance.
To my international HEPL 2014-15 fellows, the pool of resilience, the hands of support: 
Monica and Sellie, those who went their way, those who recently proved to be only one 
call away.
To my expat circle, my cinema and sport partners in Rotterdam, to Marianne and Marine: 
thank you for the much-needed fun of racket games, for some vital movie escapes and 
for the taste of simple things that are shared.
To Johan and Nick, who helped me with my administrative duties and are part of nice 
memories.
I would like to acknowledge Marcel Jonker: I benefited immensely from your advice dur-
ing the first year of my PhD and more recently. And the cheerful ladies who kept J8-11 
under positive energy.
I am thankful to those who believed in me and encouraged me as a child, as a girl, as a 
student and as a young female professional. Although difficult to quantify, the positive 
impact that some mentors, teachers and first managers had is undeniable. There is one 
gentleman with whom I worked in Florida 12 years back: thank you, Zaheer, for your 
courageous leadership and your active role in promoting corporate gender equality.
To the few people who showed me the importance of love.
Finally, I would like to dedicate this work to many known and unknown people con-
fronted to the injustice and adversity of poor health. It brings me happiness to support 
a field that advances the physical and mental well-being of populations and individuals. 
I keep the dream that one day everybody will receive the same chance to conquer the 






Academic writing in English, Erasmus University Rotterdam, Rotterdam, The Nether-
lands, 2016.
Professionalism and integrity in research, Erasmus University Rotterdam, Rotterdam, The 
Netherlands, 2017.
Cross-cultural awareness and communication, Erasmus University Rotterdam, Rotter-
dam, The Netherlands, 2017.
Advanced decision analytic modelling for economic evaluation, University of Glasgow, 
Scotland, 2017.
Collecting health-state utility estimates for economic models in clinical studies, short 
course, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
20th Annual European Congress, Glasgow, Scotland, 2017.
Introduction to R, Decision Analysis in R for Technologies in Health (DARTH group), 
Leiden, The Netherlands, 2018.
Decision modelling using R, Decision Analysis in R for Technologies in Health (DARTH 
group), Leiden, The Netherlands, 2018.
Budget impact analysis I and II, short course, International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) 21st Annual European Congress, Barcelona, 
Spain, 2018.
Introduction to Infectious Disease Modelling and its Applications, London School of 
Hygiene & Tropical Medicine, online, 2020.
Communicating your research: lessons from Bitescience, Erasmus University Rotterdam, 
Rotterdam, The Netherlands, 2020.
Self-presentation: focus, structure, interaction and visualisation, Erasmus University Rot-




Supervision of 1 thesis, master program Health Economics, Policy and Law, Erasmus 
School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, 
The Netherlands, 2019.
(Co-)supervision of 1 thesis, research master program Health Sciences NIHES, Erasmus 
Medical Center Rotterdam, Rotterdam, The Netherlands, 2018-2019.
Supervision of 6 theses, European Master in Health Economics and Management, 
Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rot-
terdam, The Netherlands, 2018-2020.
Co-evaluation of 1 thesis, master program Health Economics, Policy and Law, Erasmus 
School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, 
The Netherlands, 2020.
Pharmaceutical pricing and market access, master program Health Economics, Policy 
and Law, Erasmus School of Health Policy and Management, Erasmus University Rot-
terdam, Rotterdam, The Netherlands, 2016-2020.
Advanced health economic modelling, master program Health Economics, Policy and 
Law, Erasmus School of Health Policy and Management, Erasmus University Rotterdam, 
Rotterdam, The Netherlands, 2018.
Health economics, summer course NIHES, Erasmus Medical Center Rotterdam, Rotter-
dam, The Netherlands, 2017-2019.
Podium presentations
Spectral photon counting computed tomography, SPCCT semi-annual meeting, Cli-
niques Universitaires Saint-Luc, Brussels, Belgium, 14-15 December 2016.
Spectral photon counting computed tomography, SPCCT semi-annual meeting, Erasmus 
School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, 
The Netherlands, 22-23 June 2017.
Role and contribution of health technology assessment (HTA) in positioning imaging 
innovation; 2nd Spectral CT Workshop, Lyon, France, 17 November 2017.
307
PhD portfolio
Spectral photon counting computed tomography, SPCCT semi-annual meeting, St. 
Thomas Hospital, London, United Kingdom, 4-5 December 2018.
Spectral photon counting computed tomography, SPCCT semi-annual meeting, Mo-
lecular Biotechnology Center MBC – University of Turin, Turin, Italy, 3-4 July 2018.
Spectral photon counting computed tomography, SPCCT semi-annual meeting, Philips 
site, Hamburg, Germany, 20 September 2019.
Exploring the window of opportunity: Cost-effectiveness of mechanical thrombectomy 
beyond six hours following advanced imaging (versus thrombectomy within six hours 
following CT-CTA) in acute ischemic stroke in the UK. The 11th lowlands Health Economic 
Study Group (lolaHESG), Almen, The Netherlands, 23-24 May 2019.
Validity and comparison of transferred cost-effectiveness results across 4 countries: the 
case of advanced imaging + late thrombectomy in stroke care. The 12th lowlands Health 
Economic Study Group (lolaHESG), online, 24 September 2020.
Poster presentations
What are the images used to diagnose and assess suspected strokes?: A systematic 
literature review of care in four European countries. International Society for Pharmaco-
economics and Outcomes Research (ISPOR) 20th Annual European Congress, Glasgow, 
Scotland. Research poster presentation, 4-8 November 2017.
What stroke image do we want? European clinician survey on acute stroke imaging and 
revascularisation treatment. International Society for Pharmacoeconomics and Out-
comes Research (ISPOR) 20th Annual European Congress, Glasgow, Scotland. Research 
poster presentation, 4-8 November 2017.
Potential cost-effectiveness of spectral photon-counting computed tomography 
(SPCCT) versus CT combined to CT angiography (CTA) in the identification and treat-
ment of ischaemic stroke patients in the UK. International Society for Pharmacoeconom-
ics and Outcomes Research (ISPOR) 21st Annual European Congress, Barcelona, Spain. 
Research poster presentation, 10-14 November 2018.
Exploring the daily clinical practice in myocardial infarction (MI) care in Europe: survey 
of diagnostic and treatment strategies for theoretical patients. International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual European Congress, 
Barcelona, Spain. Research poster presentation, 10-14 November 2018.
308
PhD portfolio
Transferability of UK-based cost-effectiveness model to Hungary, Sweden, and Germany: 
the case of mechanical thrombectomy beyond six hours following advanced-imaging 
(versus mechanical thrombectomy within six hours following CT+CTA) in acute isch-
aemic stroke. International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) 22nd Annual European Congress, Copenhagen, Denmark, 2-6 November 2019.
Preliminary budget impact analysis of advanced imaging and mechanical thrombec-
tomy for acute ischaemic stroke beyond 6 hours from onset in the United Kingdom. 
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd 
Annual European Congress, virtual, 16-19 November 2020.
Cost-effectiveness of imaging strategies to diagnose and select patients with non-
obstructive coronary artery disease for statin treatment in the United Kingdom. 
European Association of Cardiovascular Imaging (EACVI) - Best of Imaging 2020, virtual, 
11-12 December 2020.
Co-authored poster presentations
Access to intravenous tissue-like plasminogen activator (IV TPA) therapy and mechanical 
thrombectomy (MT) for patients with acute ischemic stroke in Hungary. International 
Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual European 
Congress, Copenhagen, Denmark, 2-6 November 2019.
Beyond Acute Neisseria gonorrhoea infection: a model-based analysis estimating the 
holistic humanistic burden in England and the USA. International Society for Pharma-
coeconomics and Outcomes Research (ISPOR) 23rd Annual European Congress, virtual, 
16-19 November 2020.
Co-authored podium presentation
A model-based estimation of the cost-of-illness associated with Neisseria gonorrhoea 
in England and the USA: assessing the potential impact of antimicrobial resistance and 
long-term health problems. International Society for Pharmacoeconomics and Out-




related to this thesis and published in peer-reviewed journals
Peultier AC, Redekop K, Coche E, Severens JL. What are the images used to diagnose 
and assess suspected strokes?: A systematic literature review of care in four Euro-
pean countries. Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):177-189. doi: 
10.1080/14737167.2018.1429270.
Peultier AC, Redekop WK, Dippel DWJ, Bereczki D, Si-Mohamed S, Douek PC. Severens, 
JL. What stroke image do we want? European survey on acute stroke imaging and revas-
cularisation treatment. Health Policy and Technology 2019; 8 (3): 261-267. doi: 10.1016/j.
hlpt.2019.08.005.
Peultier AC, Redekop WK, Allen M, Peters J, Eker OF, Severens JL. Exploring the Cost-
Effectiveness of Mechanical Thrombectomy Beyond 6 Hours Following Advanced 
Imaging in the United Kingdom. Stroke. 2019 Nov;50(11):3220-3227. doi: 10.1161/
STROKEAHA.119.026816.
Peultier AC, Venetsanos D, Rashid I, Severens JL, Redekop WK. European survey on acute 
coronary syndrome diagnosis and revascularisation treatment: Assessing differences in 
reported clinical practice with a focus on strategies for specific patient cases. J Eval Clin 
Pract. 2020 Oct;26(5):1457-1466. doi: 10.1111/jep.13333. 
Peultier AC, Pandya A, Sharma R, Severens JL, Redekop WK. Cost-effectiveness of 
Mechanical Thrombectomy More Than 6 Hours After Symptom Onset Among Patients 
With Acute Ischemic Stroke. JAMA Netw Open. 2020 Aug 3;3(8):e2012476. doi: 10.1001/
jamanetworkopen.2020.12476.
related to this thesis and submitted to peer-reviewed journals
Peultier AC, Redekop WK, Zemplényi A, Kovács S, Severens JL. Validity of transferring a 
cost-effectiveness model across countries: the case of advanced imaging + late throm-
bectomy in stroke care.
Peultier AC, Redekop WK, Boccalini S, Clayton B, Severens JL. Cost-effectiveness of im-
aging strategies to diagnose and select patients with nonobstructive coronary artery 




Lenk EJ, Moungui HC, Boussinesq M, Kamgno J, Nana-Djeunga HC, Fitzpatrick C, Peultier 
AMM, Klion AD, Fletcher DA, Nutman TB, Pion SD, Niamsi-Emalio Y, Redekop WK, Seve-
rens JL, Stolk WA. A Test-and-Not-Treat Strategy for Onchocerciasis Elimination in Loa 
loa-coendemic Areas: Cost Analysis of a Pilot in the Soa Health District, Cameroon. Clin 




Anne-Claire Marie Monique Peultier was born in Nancy, France in 1985. After her 
bachelor’s degree in Economics and Social Sciences, she obtained a master’s degree in 
Management in 2008 (Institut Mines-Télécom Business School, Évry, France). During her 
master’s, she studied one semester in Germany (Pforzheim University) and one year in 
Mexico (MBA program, Monterrey Institute of Technology).
Anne-Claire started her career in 2006 as an intern in marketing within the global team 
in Alcatel-Lucent France. From 2008 to 2010, she worked within the regional team in 
the United States of America and within the local team in Mexico. Subsequently, she 
joined Amadeus, where she carried out project management and product management 
responsibilities in France until 2016.
In 2015, she obtained a master’s degree in Health Economics, Policy and Management 
(Erasmus University Rotterdam). In 2016, she joined the Health Technology Assessment 
section of the Erasmus School of Health Policy and Management (Erasmus University 
Rotterdam) as a PhD candidate. Her core research focused on health-economic model-
ling of a new diagnostic imaging technique.
Alongside her doctoral research, Anne-Claire was involved in projects focusing on infec-
tious diseases such as field work in Cameroon for a micro-costing study and supervision 
of various master thesis students in collaboration with the pharmaceutical industry.
Cost-effectiveness modelling of complex diagnostic strategies 
in cardiovascular diseases;




plex diagnostic strategies in cardiovascular diseases; early H
TA






Cost-effectiveness modelling of complex 
diagnostic strategies in cardiovascular diseases; 
early HTA supporting healthcare 
decision making
